10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________________________

FORM 10-Q

_________________________________________________________________________________

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to            

Commission file number 1-4448

_________________________________________________________________________________

BAXTER INTERNATIONAL INC.

(Exact name of registrant as specified in its charter)

_________________________________________________________________________________

Delaware			36-0781620
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
One Baxter Parkway,	Deerfield,	Illinois	60015
(Address of Principal Executive Offices)			(Zip Code)

224.	948.2000
(Registrant’s telephone number, including area code)

_________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $1.00 par value	BAX (NYSE)	New York Stock Exchange
		Chicago Stock Exchange
0.4% Global Notes due 2024	BAX 24	New York Stock Exchange
1.3% Global Notes due 2025	BAX 25	New York Stock Exchange
1.3% Global Notes due 2029	BAX 29	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x  No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes ☐   No x

The number of shares of the registrant’s Common Stock, par value $1.00 per share, outstanding as of April 21, 2020 was 508,836,225 shares.

BAXTER INTERNATIONAL INC.

FORM 10-Q

For the quarterly period ended March 31, 2020

TABLE OF CONTENTS

		Page Number
PART I.	FINANCIAL INFORMATION	2
Item 1.	Financial Statements (unaudited)	2
	Condensed Consolidated Balance Sheets	2
	Condensed Consolidated Statements of Income	3
	Condensed Consolidated Statements of Comprehensive Income (Loss)	4
	Condensed Consolidated Statements of Changes in Equity	5
	Condensed Consolidated Statements of Cash Flows	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	34
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	46
Item 4.	Controls and Procedures	47
Review by Independent Registered Public Accounting Firm		49
Report of Independent Registered Public Accounting Firm		50
PART II.	OTHER INFORMATION	51
Item 1.	Legal Proceedings	51
Item 1A.	Risk Factors	51
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	51
Item 6.	Exhibits	52
Signature		53

Explanatory Note

As previously disclosed, we restated our audited consolidated financial statements as of December 31, 2018 and for the years ended December 31, 2018 and December 31, 2017. The restatements of those consolidated financial statements were presented within our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Annual Report). See Note 2, Restatement of Previously Issued Consolidated Financial Statements, to the consolidated financial statements in the 2019 Annual Report for additional information related to those restatements.

Additionally, as previously disclosed, we restated our unaudited interim financial information as of and for the quarterly periods ended June 30, 2019, March 31, 2019, June 30, 2018, and March 31, 2018, for the quarterly period ended December 31, 2018, for the six months ended June 30, 2019 and as of September 30, 2018. The restatements of that unaudited interim financial information were presented within our 2019 Annual Report. See Note 19, Quarterly Financial Data (unaudited), to the consolidated financial statements in the 2019 Annual Report for additional information related to those restatements.

Additionally, as previously disclosed, we restated our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2018. The restatements of those unaudited condensed consolidated financial statements were presented within our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019. See Note 2, Restatement of Previously Issued Consolidated Financial Statements, to the condensed consolidated financial statements in that Quarterly Report on Form 10-Q for additional information related to those restatements.

This Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 includes unaudited condensed consolidated financial statements as of March 31, 2020 and December 31, 2019 and for the three months ended March 31, 2020 and 2019. As previously disclosed in our 2019 Annual Report, we have restated certain information within this Quarterly Report on Form 10-Q, including the condensed consolidated financial statements for the three months ended March 31, 2019. See Note 2, Restatement of Previously Issued Condensed Consolidated Financial Statements, in Item 1, Financial Statements, for additional information related to the restatement.

1

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Baxter International Inc.

Condensed Consolidated Balance Sheets (unaudited)

(in millions, except share information)

	March 31, 2020		December 31, 2019
Current assets:
Cash and cash equivalents	$	4,110	$	3,335
Accounts receivable, net of allowances of $114 in 2020 and $112 in 2019	1,892		1,896
Inventories	1,694		1,653
Prepaid expenses and other current assets	637		619
Total current assets	8,333		7,503
Property, plant and equipment, net	4,340		4,512
Goodwill	2,961		3,030
Other intangible assets, net	1,759		1,471
Operating lease right-of-use assets	577		608
Other non-current assets	1,105		1,069
Total assets	$	19,075	$	18,193
Current liabilities:
Short-term debt	$	221	$	226
Current maturities of long-term debt and finance lease obligations	315		315
Accounts payable and accrued liabilities	2,500		2,689
Total current liabilities	3,036		3,230
Long-term debt and finance lease obligations	5,996		4,809
Operating lease liabilities	486		510
Other non-current liabilities	1,827		1,732
Total liabilities	11,345		10,281
Commitments and contingencies
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2020 and 2019	683		683
Common stock in treasury, at cost, 175,106,170 shares in 2020 and 177,340,358 shares in 2019	(10,677)		(10,764)
Additional contributed capital	5,935		5,955
Retained earnings	15,935		15,718
Accumulated other comprehensive (loss) income	(4,177)		(3,710)
Total Baxter stockholders’ equity	7,699		7,882
Noncontrolling interests	31		30
Total equity	7,730		7,912
Total liabilities and equity	$	19,075	$	18,193

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

Baxter International Inc.

Condensed Consolidated Statements of Income (unaudited)

(in millions, except per share data)

	Three months ended March 31,
			As Restated
	2020		2019
Net sales	$	2,802	$	2,638
Cost of sales	1,639		1,558
Gross margin	1,163		1,080
Selling, general and administrative expenses	628		601
Research and development expenses	146		129
Other operating income, net	(20)		(33)
Operating income	409		383
Interest expense, net	21		18
Other (income) expense, net	10		(21)
Income before income taxes	378		386
Income tax expense	45		44
Net income	333		342
Net income attributable to noncontrolling interests	1		—
Net income attributable to Baxter stockholders	$	332	$	342
Earnings per share
Basic	$	0.65	$	0.67
Diluted	$	0.64	$	0.66
Weighted-average number of shares outstanding
Basic	507		512
Diluted	516		522

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Baxter International Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)

(in millions)

	Three months ended March 31,
			As Restated
	2020		2019
Net income	$	333	$	342
Other comprehensive (loss) income, net of tax:
Currency translation adjustments, net of tax benefit of ($8) and zero for the three months ended March 31, 2020 and 2019, respectively	(359)		(97)
Pension and other postretirement benefits, net of tax expense of $6 and $4 for the three months ended March 31, 2020 and 2019, respectively	22		14
Hedging activities, net of tax benefit of ($39) and ($5) for the three months ended March 31, 2020 and 2019, respectively	(130)		(15)
Total other comprehensive (loss) income, net of tax	(467)		(98)
Comprehensive (loss) income	(134)		244
Less: Comprehensive income attributable to noncontrolling interests	1		—
Comprehensive (loss) income attributable to Baxter stockholders	$	(135)	$	244

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Baxter International Inc.

Condensed Consolidated Statements of Changes in Equity (unaudited)

(in millions)

	For the three months ended March 31, 2020
	Baxter International Inc. stockholders' equity
	Common stock shares	Common stock		Common stock shares in treasury	Common stock in treasury		Additional contributed capital		Retained earnings		Accumulated other comprehensive income (loss)		Total Baxter stockholders' equity		Noncontrolling interests		Total equity
Balance as of January 1, 2020	683	$	683	177	$	(10,764)	$	5,955	$	15,718	$	(3,710)	$	7,882	$	30	$	7,912
Adoption of new accounting standards	—	—		—	—		—		(4)		—		(4)		—		(4)
Net income	—	—		—	—		—		332		—		332		1		333
Other comprehensive (loss) income	—	—		—	—		—		—		(467)		(467)		—		(467)
Stock issued under employee benefit plans and other	—	—		(2)	87		(20)		—		—		67		—		67
Dividends declared on common stock	—	—		—	—		—		(111)		—		(111)		—		(111)
Balance as of March 31, 2020	683	$	683	175	$	(10,677)	$	5,935	$	15,935	$	(4,177)	$	7,699	$	31	$	7,730

	For the three months ended March 31, 2019
	Baxter International Inc. stockholders' equity
	Common stock shares	Common stock		Common stock shares in treasury	Common stock in treasury		Additional contributed capital		Retained earnings		Accumulated other comprehensive income (loss)		Total Baxter stockholders' equity		Noncontrolling interests		Total equity
Balance as of January 1, 2019 (As Restated)	683	$	683	170	$	(9,989)	$	5,898	$	15,075	$	(3,823)	$	7,844	$	22	$	7,866
Adoption of new accounting standards	—	—		—	—		—		161		(161)		—		—		—
Net income	—	—		—	—		—		342		—		342		—		342
Other comprehensive (loss) income	—	—		—	—		—		—		(98)		(98)		—		(98)
Purchases of treasury stock	—	—		8	(586)		—		—		—		(586)		—		(586)
Stock issued under employee benefit plans and other	—	—		(5)	291		(59)		(66)		—		166		—		166
Dividends declared on common stock	—	—		—	—		—		(98)		—		(98)		—		(98)
Change in noncontrolling interests	—	—		—	—		—		—		—		—		1		1
Balance as of March 31, 2019 (As Restated)	683	$	683	173	$	(10,284)	$	5,839	$	15,414	$	(4,082)	$	7,570	$	23	$	7,593

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Baxter International Inc.

Condensed Consolidated Statements of Cash Flows (unaudited)

(in millions)

	Three months ended March 31,
			As Restated
	2020		2019
Cash flows from operations
Net income	$	333	$	342
Adjustments to reconcile net income to cash flows from operations:
Depreciation and amortization	199		192
Deferred income taxes	(17)		(6)
Stock compensation	29		22
Net periodic pension benefit and other postretirement costs	20		3
Other	13		14
Changes in balance sheet items:
Accounts receivable, net	(60)		32
Inventories	(83)		(82)
Accounts payable and accrued liabilities	(110)		(335)
Other	(50)		(48)
Cash flows from operations – continuing operations	274		134
Cash flows from operations – discontinued operations	(2)		(6)
Cash flows from operations	272		128
Cash flows from investing activities
Capital expenditures	(172)		(193)
Acquisitions and investments, net of cash acquired	(443)		(109)
Other investing activities, net	11		1
Cash flows from investing activities	(604)		(301)
Cash flows from financing activities
Issuances of debt	1,240		—
Net increases in debt with original maturities of three months or less	—		795
Cash dividends on common stock	(111)		(101)
Proceeds from stock issued under employee benefit plans	66		173
Purchases of treasury stock	—		(597)
Other financing activities, net	(25)		(32)
Cash flows from financing activities	1,170		238
Effect of foreign exchange rate changes on cash and cash equivalents	(63)		(1)
Increase in cash and cash equivalents	775		64
Cash and cash equivalents at beginning of period	3,335		1,838
Cash and cash equivalents at end of period	$	4,110	$	1,902

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Baxter International Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

1. BASIS OF PRESENTATION

The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we or our) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Annual Report).

In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year.

Certain reclassifications have been made to conform the prior period condensed consolidated statements to the current period presentation.

Risks and Uncertainties Related to COVID-19

Our global operations expose us to risks associated with public health crises and epidemics/pandemics, such as the novel strain of coronavirus (COVID-19). COVID-19 may have an adverse impact on our operations, supply chains and distribution systems and increase our expenses, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking. Due to these impacts and measures, we have experienced and may continue to experience reductions or increases in demand for certain of our products as health care customers re-prioritize the treatment of patients. For example, elective surgeries are being de-prioritized which has negatively impacted the usage of certain of our products, while other of our products are experiencing an increase in demand which we may not be able to meet in accordance with the customer’s desired timing. In addition to travel restrictions, countries have closed borders and imposed prolonged quarantines, often with uncertain duration, which has significantly impacted the ability of our employees to get to their places of work to produce products and may significantly hamper our products from moving through the supply chain. As a result, given the rapid and evolving nature of the virus, COVID-19 could negatively affect our sales, and it is uncertain how COVID-19 will affect our global operations generally if these impacts persist or exacerbate over an extended period of time.

New Accounting Standards

Recently adopted accounting pronouncements

As of January 1, 2020, we adopted Accounting Standards Update (ASU) No. 2016-13, Financial Instruments - Credit Losses, which requires the measurement of expected lifetime credit losses, rather than incurred losses, for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. We adopted this ASU using the modified retrospective approach. The impact of the adoption of this ASU was an increase to our allowance for doubtful accounts and a decrease to retained earnings of $4 million.

7

The following table is a summary of the changes in our allowance for doubtful accounts for the three months ended March 31, 2020:

(in millions)	March 31, 2020
Balance at beginning of period	$	112
Adoption of new accounting standard	4
Charged to costs and expenses	7
Currency translation adjustments	(9)
Balance at end of period	$	114

ASU 2016-13 also requires disclosure by vintage year of origination for net investment in leases. Our net investment in sales-type leases was $127 million as of March 31, 2020, of which $21 million originated in 2016 and prior, $18 million in 2017, $46 million in 2018, $36 million in 2019 and $6 million in 2020.

As of January 1, 2020, we adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Our policies for capitalizing implementation costs incurred in a hosting arrangement were not impacted by this ASU. However, we have historically classified those capitalized costs within property, plant and equipment, net on our condensed consolidated balance sheets and as capital expenditures on our condensed consolidated statements of cash flows. Under the new ASU, those capitalized costs are presented as other non-current assets on our condensed consolidated balance sheets and within operating cash flows on our condensed consolidated statements of cash flows. We adopted this ASU on a prospective basis and capitalized $8 million of implementation costs related to hosting arrangements that are service contracts during the three months ended March 31, 2020.

2. RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

We have restated herein our condensed consolidated financial statements for the three months ended March 31, 2019. We have also restated impacted amounts within the accompanying notes to the consolidated financial statements, as applicable. The restatement of our condensed consolidated financial statements for the three months ended March 31, 2019 was previously reported in our annual report on Form 10-K for the year ended December 31, 2019.

Restatement Background

On October 24, 2019, we reported that we had commenced an internal investigation into certain intra-company transactions that impacted our previously reported non-operating foreign exchange gains and losses. Our internal investigation, as it pertains to the evaluation of related financial statement impacts, is complete.

We previously had applied a longstanding convention for the initial measurement of foreign currency transactions and the subsequent remeasurement of foreign currency denominated monetary assets and liabilities (collectively, our historical exchange rate convention) that was not consistent with U.S. GAAP. U.S. GAAP requires that foreign currency transactions be initially measured and recorded in an entity’s functional currency using the exchange rate on the date of the transaction and it requires that foreign currency denominated monetary assets and liabilities be remeasured at the end of each reporting period using the exchange rate at that date. Under our historical exchange rate convention, all foreign currency transactions in a given month were initially measured using exchange rates from a specified date near the middle of the previous month. Additionally, all foreign currency denominated monetary assets and liabilities were subsequently remeasured at the end of each month using exchange rates from a specified date near the middle of the current month. Beginning years after the adoption of our historical exchange rate convention, certain intra-company transactions were undertaken, after the related exchange rates were already known, solely for the purpose of generating non-operating foreign exchange gains or avoiding foreign exchange losses.

We identified misstatements relating to foreign currency denominated monetary assets and liabilities and foreign currency derivative contracts that caused our Other income (expense), net and Income before income taxes to be overstated by $4 million for the three months ended March 31, 2019. Our quantification of those misstatements to our previously reported foreign exchange gains and losses was not limited to intra-company transactions undertaken for the purpose of generating foreign exchange gains or avoiding foreign exchange losses after the related exchange

8

rates were already known. Rather, we identified every legal entity within our consolidated group that had foreign exchange gains or losses above an immaterial threshold and, for those entities, we remeasured all foreign exchange gains and losses from foreign currency denominated cash balances and intra-company loan receivables and payables using the exchange rates required by U.S. GAAP. For those entities, we also quantified misstatements to our previously reported gains and losses on foreign currency derivative contracts, which had used foreign exchange rates determined under our historical exchange rate convention as inputs to the fair value measurements of those contracts. Our quantification of misstatements to the condensed consolidated financial statements did not include foreign currency gains or losses from short-term third-party and intra-company trade receivables and trade payables denominated in foreign currencies. We determined that any potential misstatements relating to such balances that arise in the ordinary course of business and are ultimately settled for cash within a short period of time, generally thirty to sixty days, would not be material to our condensed consolidated financial statements.

In order to correct our previously issued financial statements, we have restated herein our condensed consolidated financial statements for the three months ended March 31, 2019, in accordance with Accounting Standards Codification (ASC) Topic 250, Accounting Changes and Error Corrections. In addition to the misstatements described above relating to foreign exchange gains and losses, we corrected additional misstatements that were not material, individually or in the aggregate, to our previously issued condensed consolidated financial statements. Those other immaterial misstatements relate to equipment leased to customers under operating leases, classification of foreign currency gains and losses on cash balances and intra-company loan receivables and payables in our condensed consolidated statements of cash flows, translation of the financial position and results of operations of our foreign operations into U.S. dollars, other miscellaneous adjustments, and the income tax effects of those items.

We believe that the use of our historical exchange rate convention to generate non-operating foreign exchange gains and avoid losses had occurred for at least ten years. The cumulative impact of misstatements related to non-operating foreign exchange gains and losses that we corrected for periods earlier than 2019, as well as the cumulative impact of correcting other immaterial misstatements relating to those earlier periods, have been recorded as a reduction to our opening retained earnings as of January 1, 2019.

The categories of misstatements and their impact on our previously issued condensed consolidated financial statements for the three months ended March 31, 2019 are described in more detail below.

Description of Misstatements

Misstatements of Foreign Exchange Gains and Losses

(a) Foreign Currency Denominated Monetary Assets and Liabilities

As discussed above, we recorded adjustments to correct foreign exchange gains and losses on monetary assets and liabilities denominated in a foreign currency to reflect the gains and losses resulting from application of the exchange rates required by U.S. GAAP. The impacts of the foreign currency gain or loss misstatements are discussed in restatement reference (a) throughout this note.

(b) Foreign Currency Derivative Contracts

As discussed above, we recorded adjustments to correct gains and losses on foreign currency derivative contracts by using current exchange rates at the applicable measurement dates as inputs to the related fair value measurements. The impacts of the foreign currency derivative contract gain or loss misstatements are discussed in restatement reference (b) throughout this note.

Additional Misstatements

(c) Equipment Leased to Customers under Operating Leases

Our manufacturing subsidiaries often sell products to commercial subsidiaries within our consolidated group which then sell or lease those products to third-party customers. Under U.S. GAAP, intra-company sales, intra-company cost of sales, and any step-ups in the carrying amount of inventory from intra-company transactions are eliminated in consolidation. If we subsequently sell the products to a third-party customer, the related intra-company profit previously eliminated in consolidation is recognized in our condensed consolidated statements of income. For transactions in which we lease, rather than sell, our products to customers under operating lease arrangements, no profit or loss should be recognized at inception of the arrangement and any intra-company profit previously eliminated

9

in consolidation should be recognized as a reduction to the carrying amount of the related leased assets. Prior to the third quarter of 2019, our international operations incorrectly recognized intra-company profit previously eliminated in consolidation as a reduction of cost of sales, rather than as a reduction of leased assets, at inception of operating lease arrangements. Accordingly, we have recorded adjustments to increase cost of sales and decrease property, plant, and equipment, net in our condensed consolidated financial statements. Those adjustments include corrections of depreciation expense and accumulated depreciation resulting from the decreases to the carrying amounts of the related leased equipment. The impacts of the operating lease misstatements are discussed in restatement reference (c) throughout this note.

(d) Classification of Foreign Currency Gains and Losses in our Condensed Consolidated Statements of Cash Flows

We previously included foreign exchange gains and losses related to intra-company receivables and payables and cash balances within our cash flows from operations. In the accompanying condensed consolidated statements of cash flows, foreign exchange gains and losses, as restated, related to intra-company receivables and payables and cash balances are presented as reconciling items between income from continuing operations and cash flows from operations. The impacts of those misclassifications on our operating cash flows are discussed in restatement reference (d) throughout this note.

(e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars

U.S. GAAP specifies that the income statement of a foreign operation should be translated into the reporting currency using the exchange rates on the dates the income or expense was recognized and indicates that the use of weighted-average exchange rates during the period is generally appropriate. Similar to our convention for the initial measurement of foreign currency transactions, we historically translated the results of operations of our foreign operations for a given month into U.S. dollars using exchange rates from a specified date near the middle of the previous month. Accordingly, we have recorded adjustments to translate the income statements of our foreign operations into U.S. dollars using the applicable average foreign exchange rates for each month.

U.S. GAAP specifies that the assets and liabilities of foreign operations be translated into the reporting currency at the end of each reporting period using the exchange rate at that date. Similar to our convention for the subsequent remeasurement of foreign currency denominated monetary assets and liabilities, our financial reporting systems were previously configured to translate assets and liabilities at the end of each month using exchange rates from a specified date near the middle of the current month. In recent years, we separately computed the impact of translating assets and liabilities at period-end exchange rates and adjusted our condensed consolidated balance sheets to reflect that difference. However, due to an incorrect input in those manual calculations as of December 31, 2018, the currency translation adjustments component of our other comprehensive income (loss) was misstated in our condensed consolidated statement of comprehensive income (loss) for the three months ended March 31, 2019.

The impacts of misstatements related to the translation of the financial position and results of operations of our foreign operations are discussed in restatement reference (e) throughout this note.

(f) Other Miscellaneous Adjustments

We recorded adjustments to correct other out-of-period items and previously uncorrected misstatements that were not material, individually or in the aggregate, to our condensed consolidated financial statements. Those other misstatements were primarily related to a historical restructuring liability and amounts related to our separation of Baxalta in 2015. The impacts of the other miscellaneous adjustments are discussed in restatement reference (f) throughout this note.

Description of Restatement Tables

The following tables were previously presented in our Annual Report on Form 10-K for the year ended December 31, 2019. See Note 19, Quarterly Financial Data (unaudited), to the consolidated financial statements in our Annual Report on Form 10-K. Below, we have presented reconciliations from our prior periods as previously reported to the restated amounts for each of our condensed consolidated financial statements for the three months ended March 31, 2019. The amounts as previously reported were derived from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 7, 2019.

10

Baxter International Inc.
Condensed Consolidated Statement of Income
(in millions, except per share)
	Three months ended March 31, 2019
	As previously reported		Restatement impacts		Restatement reference	As restated
Net sales	$	2,632	$	6	(e)	$	2,638
Cost of sales	1,552		6		(c)(e)	1,558
Gross margin	1,080		—			1,080
Selling, general and administrative expenses	600		1		(e)	601
Research and development expenses	129		—			129
Other operating income, net	(33)		—			(33)
Operating income	384		(1)			383
Interest expense, net	18		—			18
Other (income) expense, net	(25)		4		(a)(b)	(21)
Income before income taxes	391		(5)			386
Income tax expense	44		—			44
Net income	$	347	$	(5)		$	342
Earnings per share
Basic	$	0.68	$	(0.01)		$	0.67
Diluted	$	0.66	$	—		$	0.66
Weighted-average number of shares outstanding
Basic	512		—			512
Diluted	522		—			522

(a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in a decrease to other (income) expense, net of $5 million for the three months ended March 31, 2019.

(b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in an increase to other (income) expense, net of $1 million for the three months ended March 31, 2019.

(c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in an increase to cost of sales of $2 million for the three months ended March 31, 2019.

(e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to net sales of $6 million, cost of sales of $4 million and selling, general and administrative (SG&A) expense of $1 million for the three months ended March 31, 2019.

11

Baxter International Inc.
Condensed Consolidated Statement of Comprehensive Income
(in millions)
	Three months ended March 31, 2019
	As previously reported		Restatement impacts		As restated
Net income	$	347	$	(5)	$	342
Other comprehensive (loss) income, net of tax:
Currency translation adjustments	30		(127)		(97)
Pension and other postretirement benefit plans	8		6		14
Hedging activities	(15)		—		(15)
Total other comprehensive loss, net of tax	23		(121)		(98)
Comprehensive income	$	370	$	(126)	$	244

The $5 million decrease to net income was driven by the items described above in the condensed consolidated statement of income for the three months ended March 31, 2019 section.

The $127 million decrease to currency translation adjustments for the three months ended March 31, 2019 is comprised of a $132 million decrease to correct the foreign exchange rates used to translate the financial position and results of operations of our foreign operations into U.S. dollars partially offset by a $5 million increase from the offsetting balance sheet impact of the adjustments to foreign exchange gains and losses on intra-company receivables and payables.

The $6 million increase to pension and other postretirement benefit plans for the three months ended March 31, 2019 is a result of the correction of the foreign exchange rates used to translate the financial position and results of operations of our foreign operations into U.S. dollars.

12

Baxter International Inc.
Condensed Consolidated Statement of Changes in Equity
(in millions)
	For the Three Months Ended March 31, 2019
	Baxter International Inc. stockholders' equity
	Common stock shares	Common stock		Common stock shares in treasury	Common stock in treasury		Additional contributed capital		Retained earnings		Accumulated other comprehensive income (loss)		Total Baxter stockholders' equity		Noncontrolling interests		Total equity
As previously reported
Balance as of January 1, 2019	683	$	683	170	$	(9,989)	$	5,898	$	15,626	$	(4,424)	$	7,794	$	22	$	7,816
Adoption of new accounting standards	—	—		—	—		—		161		(161)		—		—		—
Net income	—	—		—	—		—		347		—		347		—		347
Other comprehensive income (loss)	—	—		—	—		—		—		23		23		—		23
Purchases of treasury stock	—	—		8	(586)		—		—		—		(586)		—		(586)
Stock issued under employee benefit plans and other	—	—		(5)	291		(59)		(66)		—		166		—		166
Dividends declared on common stock	—	—		—	—		—		(98)		—		(98)		—		(98)
Changes in noncontrolling interests	—	—		—	—		—		—		—		—		1		1
Balance as of March 31, 2019	683	$	683	173	$	(10,284)	$	5,839	$	15,970	$	(4,562)	$	7,646	$	23	$	7,669
Restatement impacts
Balance as of January 1, 2019	—	$	—	—	$	—	$	—	$	(551)	$	601	$	50	$	—	$	50
Net income	—	—		—	—		—		(5)		—		(5)		—		(5)
Other comprehensive income (loss)	—	—		—	—		—		—		(121)		(121)		—		(121)
Balance as of March 31, 2019	—	$	—	—	$	—	$	—	$	(556)	$	480	$	(76)	$	—	$	(76)
As restated
Balance as of January 1, 2019	683	$	683	170	$	(9,989)	$	5,898	$	15,075	$	(3,823)	$	7,844	$	22	$	7,866
Adoption of new accounting standards	—	—		—	—		—		161		(161)		—		—		—
Net income	—	—		—	—		—		342		—		342		—		342
Other comprehensive income (loss)	—	—		—	—		—		—		(98)		(98)		—		(98)
Purchases of treasury stock	—	—		8	(586)		—		—		—		(586)		—		(586)
Stock issued under employee benefit plans and other	—	—		(5)	291		(59)		(66)		—		166		—		166
Dividends declared on common stock	—	—		—	—		—		(98)		—		(98)		—		(98)
Changes in noncontrolling interests	—	—		—	—		—		—		—		—		1		1
Balance as of March 31, 2019	683	$	683	173	$	(10,284)	$	5,839	$	15,414	$	(4,082)	$	7,570	$	23	$	7,593

The adjustments to the January 1, 2019 retained earnings and accumulated other comprehensive loss represent the cumulative impacts of foreign exchange gains and losses and the translation of our financial position and results of operations for our foreign operations into U.S. dollars for the periods prior to January 1, 2019. Retained earnings also includes the cumulative impacts of equipment leased to customers under operating leases and other miscellaneous adjustments for the periods prior to January 1, 2019.

See descriptions of the net income and other comprehensive income impacts in the condensed consolidated statement of income and condensed consolidated statement of comprehensive income for the three months ended March 31, 2019 sections above.

13

Baxter International Inc.
Condensed Consolidated Statement of Cash Flows
(in millions)
	For the Three Months Ended March 31, 2019
	As previously reported		Restatement impacts		Restatement reference	As restated
Cash flows from operations
Net income	$	347	$	(5)		$	342
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	195		(3)		(c)	192
Deferred income taxes	(6)		—			(6)
Stock compensation	22		—			22
Net periodic pension benefit and other postretirement costs	3		—			3
Other	19		(5)		(d)	14
Changes in balance sheet items:
Accounts receivable, net	32		—			32
Inventories	(82)		—			(82)
Accounts payable and accrued liabilities	(333)		(2)		(b)(f)	(335)
Other	(49)		1		(b)(e)(f)	(48)
Cash flows from operations - continuing operations	148		(14)			134
Cash flows from operations - discontinued operations	(6)		—			(6)
Cash flows from operations	142		(14)			128
Cash flows from investing activities
Capital expenditures	(198)		5		(c)	(193)
Acquisitions and investments, net of cash acquired	(109)		—			(109)
Other investing activities, net	1		—			1
Cash flows from investing activities	(306)		5			(301)
Cash flows from financing activities
Net increases in debt obligations with original maturities of three months or less	795		—			795
Cash dividends on common stock	(101)		—			(101)
Proceeds from stock issued under employee benefit plans	173		—			173
Purchases of treasury stock	(597)		—			(597)
Other financing activities, net	(32)		—			(32)
Cash flows from financing activities	238		—			238
Effect of foreign exchange rate changes on cash and cash equivalents	2		(3)		(a)(d)(e)	(1)
Increase (decrease) in cash and cash equivalents	76		(12)			64
Cash and cash equivalents at beginning of period	1,832		6		(e)	1,838
Cash and cash equivalents at end of period	$	1,908	$	(6)	(e)	$	1,902

14

The $5 million decrease to net income was driven by the items described above in the condensed consolidated statement of income for the three months ended March 31, 2019 section.

(a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in an increase to the effect of foreign exchange rate changes on cash and cash equivalents of $4 million for the three months ended March 31, 2019.

(b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in a decrease to changes in accounts payable and accrued liabilities of $1 million and an increase in other changes in balance sheet items of $1 million for the three months ended March 31, 2019.

(c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to depreciation and amortization of $3 million and capital expenditures of $5 million for the three months ended March 31, 2019.

(d) Classification of Foreign Currency Gains and Losses in our Consolidated Statements of Cash Flows—The corrections of these misstatements resulted in an increase to the effect of foreign exchange rate changes on cash and cash equivalents and a decrease to other adjustments to reconcile net income to net cash from operating activities of $5 million for the three months ended March 31, 2019.

(e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The corrections of these misstatements resulted in an increase in cash and cash equivalents at the beginning of the period of $6 million and decreases to other changes in balance sheet items of $1 million, cash and cash equivalents at the end of the period of $6 million and the effect of foreign exchange rate changes on cash and cash equivalents of $12 million for the three months ended March 31, 2019.

(f) Other miscellaneous adjustments—The correction of these misstatements resulted in an increase to other changes in balance sheet items of $1 million and a decrease in changes in accounts payable and accrued liabilities of $1 million for the three months ended March 31, 2019.

3. ACQUISITIONS AND OTHER ARRANGEMENTS

Seprafilm Adhesion Barrier

In February 2020, we acquired the product rights to Seprafilm Adhesion Barrier (Seprafilm) from Sanofi. The transaction closed in February 2020 and we paid approximately $342 million in cash for the acquired assets. Seprafilm is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera such as omentum, small bowel, bladder, and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel, and bladder. We concluded that the acquired assets met the definition of a business and accounted for the transaction as a business combination using the acquisition method of accounting.

The following table summarizes the fair values of the assets acquired as of the acquisition date:

(in millions)
Assets acquired
Inventories	$	16
Goodwill	29
Other intangible assets	297
Total assets acquired	$	342

The valuation of the assets acquired are preliminary and measurement period adjustments may be recorded in the future as we finalize our fair value estimates. The results of operations of the acquired business have been included in our condensed consolidated statement of income since the date the business was acquired. The acquisition contributed $13 million of net sales for the three months ended March 31, 2020. Net earnings from the acquisition were not significant during the three months ended March 31, 2020 and included acquisition and integration costs, primarily incremental cost of sales relating to inventory fair value step-ups, of $9 million.

15

We allocated $287 million and $10 million of the total consideration to the Seprafilm developed product rights and customer relationships with useful lives of 10 and 7 years, respectively. The fair values of the intangible assets were determined using the income approach. The discount rates used to measure the developed product rights and customer relationship intangible assets were 14.8% and 11.0%, respectively. We consider the fair value of the intangible assets to be Level 3 measurements due to the significant estimates and assumptions used by management in establishing the estimated fair values.

The goodwill, which is deductible for tax purposes, includes the value of potential future indications as well as the overall strategic benefits provided to our product portfolio of hemostats and sealants and is included in the Americas and APAC segments.

Other Business Combinations

We completed other individually immaterial acquisitions in the three months ended March 31, 2020 for total consideration of $13 million in cash at closing plus aggregate future potential contingent consideration of up to $12 million with an acquisition date fair value of $4 million. The acquisitions primarily resulted in the recognition of goodwill and other intangible assets.

We have not presented pro forma financial information for any of our acquisitions because their results are not material to our condensed consolidated financial statements.

Other Business Development Activities

In January 2020, we acquired the U.S. rights to an additional product for $60 million. The purchase price was capitalized as a developed-technology intangible asset in the quarter ended March 31, 2020 and is being amortized over its estimated useful life of 11 years.

In the three months ended March 31, 2020, we entered into distribution license arrangements for multiple products that have not yet obtained regulatory approval for upfront cash payments of $21 million. The cash paid was treated as research and development (R&D) expenses on our condensed consolidated statement of income. We could make additional payments of up to $41 million upon the achievement of certain development, regulatory or commercial milestones.

4. SUPPLEMENTAL FINANCIAL INFORMATION

Interest Expense, Net

	Three months ended March 31,
(in millions)	2020		2019
Interest expense, net of capitalized interest	$	30	$	25
Interest income	(9)		(7)
Interest expense, net	$	21	$	18

Other (Income) Expense, Net

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Foreign exchange losses (gains), net	$	11	$	(1)
Pension and other postretirement benefit plans	(1)		(15)
Other, net	—		(5)
Other (income) expense, net	$	10	$	(21)

16

Inventories

(in millions)	March 31, 2020		December 31, 2019
Raw materials	$	402	$	377
Work in process	188		185
Finished goods	1,104		1,091
Inventories	$	1,694	$	1,653

Property, Plant and Equipment, Net

(in millions)	March 31, 2020		December 31, 2019
Property, plant and equipment, at cost	$	10,443	$	10,660
Accumulated depreciation	(6,103)		(6,148)
Property, plant and equipment, net	$	4,340	$	4,512

Non-Cash Operating and Investing Activities

Right-of-use operating lease assets obtained in exchange for lease obligations for the three months ended March 31, 2020 and 2019 were $15 million and $42 million, respectively.

Purchases of property, plant and equipment included in accounts payable and accrued liabilities as of March 31, 2020 and 2019 was $49 million and $39 million, respectively.

5. GOODWILL AND OTHER INTANGIBLE ASSETS, NET

Goodwill

The following is a reconciliation of goodwill by business segment.

(in millions)	Americas		EMEA		APAC		Total
Balance as of December 31, 2019	$	2,428	$	385	$	217	$	3,030
Acquisitions	32		—		7		39
Currency translation adjustments	(86)		(14)		(8)		(108)
Balance as of March 31, 2020	$	2,374	$	371	$	216	$	2,961

As of March 31, 2020, there were no reductions in goodwill relating to impairment losses.

Other intangible assets, net

The following is a summary of our other intangible assets.

(in millions)	Developed technology, including patents		Other amortized intangible assets		Indefinite-lived intangible assets		Total
March 31, 2020
Gross other intangible assets	$	2,612	$	461	$	179	$	3,252
Accumulated amortization	(1,209)		(284)		—		(1,493)
Other intangible assets, net	$	1,403	$	177	$	179	$	1,759
December 31, 2019
Gross other intangible assets	$	2,309	$	464	$	173	$	2,946
Accumulated amortization	(1,190)		(285)		—		(1,475)
Other intangible assets, net	$	1,119	$	179	$	173	$	1,471

Intangible asset amortization expense was $52 million and $43 million for the three months ended March 31, 2020 and 2019, respectively.

17

6. FINANCING ARRANGEMENTS

Debt Issuance

In March 2020, we issued $750 million of 3.75% senior notes due in March 2025 and $500 million of 3.95% senior notes due in March 2030 (collectively, the senior notes). Pursuant to a registration rights agreement (the Registration Rights Agreement) with the initial purchasers of the senior notes, we agreed to use our commercially reasonable efforts to file a registration statement with respect to a registered offer to exchange the senior notes for new notes with terms substantially identical in all material respects to the senior notes and to have such registration statement declared effective under the U.S. Securities Act of 1933. If we fail to have such registration statement declared effective by September 17, 2021 (a registration default), the annual interest rate on the senior notes would increase by 0.25% for the 90-day period immediately following such registration default and by an additional 0.25% thereafter. The maximum additional interest rate is 0.50% per annum and if a registration default is corrected, the senior notes would revert to the original interest rates. The payment of additional interest is the sole remedy for the holders of the senior notes in the event of a registration default.

Credit Facilities

As of March 31, 2020 and December 31, 2019, we had €200 million ($220 million and $224 million, respectively) outstanding under our Euro-denominated credit facility at a 0.91% interest rate and no borrowings outstanding under our U.S. dollar-denominated credit facility.

7. COMMITMENTS AND CONTINGENCIES

We are involved in product liability, patent, commercial, and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of March 31, 2020 and December 31, 2019, our total recorded reserves with respect to legal and environmental matters were $53 million and $56 million, respectively, and there were no related receivables.

We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims.

In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.

Environmental

We are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from the Superfund cases noted above, we are involved in an ongoing voluntary environmental remediation associated with historic operations at our Irvine, California, United States facility. As of March 31, 2020 and December 31, 2019, our environmental reserves, which are measured on an undiscounted basis, were $18 million. After considering these reserves, management is of the opinion that the outcome of these matters will not have a material adverse effect on our financial position or results of operations.

18

General Litigation

In November 2016, a putative antitrust class action complaint seeking monetary and injunctive relief was filed in the United States District Court for the Northern District of Illinois. The complaint alleges a conspiracy among manufacturers of IV solutions to restrict output and affect pricing in connection with a shortage of such solutions. Similar parallel actions subsequently were filed. In January 2017, a single consolidated complaint covering these matters was filed in the Northern District of Illinois. We filed a motion to dismiss the consolidated complaint in February 2017. The court granted our motion to dismiss the consolidated complaint without prejudice in July 2018. The plaintiffs filed an amended complaint, which we moved to dismiss on November 9, 2018. The court granted our motion to dismiss the amended complaint with prejudice on April 3, 2020.

In April 2017, we became aware of a criminal investigation by the U.S. Department of Justice (DOJ), Antitrust Division and a federal grand jury in the United States District Court for the Eastern District of Pennsylvania. We and an employee received subpoenas seeking production of documents and testimony regarding the manufacturing, selling, pricing and shortages of IV solutions and containers (including saline solutions and certain other injectable medicines sold by us) and communications with competitors regarding the same. On November 30, 2018, the DOJ notified us that it had closed the investigation. The New York Attorney General has also requested that we provide information regarding business practices in the IV saline industry. We have cooperated with the New York Attorney General.

In August 2019, we were named in an amended complaint filed by Fayette County, Georgia in the MDL In re: National Prescription Opiate Litigation pending in the U.S. District Court, Northern District of Ohio. The complaint alleges that multiple manufacturers and distributors of opiate products improperly marketed and diverted these products, which caused harm to Fayette County. The complaint is limited in its allegations as to Baxter and does not distinguish between injectable opiate products and orally administered opiates. We manufactured generic injectable opiate products in our facility in Cherry Hill, NJ, which we divested in 2011.

In November 2019, we and certain of our officers were named in a class action complaint captioned Ethan E. Silverman et al. v. Baxter International Inc. et al. that was filed in the United States District Court for the Northern District of Illinois. The plaintiff, who allegedly purchased shares of our common stock during the specified class period, filed this putative class action on behalf of himself and shareholders who acquired Baxter common stock between February 21, 2019 and October 23, 2019. The plaintiff alleges that we and certain officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by making allegedly false and misleading statements and failing to disclose material facts relating to certain intra-company transactions undertaken for the purpose of generating foreign exchange gains or avoiding foreign exchange losses, as well as our internal controls over financial reporting. On January 29, 2020, the Court appointed Varma Mutual Pension Insurance Company and Louisiana Municipal Police Employees Retirement System as lead plaintiffs in the case. In addition, we have received a stockholder request for inspection of our books and records in connection with the announcement made in our Form 8-K on October 24, 2019 that we had commenced an internal investigation into certain intra-company transactions that impacted our previously reported non-operating foreign exchange gains and losses. As initially disclosed on October 24, 2019, we also voluntarily advised the staff of the SEC of our internal investigation and we are continuing to cooperate with the staff of the SEC.

In March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products. The plaintiffs seek damages, including compensatory and punitive damages in an unspecified amount, and unspecified injunctive and declaratory relief.

Other

As previously disclosed, in 2008 we recalled our heparin sodium injection products in the United States. Following the recall, more than 1,000 lawsuits alleging that plaintiffs suffered various reactions to a heparin contaminant, in some cases resulting in fatalities, were filed. In January 2019, the last of these cases was settled. In the first three months of 2019, following the resolution of an insurance dispute, we received cash proceeds of $35 million for our allocation of the insurance proceeds under a settlement and cost-sharing agreement related to the defense of the heparin product liability cases. We recognized a $33 million gain in connection with the resolution of the dispute with the insurer that is classified within other operating income, net on the condensed consolidated statement of income for the three months ended March 31, 2019.

19

8. STOCKHOLDERS’ EQUITY

Stock-Based Compensation

Stock compensation expense totaled $29 million and $22 million in the first quarter of 2020 and 2019, respectively. Approximately 70% of stock compensation expense is classified within SG&A expense with the remainder classified in cost of sales and R&D expense.

We awarded stock compensation grants which consisted of 3.7 million stock options, 0.5 million restricted stock units (RSUs) and 0.4 million performance stock units (PSUs) during the first quarter of 2020. The grant date fair values of stock options, RSUs and PSUs awarded in the first quarter of 2020 were $59 million, $37 million and $29 million, respectively. Stock options and RSUs generally vest in one-third increments over a three-year period. One-fourth of the PSUs granted related to the establishment of the adjusted operating margin vesting condition for awards issued in 2018 and 2019 whereas the remainder were related to awards made in March 2020, which are equally divided into PSUs based on our compound annual sales growth rate performance, our adjusted return on invested capital performance and on our stock performance relative to our peer group. All of the PSUs granted vest at the end of the applicable three-year service period.

Stock Options

The weighted-average Black-Scholes assumptions used in establishing the fair value of stock options granted during the period, along with weighted-average grant date fair values, were as follows:

	Three months ended March 31,
	2020			2019
Expected volatility	26		%	19		%
Expected life (in years)	5.5			5.5
Risk-free interest rate	0.6		%	2.6		%
Dividend yield	1.2		%	1.0		%
Fair value per stock option	$	16		$	15

The total intrinsic value of stock options exercised was $52 million and $153 million during the first quarters of 2020 and 2019, respectively.

As of March 31, 2020, the unrecognized compensation cost related to all unvested stock options of $103 million is expected to be recognized as expense over a weighted-average period of 2.1 years.

RSUs

As of March 31, 2020, the unrecognized compensation cost related to all unvested RSUs of $73 million is expected to be recognized as expense over a weighted-average period of 2.0 years.

PSUs

As of March 31, 2020, the unrecognized compensation cost related to all unvested PSUs of $44 million is expected to be recognized as expense over a weighted-average period of 2.1 years.

Stock Options Award Modification

In the first quarter of 2020, we modified the terms of stock option awards granted to 123 employees. Specifically, we extended the term for certain stock options that were scheduled to expire in the first quarter of 2020 as applicable employees were not permitted to exercise these awards due to our announcement in February 2020 that our previously issued financial statements should no longer be relied upon. The stock options were extended in order to allow impacted employees to exercise their stock option awards for a brief period once we became current with our

20

SEC reporting obligations, which occurred in March 2020. As a result of the modifications, we recognized an additional $8 million of stock compensation expense during the quarter ended March 31, 2020.

Cash Dividends

Cash dividends declared per share for the three months ended March 31, 2020 and March 31, 2019 were $0.22 and $0.19, respectively.

Stock Repurchase Programs

In July 2012, the Board of Directors authorized the repurchase of up to $2.0 billion of our common stock. The Board of Directors increased this authority by an additional $1.5 billion in each of November 2016 and February 2018 and by an additional $2.0 billion in November 2018. During the first quarter of 2020, we did not repurchase any shares under this authority. During the first quarter of 2019, we repurchased 8.1 million shares pursuant to Rule 10b5-1 plans. We had $897 million remaining available under the authorization as of March 31, 2020.

9. ACCUMULATED OTHER COMPREHENSIVE INCOME

Comprehensive income includes all changes in stockholders’ equity that do not arise from transactions with stockholders, and consists of net income, currency translation adjustments (CTA), certain gains and losses from pension and other postretirement employee benefit (OPEB) plans and gains and losses on cash flow hedges.

The following table is a net-of-tax summary of the changes in AOCI by component for the three months ended March 31, 2020 and 2019.

(in millions)	CTA		Pension and OPEB plans		Hedging activities		Total
Gains (losses)
Balance as of December 31, 2019	$	(2,954)	$	(715)	$	(41)	$	(3,710)
Other comprehensive income (loss) before reclassifications	(359)		10		(131)		(480)
Amounts reclassified from AOCI (a)	—		12		1		13
Net other comprehensive income (loss)	(359)		22		(130)		(467)
Balance as of March 31, 2020	$	(3,313)	$	(693)	$	(171)	$	(4,177)

	As Restated
(in millions)	CTA		Pension and OPEB plans		Hedging activities		Total
Gains (losses)
Balance as of December 31, 2018	$	(2,868)	$	(954)	$	(1)	$	(3,823)
Adoption of new accounting standard	9		(169)		(1)		(161)
Other comprehensive income (loss) before reclassifications	(97)		7		(15)		(105)
Amounts reclassified from AOCI (a)	—		7		—		7
Net other comprehensive income (loss)	(97)		14		(15)		(98)
Balance as of March 31, 2019	$	(2,956)	$	(1,109)	$	(17)	$	(4,082)

(a) See table below for details about these reclassifications.

21

The following is a summary of the amounts reclassified from AOCI to net income during the three months ended March 31, 2020 and 2019.

	Amounts reclassified from AOCI (a)
			As Restated
(in millions)	Three months ended March 31, 2020		Three months ended March 31, 2019		Location of impact in income statement
Amortization of pension and OPEB items
Amortization of net losses and prior service costs or credits	$	(15)	$	(8)	Other (income) expense, net
Less: Tax effect	3		1		Income tax expense
	$	(12)	$	(7)	Net of tax
Gains on hedging activities
Foreign exchange contracts	$	(1)	$	—	Cost of sales
Less: Tax effect	—		—		Income tax expense
	$	(1)	$	—	Net of tax
Total reclassifications for the period	$	(13)	$	(7)	Total net of tax

(a) Amounts in parentheses indicate reductions to net income.

Refer to Note 12 for additional information regarding the amortization of pension and OPEB items and Note 15 for additional information regarding hedging activity.

10. REVENUES

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30-90 days.

The majority of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our geographic segments including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. For a majority of these sales, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.

To a lesser extent, in all of our segments, we enter into other types of contracts including contract manufacturing arrangements, equipment leases, and certain subscription software and licensing arrangements. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.

On March 31, 2020, we had $8.2 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more, which are primarily included in the Americas segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 20% of this amount as revenue over the remainder of 2020, 25% in 2021, 20% in each of 2022 and 2023, 5% in each of 2024 and 2025, and the remaining balance thereafter.

Significant Judgments

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration related to rebates, product returns, sales discounts and wholesaler chargebacks. These

22

reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accounts receivable, net and accounts payable and accrued liabilities on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. Revenue recognized during the three months ended March 31, 2020 and 2019 related to performance obligations satisfied in prior periods was not material.

Contract Balances

The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable was $1.7 billion and $1.8 billion as of March 31, 2020 and December 31, 2019, respectively.

For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are provided and billed, generally over one to seven years. Our contract asset balances totaled $133 million as of March 31, 2020, of which $37 million related to contract manufacturing services, $47 million related to software sales and $49 million related to bundled equipment and consumable medical products contracts. Our contract asset balances totaled $131 million as of December 31, 2019, of which $36 million related to contract manufacturing services, $43 million related to software sales and $52 million related to bundled equipment and consumable medical products contracts. Contract assets are presented within accounts receivable, net ($66 million and $63 million as of March 31, 2020 and December 31, 2019, respectively) and other non-current assets ($67 million and $68 million as of March 31, 2020 and December 31, 2019, respectively) in the accompanying condensed consolidated balance sheets. Contract liabilities as of March 31, 2020 and December 31, 2019 were $19 million and $12 million, respectively, and were included in accounts payable and other accrued liabilities ($7 million as of March 31, 2020) and other non-current liabilities ($12 million as of March 31, 2020 and December 31, 2019, respectively) in the accompanying condensed consolidated balance sheets.

23

Disaggregation of Net Sales

The following tables disaggregate our net sales from contracts with customers by Global Business Unit (GBU) between the U.S. and international:

	Three months ended March 31,
							As Restated
	2020						2019
(in millions)	U.S.		International		Total		U.S.		International		Total
Renal Care 1	$	204	$	666	$	870	$	192	$	662	$	854
Medication Delivery 2	461		229		690		406		228		634
Pharmaceuticals 3	231		296		527		232		278		510
Clinical Nutrition 4	82		138		220		77		128		205
Advanced Surgery 5	137		87		224		120		79		199
Acute Therapies 6	60		96		156		48		81		129
Other 7	42		73		115		45		62		107
Total Baxter	$	1,217	$	1,585	$	2,802	$	1,120	$	1,518	$	2,638

1Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.

2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.

3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.

4Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.

5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.

6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).

7Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.

Lease Revenue

We lease medical equipment, such as renal dialysis equipment and infusion pumps, to customers, primarily in conjunction with arrangements to provide consumable medical products such as dialysis therapies, IV fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices.

The components of lease revenue for the three months ended March 31, 2020 and March 31, 2019 were:

(in millions)	Three months ended March 31, 2020		Three months ended March 31, 2019
Sales-type lease revenue	$	6	$	6
Operating lease revenue	14		15
Variable lease revenue	18		21
Total lease revenue	$	38	$	42

11. BUSINESS OPTIMIZATION CHARGES

In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. From the commencement of our business optimization activities in the second half of 2015 through March 31, 2020, we have incurred cumulative pre-tax costs of $1.0 billion related to these actions. The costs consisted primarily of employee termination costs, implementation costs, asset impairments and accelerated depreciation. We currently expect to incur additional pre-tax costs of approximately $30 million through the completion of these initiatives under

24

our current program. These costs will primarily include employee termination costs, implementation costs, and accelerated depreciation. To the extent further cost savings opportunities are identified, we may incur additional business optimization expenses.

During the three months ended March 31, 2020 and 2019, we recorded the following charges related to business optimization programs.

	Three months ended March 31,
(in millions)	2020		2019
Restructuring charges	$	25	$	25
Costs to implement business optimization programs	7		10
Accelerated depreciation	—		3
Total business optimization charges	$	32	$	38

For segment reporting purposes, business optimization charges are unallocated expenses.

Costs to implement business optimization programs for the three months ended March 31, 2020 and 2019, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. The costs were generally included within cost of sales, SG&A expense and R&D expense.

For the three months ended March 31, 2019, we recognized accelerated depreciation, primarily associated with facilities to be closed. The costs were recorded within cost of sales and SG&A expense.

During the three months ended March 31, 2020 and 2019, we recorded the following restructuring charges.

	Three months ended March 31, 2020
(in millions)	COGS		SG&A		R&D		Total
Employee termination costs	$	2	$	16	$	1	$	19
Asset impairments	6		—		—		6
Total restructuring charges	$	8	$	16	$	1	$	25

	Three months ended March 31, 2019
(in millions)	COGS		SG&A		R&D		Total
Employee termination costs	$	—	$	(1)	$	9	$	8
Contract termination costs	7		—		—		7
Asset impairments	9		1		—		10
Total restructuring charges	$	16	$	—	$	9	$	25

In conjunction with our business optimization initiatives, we sold property that resulted in a gain of $17 million. This benefit is reflected within other operating income, net in our condensed consolidated statement of income for the three months ended March 31, 2020.

The following table summarizes activity in the liability related to our restructuring initiatives.

(in millions)
Liability balance as of December 31, 2019	$	92
Charges	19
Payments	(21)
Currency translation	(2)
Liability balance as of March 31, 2020	$	88

Substantially all of our restructuring liabilities as of March 31, 2020 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2020.

25

12. PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS

The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Pension benefits
Service cost	$	21	$	18
Interest cost	24		47
Expected return on plan assets	(41)		(72)
Amortization of net losses and prior service costs	19		15
Net periodic pension benefit cost	$	23	$	8
OPEB
Interest cost	$	1	$	2
Amortization of net loss and prior service credit	(4)		(7)
Net periodic OPEB cost (income)	$	(3)	$	(5)

13. INCOME TAXES

Our effective income tax rate was 11.9% and 11.4% for the three months ended March 31, 2020 and 2019, respectively. Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, increases or decreases in valuation allowances and liabilities for uncertain tax positions and excess tax benefits on stock compensation awards.

For the three months ended March 31, 2020, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a favorable geographic earnings mix and excess tax benefits on stock compensation awards.

For the three months ended March 31, 2019, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to excess tax benefits on stock compensation awards.

14. EARNINGS PER SHARE

The numerator for both basic and diluted earnings per share (EPS) is net income. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.

The following table is a reconciliation of basic shares to diluted shares.

	Three months ended March 31,
(in millions)	2020	2019
Basic shares	507	512
Effect of dilutive securities	9	10
Diluted shares	516	522

The effect of dilutive securities included unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excluded 1 million and 4 million equity awards for the three months ended March 31, 2020 and 2019, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS. Refer to Note 8 for additional information regarding items impacting basic and diluted shares.

26

15. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs.

We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Chinese Yuan, Korean Won, Australian Dollar, Canadian Dollar, Japanese Yen, Colombian Peso, Brazilian Real, Mexican Peso and Swedish Krona. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce the net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.

We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using a mix of fixed- and floating-rate debt that we believe is appropriate. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.

We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features.

All derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value, or net investment hedges.

Cash Flow Hedges

We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt.

For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted third-party sales denominated in foreign currencies, forecasted intra-company sales denominated in foreign currencies, and anticipated issuances of debt, respectively.

The notional amounts of foreign exchange contracts designated as cash flow hedges were $583 million and $617 million as of March 31, 2020 and December 31, 2019, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at March 31, 2020 is 12 months for foreign exchange contracts. The total notional amounts of interest rate contracts designated as cash flow hedges were $550 million as of March 31, 2020 and December 31, 2019, respectively. The interest rate contracts have maturity dates in 2022 and hedge the variability in future benchmark interest payments attributable to changes in interest rates on the forecasted issuance of fixed-rate debt.

Fair Value Hedges

We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Fair value

27

hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt.

There were no outstanding interest rate swap contracts designated as fair value hedges as of March 31, 2020 and December 31, 2019.

Net Investment Hedges

In May 2017, we issued €600 million of senior notes due May 2025. In May 2019, we issued €750 million of senior notes due May 2024 and €750 million of senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI. As of March 31, 2020, we had an accumulated pre-tax unrealized translation gain in AOCI of $28 million related to the Euro-denominated senior notes.

Dedesignations

If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged items. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings.

There were no hedge dedesignations in the first three months of 2020 or 2019 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur.

If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first three months of 2020 or 2019.

If we remove a net investment hedge designation, any gains or losses recognized in AOCI are not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged.

Undesignated Derivative Instruments

We use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month.

The total notional amount of undesignated derivative instruments was $824 million as of March 31, 2020 and $619 million as of December 31, 2019.

Gains and Losses on Hedging Instruments

The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended March 31, 2020 and 2019.

	Gain (loss) recognized in OCI				Location of gain (loss) in income statement	Gain (loss) reclassified from AOCI into income
(in millions)	2020		2019			2020		2019
Cash flow hedges
Interest rate contracts	$	(184)	$	(11)	Interest expense, net	$	—	$	—
Foreign exchange contracts	14		(9)		Cost of sales	(1)		—
Net investment hedges	49		14		Other (income) expense, net	—		—
Total	$	(121)	$	(6)		$	(1)	$	—

28

	Location of gain (loss) in income statement	Gain (loss) recognized in income
				As Restated
(in millions)		2020		2019
Undesignated derivative instruments
Foreign exchange contracts	Other (income) expense, net	$	2	$	(8)

As of March 31, 2020, $6 million of deferred, net after-tax gains on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings.

Derivative Assets and Liabilities

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2020.

	Derivatives in asset positions			Derivatives in liability positions
(in millions)	Balance sheet location	Fair value		Balance sheet location	Fair value
Derivative instruments designated as hedges
Interest rate contracts	Other non-current assets	$	—	Other non-current liabilities	$	226
Foreign exchange contracts	Prepaid expenses and other current assets	24		Accounts payable and accrued liabilities	3
Total derivative instruments designated as hedges		24			229
Undesignated derivative instruments
Foreign exchange contracts	Prepaid expenses and other current assets	5		Accounts payable and accrued liabilities	4
Total derivative instruments		$	29		$	233

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2019.

	Derivatives in asset positions			Derivatives in liability positions
(in millions)	Balance sheet location	Fair value		Balance sheet location	Fair value
Derivative instruments designated as hedges
Interest rate contracts	Other non-current assets	$	10	Other non-current liabilities	$	52
Foreign exchange contracts	Prepaid expenses and other current assets	10		Accounts payable and accrued liabilities	—
Total derivative instruments designated as hedges		20			52
Undesignated derivative instruments
Foreign exchange contracts	Prepaid expenses and other current assets	1		Accounts payable and accrued liabilities	2
Total derivative instruments		$	21		$	54

While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives.

29

The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.

	March 31, 2020				December 31, 2019
(in millions)	Asset		Liability		Asset		Liability
Gross amounts recognized in the consolidated balance sheet	$	29	$	233	$	21	$	54
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet	(7)		(7)		(11)		(11)
Total	$	22	$	226	$	10	$	43

The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:

	Carrying amount of hedged item				Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item (a)
(in millions)	Balance as of March 31, 2020		Balance as of December 31, 2019		Balance as of March 31, 2020		Balance as of December 31, 2019
Long-term debt	$	103	$	103	$	6	$	6

(a) These fair value hedges were terminated prior to December 31, 2019.

16. FAIR VALUE MEASUREMENTS

The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.

			Basis of fair value measurement
(in millions)	Balance as of March 31, 2020		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Foreign exchange contracts	$	29	$	—	$	29	$	—
Marketable equity securities	3		3		—		—
Total	$	32	$	3	$	29	$	—
Liabilities
Foreign exchange contracts	$	7	$	—	$	7	$	—
Interest rate contracts	226		—		226		—
Contingent payments related to acquisitions	39		—		—		39
Total	$	272	$	—	$	233	$	39

30

			Basis of fair value measurement
(in millions)	Balance as of December 31, 2019		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Foreign exchange contracts	$	11	$	—	$	11	$	—
Interest rate contracts	10		—		10		—
Marketable equity securities	3		3		—		—
Total	$	24	$	3	$	21	$	—
Liabilities
Foreign exchange contracts	$	2	$	—	$	2	$	—
Interest rate contracts	52		—		52		—
Contingent payments related to acquisitions	39		—		—		39
Total	$	93	$	—	$	54	$	39

As of March 31, 2020 and December 31, 2019, cash and cash equivalents of $4.1 billion and $3.3 billion, respectively, included money market and other short-term funds of approximately $2.3 billion and $1.7 billion, respectively, which are considered Level 2 in the fair value hierarchy.

For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility.

Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques. The fair value of milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated. The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions.

	Three months ended March 31,
(in millions)	2020		2019
Fair value at beginning of period	$	39	$	32
Additions	4		—
Change in fair value recognized in earnings	(3)		—
Payments	(1)		(1)
Fair value at end of period	$	39	$	31

31

Financial Instruments Not Measured at Fair Value

In addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of March 31, 2020 and December 31, 2019.

	Book values				Fair values(a)
(in millions)	2020		2019		2020		2019
Liabilities
Short-term debt	$	221	$	226	$	221	$	226
Current maturities of long-term debt and finance lease obligations	315		315		315		315
Long-term debt and finance lease obligations	5,996		4,809		6,324		5,156

(a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.

The carrying value of short-term debt approximates its fair value due to the short-term maturities of the obligations. The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments approximate their fair values due to the short-term maturities of most of those assets and liabilities.

Equity investments not measured at fair value are comprised of other equity investments without readily determinable fair values and were $77 million at March 31, 2020 and $73 million at December 31, 2019. These amounts are included in Other non-current assets on our condensed consolidated balance sheets.

17. SEGMENT INFORMATION

We manage our business based on three geographical segments: Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia Pacific). Our segments provide a broad portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products.

We use operating income on a segment basis to make resource allocation decisions and assess the ongoing performance of our business segments. Intersegment sales are eliminated in consolidation.

Certain items are maintained at Corporate and are not allocated to a segment. They primarily include the majority of foreign currency hedging activities, corporate headquarters costs, certain R&D costs, certain GBU support costs, stock compensation expense, certain employee benefit plan costs, and certain gains, losses, and other charges (such as business optimization, acquisition and integration costs, intangible asset amortization and asset impairments). Our chief operating decision maker does not receive any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

32

Financial information for our segments is as follows.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Net sales:
Americas	$	1,499	$	1,409
EMEA	754		707
APAC	549		522
Total net sales	$	2,802	$	2,638
Operating income:
Americas	$	544	$	538
EMEA	161		144
APAC	128		120
Total segment operating income	$	833	$	802

The following is a reconciliation of segment operating income to income before income taxes per the condensed consolidated statements of income.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Total segment operating income	$	833	$	802
Corporate and other	(424)		(419)
Total operating income	409		383
Net interest expense	21		18
Other (income) expense, net	10		(21)
Income before income taxes	$	378	$	386

Refer to Note 10 for additional information on Net Sales by GBU.

33

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Refer to our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Annual Report) for management’s discussion and analysis of our financial condition and results of operations. The following is management’s discussion and analysis of our financial condition and results of operations for the three months ended March 31, 2020 and 2019.

Restatement of Previously Issued Condensed Consolidated Financial Statements

As previously disclosed, we have restated our condensed consolidated financial statements for the three months ended March 31, 2019 contained in this Quarterly Report on Form 10-Q. In addition, we have restated certain previously reported financial information for the three months ended March 31, 2019 in this Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, including but not limited to information within the Results of Operations section. See Note 2, Restatement of Previously Issued Condensed Consolidated Financial Statements, in Item 1, Financial Statements, for additional information related to the restatement, including descriptions of the misstatements and the impacts on our condensed consolidated financial statements.

RESULTS OF OPERATIONS

Net income attributable to Baxter stockholders for the three months ended March 31, 2020 totaled $332 million, or $0.64 per diluted share, compared to $342 million, or $0.66 per diluted share, for the three months ended March 31, 2019. Net income for the three months ended March 31, 2020 included special items which decreased net income by $93 million, or $0.18 per diluted share, as further discussed below. Net income for the three months ended March 31, 2019 included special items which decreased net income by $52 million, or $0.09 per diluted share, as further discussed below.

34

Special Items

The following table provides a summary of our special items and the related impact by line item on our results for the three months ended March 31, 2020 and 2019.

	Three months ended March 31,
(in millions)	2020		2019
Gross Margin
Intangible asset amortization expense	$	(52)	$	(43)
Business optimization items 1	(10)		(19)
Acquisition and integration expenses 2	(7)		(5)
European medical devices regulation 3	(6)		(4)
Investigation and other related costs 4	(3)		—
Total Special Items	$	(78)	$	(71)
Impact on Gross Margin Ratio	(2.8 pts)		(2.7 pts)
Selling, General and Administrative (SG&A) Expenses
Business optimization items 1	$	21	$	8
Acquisition and integration expenses 2	3		5
Investigation and other related costs 4	14		—
Total Special Items	$	38	$	13
Impact on SG&A Ratio	1.3 pts		0.5 pts
Research and Development (R&D) Expenses
Business optimization items 1	$	1	$	11
Acquisition and integration expenses 2	21		4
Investigation and other related costs 4	1		—
Total Special Items	$	23	$	15
Impact on R&D Ratio	0.8 pts		0.6 pts
Other Operating Income, net
Business optimization items 1	$	(17)	$	—
Acquisition and integration expenses 2	(3)		—
Insurance recoveries from a legacy product-related matter 5	—		(33)
Total Special Items	$	(20)	$	(33)
Income Tax Expense
Tax effects of special items 6	$	(26)	$	(14)
Total Special Items	$	(26)	$	(14)
Impact on Effective Tax Rate	(2.4 pts)		(1.4 pts)

Intangible asset amortization expense is identified as a special item to facilitate an evaluation of current and past operating performance and is consistent with how management and our Board of Directors assess performance. Additional special items are identified above because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period. Management believes that providing the separate impact of those items may provide a more complete understanding and facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.

1In 2020 and 2019, our results were impacted by costs associated with our execution of programs to optimize our organization and cost structure on a global basis. These actions included streamlining our international operations, rationalizing our manufacturing facilities, reducing our general and administrative infrastructure, re-aligning certain R&D activities and cancelling certain R&D programs. Our results in 2020 and 2019 included business optimization charges of $32 million and $38 million, respectively. Additionally, we recognized a gain of $17 million in 2020 for property we sold in conjunction with our business optimization

35

initiatives. Refer to Note 11 in Item 1 of this Quarterly Report on Form 10-Q for further information regarding these charges and related liabilities.

2Our results in 2020 included $28 million of acquisition and integration expenses. This included acquisition and integration expenses related to our acquisitions of Cheetah Medical and Seprafilm of $10 million and the purchase of in-process R&D assets of $21 million, partially offset by the change in the estimated fair value of contingent consideration liabilities of $3 million. Our results in 2019 included $14 million of acquisition and integration expenses. This included acquisition and integration expenses related to our acquisitions of Claris and the RECOTHROM and PREVELEAK products in prior periods of $10 million and the purchase of in-process R&D assets of $4 million. Refer to Note 3 in Item 1 of this Quarterly Report on Form 10-Q for further information regarding business development activities.

3Our results in 2020 and 2019 included $6 million and $4 million, respectively, of costs related to updating our quality systems and product labeling to comply with the new medical device reporting regulation and other requirements of the European Union’s regulations for medical devices that are scheduled to become effective in 2020.

4Our results in 2020 included costs of $18 million for investigation and related costs. This included $10 million of costs related to our investigation of foreign exchange gains and losses associated with certain intra-company transactions. Additionally, we recorded incremental stock compensation expense of $8 million as we extended the term of certain stock options that were scheduled to expire in the first quarter of 2020. Refer to Notes 7 and 8 in Item 1 of this Quarterly Report on Form 10-Q for further information regarding the investigation and stock compensation expense.

5Our results in 2019 included a benefit of $33 million for our allocation of insurance proceeds received pursuant to a settlement and cost-sharing arrangement for a legacy product-related matter. Refer to Note 7 in Item 1 of this Quarterly Report on Form 10-Q for further information.

6Reflected in this item is the income tax impact of the special items identified in this table. The tax effect of each adjustment is based on the jurisdiction in which the adjustment is incurred and the tax laws in effect for each such jurisdiction.

NET SALES

	Three months ended March 31,				Percent change
			As Restated
(in millions)	2020		2019		At actual currency rates		At constant currency rates
United States	$	1,217	$	1,120	9	%	9	%
International	$	1,585	1,518		4	%	8	%
Total net sales	$	2,802	$	2,638	6	%	8	%

Foreign currency unfavorably impacted net sales by 2 percentage points during the first quarter of 2020 compared to the prior-year period principally due to the strengthening of the U.S. Dollar relative to the Euro, Australian Dollar, Brazilian Real and Colombian Peso.

The comparisons presented at constant currency rates reflect local currency sales at the prior period’s foreign exchange rates. This measure provides information on the change in net sales assuming that foreign currency exchange rates had not changed between the prior and the current period. We believe that the non-GAAP measure of change in net sales at constant currency rates, when used in conjunction with the U.S. GAAP measure of change in net sales at actual currency rates, may provide a more complete understanding and facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.

Our global operations expose us to risks associated with public health crises and epidemics/pandemics, such as the novel strain of coronavirus (COVID-19). COVID-19 may have an adverse impact on our operations, supply chains and distribution systems and increase our expenses, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking. Due to these impacts and measures, we have experienced and may continue to experience reductions or increases in demand for certain of our products as health care customers re-prioritize the treatment of patients. For example, elective surgeries are being de-prioritized which has negatively impacted the usage of certain of our products, while other of our products are experiencing an increase in demand which we may not be able to meet in accordance with the customer’s desired

36

timing. In addition to travel restrictions, countries have closed borders and imposed prolonged quarantines, often with uncertain duration, which has significantly impacted the ability of our employees to get to their places of work to produce products and may significantly hamper our products from moving through the supply chain. As a result, given the rapid and evolving nature of the virus, COVID-19 could negatively affect our sales, and it is uncertain how COVID-19 will affect our global operations generally if these impacts persist or exacerbate over an extended period of time. For further discussion, refer to the Global Business Unit Net Sales Reporting section below and Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2019.

Global Business Unit Net Sales Reporting

Our global business units (GBUs) include the following:

• Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.

• Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.

• Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.

• Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.

• Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.

• Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).

• Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.

The following is a summary of net sales by GBU.

	Three months ended March 31,				Percent change
			As Restated
(in millions)	2020		2019		At actual currency rates		At constant currency rates
Renal Care	$	870	$	854	2	%	4	%
Medication Delivery	690		634		9	%	10	%
Pharmaceuticals	527		510		3	%	6	%
Clinical Nutrition	220		205		7	%	10	%
Advanced Surgery	224		199		13	%	14	%
Acute Therapies	156		129		21	%	23	%
Other	115		107		7	%	9	%
Total Baxter	$	2,802	$	2,638	6	%	8	%

Renal Care net sales increased 2% in the first quarter of 2020, as compared to the prior-year period. That increase was driven by global patient growth in PD, partially offset by a 2% adverse impact from foreign exchange rate changes. The COVID-19 pandemic contributed to the increase in demand for PD products in the current period.

Medication Delivery net sales increased 9% in the first quarter of 2020, as compared to the prior-year period. That increase was attributable to increased sales of our Spectrum IQ Infusion System in the U.S. and EVO IQ Infusion System internationally and related IV administration sets and solutions, partially offset by a 1% adverse impact from foreign exchange rate changes. The COVID-19 pandemic contributed to the increases in demand for those products in the current period and we currently anticipate that increased demand will continue in the second quarter of 2020.

Pharmaceuticals net sales increased 3% in the first quarter of 2020, as compared to the prior-year period. That increase was driven by growth in international pharmacy compounding sales and increased sales of our generic injectables and U.S. cyclophosphamide, partially offset by lower sales of inhaled anesthesia products and Transderm Scop and by a 3% adverse impact from foreign exchange rate changes. The COVID-19 pandemic increased demand for our generic injectables and decreased demand for our inhaled anesthesia products in the current period and we currently anticipate that such demand trends will continue in the second quarter of 2020.

37

Clinical Nutrition net sales increased 7% in the first quarter of 2020, as compared to the prior-year period. That increase was driven by increased demand for our PN therapies and related products, partially offset by a 3% adverse impact from foreign exchange rate changes. The COVID-19 pandemic contributed to the increases in demand for those therapies and related products in the current period and we currently anticipate that increased demand will continue in the second quarter of 2020.

Advanced Surgery net sales increased 13% the first quarter of 2020, as compared to the prior-year period. Most of the increase was driven by the acquisition of Seprafilm, which contributed $13 million in net sales during the quarter. Additionally, contributing to the increase in the first two months of the quarter was increased demand for our hemostats and sealants due, in part, to competitive supply disruptions. Those increases were partially offset by a 1% adverse impact from foreign exchange rate changes. The COVID-19 pandemic began to have a significant adverse impact on Advanced Surgery net sales during the latter part of the quarter and we currently anticipate a substantial decline in those net sales in the second quarter of 2020 as many elective surgeries have been and continue to be postponed.

Acute Therapies net sales increased 21% in the first quarter of 2020, as compared to the prior-year period. The increase was driven by increased global demand for our CRRT systems to treat acute kidney injuries, partially offset by a 2% adverse impact from foreign exchange rate changes. The COVID-19 pandemic drove the increases in demand for those products in the current period and we currently anticipate that increased demand will continue in the second quarter of 2020.

Other net sales increased 7% in the first quarter 2020, as compared to the prior-year period. The increase was driven by increased demand for our contract manufacturing services, partially offset by a 2% adverse impact from foreign exchange rate changes.

Gross Margin and Expense Ratios

	Three months ended March 31,
					As Restated
	2020		% of net sales		2019		% of net sales		$ change		% change
Gross margin	$	1,163	41.5	%	$	1,080	40.9	%	$	83	7.7	%
SG&A	$	628	22.4	%	$	601	22.8	%	$	27	4.5	%
R&D	$	146	5.2	%	$	129	4.9	%	$	17	13.2	%

Gross Margin

The gross margin ratio was 41.5% and 40.9% in the first quarter of 2020 and 2019, respectively. The special items identified above had an unfavorable impact of approximately 2.8 and 2.7 percentage points on the gross margin ratio in the first quarter of 2020 and 2019, respectively. Refer to the Special Items caption above for additional detail.

Excluding the impact of the special items, the gross margin ratio increased in the first quarter of 2020 compared to the prior year due to a favorable product mix and manufacturing efficiencies.

We expect the gross margin ratio for full year 2020 to be negatively impacted by an unfavorable product mix, additional compensation costs, primarily for our manufacturing employees, and incremental logistics costs in response to the COVID-19 pandemic.

SG&A

The SG&A expenses ratio was 22.4% and 22.8% in the first quarter of 2020 and 2019, respectively. The special items identified above had an unfavorable impact of approximately 1.3 and 0.5 percentage points on the SG&A expenses ratio in the first quarter of 2020 and 2019, respectively. Refer to the Special Items caption above for additional detail.

Excluding the impact of the special items, the SG&A expenses ratio decreased in the first quarter of 2020 primarily due to actions we took to restructure our cost position and focus on expense management and reduced travel and related expenses due to the COVID-19 pandemic.

38

R&D

The R&D expenses ratio was 5.2% and 4.9% in the first quarter of 2020 and 2019, respectively. The special items identified above had an unfavorable impact of approximately 0.8 and 0.6 percentage points on the R&D expenses ratio in the first quarter of 2020 and 2019, respectively. Refer to the Special Items caption above for additional detail.

Excluding the impact of the special items, the R&D expenses ratio increased in the first quarter of 2020 as a result of the timing of project-related expenditures compared to the prior year, partially offset by actions we took to restructure our cost position and focus on expense management.

Business Optimization Items

Beginning in the second half of 2015, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization, optimizing our manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. Through March 31, 2020, we have incurred cumulative pre-tax costs of $1.0 billion related to these actions. The costs consisted primarily of employee termination costs, implementation costs, asset impairments, and accelerated depreciation. We currently expect to incur additional pre-tax costs of approximately $30 million related to these initiatives, primarily related to employee termination costs and implementation costs. To the extent further cost savings opportunities are identified, we may incur additional business optimization expenses. The reductions in our cost base from these actions in the aggregate are expected to provide cumulative annual pre-tax savings of approximately $1.2 billion once the remaining actions are complete. The savings from these actions will impact cost of sales, SG&A expenses, and R&D expenses. Approximately 95 percent of the expected annual pre-tax savings are expected to be realized by the end of 2020, with the remainder by the end of 2023.

Other Operating Income, Net

Other operating income, net was $20 million in the first quarter of 2020 as we recognized a $17 million gain on the sale of property in conjunction with our business optimization initiatives and a $3 million gain as a result of a change in the estimated fair value of contingent consideration liabilities. Other operating income, net was $33 million in the first quarter of 2019 as we recognized a $33 million gain when our share of the proceeds under a cost-sharing agreement became realizable following the resolution of a dispute with an insurer related to a legacy product-related matter.

Interest Expense, Net

Interest expense, net was $21 million and $18 million in the first quarter of 2020 and 2019, respectively. The increase in the first quarter of 2020 was primarily driven by higher average debt outstanding as a result of the March 2020 issuance of $750 million of 3.75% senior notes due March 2025 and $500 million of 3.95% senior notes due March 2030 and the May 2019 issuance of €750 million of 0.40% senior notes due May 2024 and €750 million of 1.3% senior notes due May 2029. The increase in interest expense, net was partially offset by higher interest income as a result of higher average cash and cash equivalents balances.

We expect that interest expense, net will increase by more than $60 million in 2020 compared to 2019 primarily due to reduced interest income as a result of lower interest rates on cash balances and higher interest expense as a result of the $1.25 billion of senior notes issued in March 2020.

Other (Income) Expense, Net

Other (income) expense, net was expense of $10 million and income of $21 million in the first quarter of 2020 and 2019, respectively. The decrease in the first quarter of 2020 compared to the prior year was primarily due to lower pension benefits and foreign exchange net losses in the current year.

Income Taxes

Our effective income tax rate was 11.9% and 11.4% in the first quarter of 2020 and 2019, respectively. Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, increases or decreases in valuation allowances and liabilities for uncertain tax positions and excess tax benefits on stock compensation awards.

39

For the three months ended March 31, 2020, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a favorable geographic earnings mix and excess tax benefits on stock compensation awards.

For the three months ended March 31, 2019, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to excess tax benefits on stock compensation awards.

Segment Results

We use operating income on a segment basis to make resource allocation decisions and assess the ongoing performance of our segments. The following is a summary of financial information for our reportable segments:

	Net sales				Operating income (loss)
	Three months ended March 31,				Three months ended March 31,
			As Restated				As Restated
(in millions)	2020		2019		2020		2019
Americas	$	1,499	$	1,409	$	544	$	538
EMEA	754		707		161		144
APAC	549		522		128		120
Corporate and other	—		—		(424)		(419)
Total	$	2,802	$	2,638	$	409	$	383

Americas

Segment net sales and operating income were $1.5 billion and $544 million, respectively, in the first quarter of 2020 and $1.4 billion and $538 million, respectively, in the first quarter of 2019. The increases in the first quarter of 2020 were primarily driven by increased sales and gross margin in multiple GBUs, particularly Medication Delivery, Advanced Surgery due to the Seprafilm acquisition, Acute Therapies and Clinical Nutrition.

EMEA

Segment net sales and operating income were $754 million and $161 million, respectively, in the first quarter of 2020 and $707 million and $144 million, respectively, in the first quarter of 2019. The increases in the first quarter of 2020 were primarily driven by increased sales and gross margin in multiple GBUs, particularly Pharmaceuticals, Clinical Nutrition, Medication Delivery and Acute Therapies.

APAC

Segment net sales and operating income were $549 million and $128 million, respectively, in the first quarter of 2020 and $522 million and $120 million, respectively, in the first quarter of 2019. The increases in the first quarter of 2020 were primarily driven by increased sales and gross margin in multiple GBUs, particularly Renal Care, Acute Therapies, Pharmaceuticals and Advanced Surgery due to the Seprafilm acquisition.

Corporate and Other

Certain items are maintained at Corporate and are not allocated to a segment. They primarily include certain foreign currency hedging activities, corporate headquarters costs, certain R&D costs, certain GBU support costs, stock compensation expense, certain employee benefit plan costs, and certain gains, losses, and other charges (such as business optimization, acquisition and integration costs, intangible asset amortization and asset impairments). The operating loss in the first quarter of 2020 was higher than the prior-year period due to the prior-year gain recognized when our share of the proceeds under a cost-sharing agreement became realizable following the resolution of a dispute with an insurer related to a legacy product-related matter and higher investigation and other related costs, acquisition and integration costs and intangible asset amortization in the current year, partially offset by the gain recognized in the current year related to the sale of property in connection with our business optimization initiatives.

40

LIQUIDITY AND CAPITAL RESOURCES

The following table is a summary of the statement of cash flows for the three-month periods ended March 31, 2020 and 2019.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Cash flows from operations - continuing operations	$	274	$	134
Cash flows from investing activities	(604)		(301)
Cash flows from financing activities	1,170		238

Cash Flows from Operations — Continuing Operations

In the first three months of 2020, cash provided by operating activities was $274 million, as compared to cash provided by operating activities of $134 million in the first three months of 2019, an increase of $140 million. The increase was primarily due to the timing of vendor payments and lower employee compensation payments in the current year, partially offset by insurance recoveries received in 2019 from a legacy product-related matter and Hurricane Maria.

While we have not yet experienced any significant collection issues related to our receivables to date, we expect that the timing of collection of our receivables may be adversely impacted by the COVID-19 pandemic in the remainder of 2020.

Cash Flows from Investing Activities

In the first three months of 2020, cash used for investing activities included payments for acquisitions of $443 million, primarily related to Seprafilm and rights to multiple products we acquired, and capital expenditures of $172 million. In the first three months of 2019, cash used for investing activities included capital expenditures of $193 million and payments for acquisitions of $109 million, primarily related to the U.S. rights to multiple products we acquired.

Cash Flows from Financing Activities

In the first three months of 2020, cash generated from financing activities included $1.2 billion of net proceeds from the issuance of $750 million of senior notes due in 2025 and $500 million of senior notes due in 2030. We will use the net proceeds from the senior notes issuances for general corporate purposes, including to strengthen our balance sheet as a precautionary measure in light of the COVID-19 pandemic. Cash generated from financing activities in the three months ended March 31, 2020 also included stock issued under employee benefit plans of $66 million and was partially offset by dividend payments of $111 million. In the first three months of 2019, cash generated from financing activities included net proceeds from short-term debt of $795 million and stock issued under employee benefit plans of $173 million, partially offset by payments for stock repurchases of $597 million and dividend payments of $101 million.

As authorized by the Board of Directors, we repurchase our stock depending upon our cash flows, net debt levels and market conditions. In July 2012, the Board of Directors authorized the repurchase of up to $2.0 billion of our common stock. The Board of Directors increased this authority by an additional $1.5 billion in each of November 2016 and February 2018 and by an additional $2.0 billion in November 2018. We did not repurchase any shares under this authority in the first three months of 2020 and had $897 million remaining available under this authorization as of March 31, 2020.

Credit Facilities and Access to Capital and Credit Ratings

Credit Facilities

As of March 31, 2020, our U.S. dollar-denominated revolving credit facility and Euro-denominated senior revolving credit facility had a maximum capacity of $2.0 billion and €200 million, respectively. There was no amount outstanding under our U.S. dollar-denominated credit facility as of March 31, 2020 or December 31, 2019, There was €200 million ($220 million and $224 million, respectively) outstanding at a 0.9% interest rate under our Euro-denominated credit facility as of March 31, 2020 and December 31, 2019. As of March 31, 2020, we were in compliance with the financial

41

covenants in these agreements. The non-performance of any financial institution supporting either of the credit facilities would reduce the maximum capacity of these facilities by each institution’s respective commitment.

Access to Capital and Credit Ratings

We intend to fund short-term and long-term obligations as they mature through cash on hand, future cash flows from operations or by issuing additional debt. We had $4.1 billion of cash and cash equivalents as of March 31, 2020, with adequate cash available to meet operating requirements in each jurisdiction in which we operate. We invest our excess cash in money market and other funds and diversify the concentration of cash among different financial institutions.

Our ability to generate cash flows from operations, issue debt or enter into other financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for our products or in the solvency of our customers or suppliers, deterioration in our key financial ratios or credit ratings or other significantly unfavorable changes in conditions. However, we believe we have sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support our growth objectives. Between March and April 2020, Standard & Poor’s, Fitch, and Moody’s reaffirmed our investment grade credit ratings that we disclosed in our 2019 Annual Report.

LIBOR Reform

In 2017, the United Kingdom’s Financial Conduct Authority announced that after 2021 it would no longer compel banks to submit the rates required to calculate the London Interbank Offered Rate (LIBOR) and other interbank offered rates, which have been widely used as reference rates for various securities and financial contracts, including loans, debt and derivatives. This announcement indicates that the continuation of LIBOR on the current basis is not guaranteed after 2021. Regulators in the U.S. and other jurisdictions have been working to replace these rates with alternative reference interest rates that are supported by transactions in liquid and observable markets, such as the Secured Overnight Financing Rate (SOFR). Currently, our credit facilities and certain of our derivative instruments reference LIBOR-based rates. The discontinuation of LIBOR will require these arrangements to be modified in order to replace LIBOR with an alternative reference interest rate, which could impact our cost of funds. Our credit facilities include a provision for the determination of a successor LIBOR rate.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. A summary of our significant accounting policies is included in Note 1 to our consolidated financial statements in our 2019 Annual Report. Certain of our accounting policies are considered critical, as these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments, often employing the use of estimates about the effects of matters that are inherently uncertain. Such policies are summarized in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in our 2019 Annual Report. There have been no significant changes in the application of our critical accounting policies during the first quarter of 2020.

RECENT ACCOUNTING PRONOUNCEMENTS

Refer to Note 1 in Item 1 of this Quarterly Report on Form 10-Q for information regarding recently adopted accounting pronouncements. There are no accounting standards issued but not yet effective that we believe will have a material impact on our condensed consolidated financial statements.

LEGAL CONTINGENCIES

Refer to Note 7 within Item 1 for a discussion of our legal contingencies. Upon resolution of any of these uncertainties, we may incur charges in excess of presently established liabilities. While our liability in connection with certain claims cannot be estimated with any certainty, and although the resolution in any reporting period of one or more of these matters could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and we may in the future incur material judgments or enter into material settlements of claims.

42

CERTAIN REGULATORY MATTERS

The U.S. Food and Drug Administration (FDA) commenced an inspection of Claris’ facilities in Ahmedabad, India in July 2017, immediately prior to the closing of the Claris acquisition. FDA completed the inspection and subsequently issued a Warning Letter based on observations identified in the 2017 inspection (Claris Warning Letter).¹

While FDA has not yet re-inspected the facilities, we are continuing to implement corrective and preventive actions to address FDA’s prior observations and other items identified in connection with integrating Claris into our quality systems.

While management cannot speculate on when the Claris Warning Letter will be lifted, management continues to pursue and implement other manufacturing locations, including contract manufacturing organizations, to support the production of new products for distribution in the U.S. in the meantime. As of December 31, 2019, we have secured alternative locations to produce a majority of the planned new products for distribution into the U.S.

On May 6, 2019, we received a Show Cause Notice under the Drugs & Cosmetics Act, 1940 and Rules thereunder (Show Cause Notice) from the Commissioner of the Food & Drugs Control Administration in the Gujarat State in Gandhinagar, India (Commissioner). The Show Cause Notice was issued regarding an April 9, 2019 inspection of our Claris facilities in Ahmedabad, India by the Commissioner. The Show Cause Notice contained a number of observations of alleged Good Manufacturing Practice related issues across a variety of areas, some of which overlap with the areas covered in the Claris 483 or the Claris Warning Letter. We responded to the Show Cause Notice and a follow up inspection occurred in July 2019. This matter resulted in a two-day suspension order for certain manufacturing operations, which occurred on March 19 and 20, 2020. This matter is now closed.

In June 2013, we received a Warning Letter from FDA regarding operations and processes at our North Cove, North Carolina and Jayuya, Puerto Rico facilities. We attended Regulatory Meetings with FDA regarding one or both of these facilities in October 2014, November 2015, July 2017, April 2018 and October 2018. The Warning Letter addresses observations related to Current Good Manufacturing Practice violations at the two facilities. The Warning Letter was closed out in September 2019.

As previously disclosed, in the fourth quarter of 2012, we received two investigative demands from the United States Attorney for the Western District of North Carolina for information regarding our quality and manufacturing practices and procedures at our North Cove facility. In January 2017, the parties resolved the matter by entering into a deferred prosecution agreement and a civil settlement whereby we agreed to pay approximately $18 million and implement certain enhanced compliance measures. In July 2019, the deferred prosecution agreement expired and, based on our fulfillment of the terms of the agreement, the court dismissed the criminal information previously filed in the case with prejudice.

¹ Available online at https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm613538.htm

FORWARD-LOOKING INFORMATION

This quarterly report on Form 10-Q includes forward-looking statements. Use of the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “seeks,” “intends,” “evaluates,” “pursues,” “anticipates,” “continues,” “designs,” “impacts,” “affects,” “forecasts,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the negative of those words or other similar expressions is intended to identify forward-looking statements that represent our current judgment about possible future events. These forward-looking statements may include statements with respect to accounting estimates and assumptions, impacts of the COVID-19 pandemic, litigation-related matters including outcomes, impacts of the internal investigation related to foreign exchange gains and losses and the material weakness identified as a result thereof, future regulatory filings and our R&D pipeline, strategic objectives, sales from new product offerings, credit exposure to foreign governments, potential developments with respect to credit ratings, investment of foreign earnings, estimates of liabilities including those related to uncertain tax positions, contingent payments, future pension plan contributions, costs, discount rates and rates of return, our exposure to financial market volatility and foreign currency and interest rate risks, potential tax liability associated with the separation of our biopharmaceuticals and medical products businesses, the impact of competition, future sales growth, business development activities (including the acquisitions of Cheetah and Seprafilm from Sanofi), business optimization initiatives, cost saving initiatives, future capital and R&D expenditures, future debt issuances, manufacturing expansion, the sufficiency of our facilities and financial flexibility, the adequacy of credit facilities, tax provisions and reserves, the effective tax rate and all other statements that do not relate to historical facts.

43

These forward-looking statements are based on certain assumptions and analyses made in light of our experience and perception of historical trends, current conditions, and expected future developments as well as other factors that we believe are appropriate in the circumstances. While these statements represent our judgment on what the future may hold, and we believe these judgments are reasonable, these statements are not guarantees of any events or financial results. Whether actual future results and developments will conform to expectations and predictions is subject to a number of risks and uncertainties, including the following factors, many of which are beyond our control:

• demand for and market acceptance risks for and competitive pressures related to new and existing products (including challenges with our ability to accurately predict these pressures and the resulting impact on customer inventory levels), and the impact of those products on quality and patient safety concerns;

• product development risks, including satisfactory clinical performance, the ability to manufacture at appropriate scale, and the general unpredictability associated with the product development cycle;

• our ability to finance and develop new products or enhancements on commercially acceptable terms or at all;

• our ability to identify business development and growth opportunities and to successfully execute on business development strategies;

• product quality or patient safety issues, leading to product recalls, withdrawals, launch delays, warning letters, import bans, sanctions, seizures, litigation, or declining sales;

• the impact of global economic conditions (including potential trade wars) and public health crises and epidemics, such as the novel strain of coronavirus (COVID-19), on us and our customers and suppliers, including foreign governments in countries in which we operate;

• the continuity, availability and pricing of acceptable raw materials and component supply, and the related continuity of our manufacturing and distribution;

• inability to create additional production capacity in a timely manner or the occurrence of other manufacturing, sterilization or supply difficulties (including as a result of natural disaster, public health crises and epidemics/pandemics, regulatory actions or otherwise);

• breaches or failures of our information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft;

• future actions of (or failures to act or delays in acting by) FDA, the European Medicines Agency or any other regulatory body or government authority (including the SEC, DOJ or the Attorney General of any State) that could delay, limit or suspend product development, manufacturing or sale or result in seizures, recalls, injunctions, monetary sanctions or criminal or civil liabilities, including the continued delay in lifting the warning letter at our Ahmedabad facility or proceedings related to the misstatements in previously reported non-operating income related to foreign exchange gains and losses;

• the impacts of the material weakness identified as a result of the internal investigation related to foreign exchange gains and losses and our remediation efforts, including the risk that we may experience additional material weaknesses;

• developments that would require the correction of additional misstatements in our previously issued financial statements;

• failures with respect to our quality, compliance or ethics programs;

44

• future actions of third parties, including third-party payers, the impact of healthcare reform and its implementation, suspension, repeal, replacement, amendment, modification and other similar actions undertaken by the United States or foreign governments, including with respect to pricing, reimbursement, taxation and rebate policies; legislation, regulation and other governmental pressures in the United States or globally, including the cost of compliance and potential penalties for purported noncompliance thereof, all of which may affect pricing, reimbursement, taxation and rebate policies of government agencies and private payers or other elements of our business, including new or amended laws, rules and regulations (such as the California Consumer Privacy Act of 2018, the European Union’s General Data Protection Regulation and proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end stage renal disease market and demand for our peritoneal dialysis products, necessitating significant multi-year capital expenditures, which are difficult to estimate in advance, for example);

• the outcome of pending or future litigation, including the opioid litigation and litigation related to the investigation of foreign exchange gains and losses;

• failure to achieve our long-term financial improvement goals;

• the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies;

• global regulatory, trade and tax policies;

• the ability to protect or enforce our owned or in-licensed patent or other proprietary rights (including trademarks, copyrights, trade secrets and know-how) or patents of third parties preventing or restricting our manufacture, sale or use of affected products or technology;

• the impact of any goodwill or other intangible asset impairments on our operating results;

• any failure by Baxalta or Shire to satisfy its obligations under the separation agreements, including the tax matters agreement, or that certain letter agreement entered into with Shire and Baxalta;

• fluctuations in foreign exchange and interest rates;

• any changes in law concerning the taxation of income (whether with respect to current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax;

• actions by tax authorities in connection with ongoing tax audits;

• loss of key employees or inability to identify and recruit new employees;

• other factors identified elsewhere in this report and other filings with the SEC, including those factors described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, all of which are available on our website.

Actual results may differ materially from those projected in the forward-looking statements. We do not undertake to update our forward-looking statements.

45

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Currency Risk

We are primarily exposed to foreign exchange risk with respect to revenues generated outside of the United States denominated in the Euro, British Pound, Chinese Yuan, Korean Won, Australian Dollar, Canadian Dollar, Japanese Yen, Colombian Peso, Brazilian Real, Mexican Peso and Swedish Krona. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative financial instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and stockholders’ equity volatility relating to foreign exchange. However, we don't hedge our entire foreign exchange exposure and are still subject to earnings and stockholders' equity volatility relating to foreign exchange risk. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.

We use options and forwards to hedge the foreign exchange risk to earnings relating to forecasted transactions denominated in foreign currencies and recognized assets and liabilities. The maximum term over which we have cash flow hedge contracts in place related to foreign exchange risk on forecasted transactions as of March 31, 2020 is 12 months. We also enter into derivative instruments to hedge foreign exchange risk on certain intra-company and third-party receivables and payables and debt denominated in foreign currencies.

As part of our risk-management program, we perform sensitivity analyses to assess potential changes in the fair value of our foreign exchange instruments relating to hypothetical and reasonably possible near-term movements in foreign exchange rates.

A sensitivity analysis of changes in the fair value of foreign exchange option and forward contracts outstanding as of March 31, 2020, while not predictive in nature, indicated that if the U.S. Dollar uniformly weakened by 10% against all currencies, on a net-of-tax basis, the net asset balance of $17 million with respect to those contracts would increase by $2 million.

The sensitivity analysis model recalculates the fair value of the foreign exchange option and forward contracts outstanding as of March 31, 2020 by replacing the actual exchange rates as of March 31, 2020 with exchange rates that are 10% weaker compared to the actual exchange rates for each applicable currency. All other factors are held constant. These sensitivity analyses disregard the possibility that currency exchange rates can move in opposite directions and that gains from one currency may or may not be offset by losses from another currency. The analyses also disregard the offsetting change in value of the underlying hedged transactions and balances.

Our operations in Argentina are reported using highly inflationary accounting effective July 1, 2018. Changes in the value of the Argentine Peso applied to our peso-denominated net monetary asset positions are recorded in income at the time of the change. As of March 31, 2020, our net monetary assets denominated in Argentine Pesos are not significant.

Interest Rate and Other Risks

Refer to the caption “Interest Rate and Other Risks” in the “Financial Instrument Market Risk” section of the 2019 Annual Report. There were no significant changes during the quarter ended March 31, 2020.

46

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of March 31, 2020.

Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer, concluded that, as of March 31, 2020, due to the material weakness in our internal control over financial reporting described below, our disclosure controls and procedures were not effective to provide reasonable assurance that the information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis.

We did not maintain effective controls over the accounting for certain foreign exchange gains and losses. Specifically, we did not have controls in place to monitor and quantify the difference between the foreign exchange gains and losses that we reported and the foreign exchange gains and losses that we would have reported using exchange rates determined in accordance with U.S. GAAP. Additionally, our policies and controls related to approvals and monitoring of intra-company transactions were insufficient to prevent or detect intra-company transactions undertaken solely for the purpose of generating foreign exchange gains or avoiding losses under our historical exchange rate convention. This material weakness resulted in the restatement of our consolidated financial statements as of December 31, 2018 and for the years ended December 31, 2018 and 2017 and each of the quarterly and year-to-date periods in the year ended December 31, 2018 and the first two quarters and related year-to-date interim period in the year ended December 31, 2019. Additionally, this material weakness could result in a misstatement of the aforementioned account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.

Remediation of the Material Weakness

Management has been implementing changes to strengthen our internal controls over the accounting for foreign exchange gains and losses. These changes are intended to address the identified material weakness and enhance our overall control environment and include the ongoing activities described below.

•Exchange Rate Policy – We have discontinued the use of our historical exchange rate convention and are using the exchange rates determined in accordance with U.S. GAAP for purposes of measuring foreign currency transactions and remeasuring monetary assets and liabilities denominated in a foreign currency.

•Automated Feed – We have implemented an automated feed that extracts foreign exchange rates on a daily basis from a recognized third-party exchange rate source.

•Daily Rate Comparison – We have implemented a daily rate comparison control that extracts foreign exchange rates from (a) a third-party exchange rate source, (b) our treasury application, and (c) our enterprise resource planning (ERP) system and compares those rates in order to identify any potential differences and provide assurance that the correct rates were captured and are being used in our financial systems.

•Intra-company Transaction Approvals – We have updated our policies to require additional approvals of intra-company transactions and implemented a requirement that such transactions be supported by a documented business purpose.

•Personnel - We have made personnel changes including hiring a new treasurer from outside Baxter with more than thirty years of treasury experience and responsibility, including at four publicly traded companies. We have also hired another experienced treasury professional in a newly created director role responsible for treasury governance and controls. Additionally, we have created a treasury controller role within our accounting function and are continuing to add resources as appropriate to improve our financial reporting controls related to treasury activities.

47

While we believe that the above actions will ultimately remediate the material weakness, we intend to continue to refine those controls and monitor their effectiveness for a sufficient period of time prior to reaching any determination as to whether the material weakness has been remediated.

Notwithstanding the identified material weakness, management believes that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial position, results of operations, and cash flows as of and for the periods presented in accordance with U.S. GAAP.

Changes in Internal Control over Financial Reporting

As previously disclosed, we are currently implementing an upgrade to our ERP software. In connection with the ERP upgrade, we are updating the processes that constitute our internal control over financial reporting, as necessary. This normal course of business ERP upgrade is being implemented to remain current with the latest release of the software.

As previously disclosed, since 2017, we have been implementing a long-term business transformation project within the finance, human resources, purchasing and information technology functions which will further centralize and standardize business processes and systems across the company.  We are transitioning some processes to our shared services centers while others have been moved to outsourced providers.  This multi-year initiative is being conducted in phases and includes modifications to the design and operation of controls over financial reporting.

Other than as described in the two preceding paragraphs and in the Remediation of Material Weakness section above, there have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

48

Review by Independent Registered Public Accounting Firm

A review of the interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2020 and 2019 has been performed by PricewaterhouseCoopers LLP, our independent registered public accounting firm. Its report on the interim condensed consolidated financial information follows. This report is not considered a report within the meaning of Sections 7 and 11 of the Securities Act of 1933 and, therefore, the independent accountants’ liability under Section 11 does not extend to it.

49

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Baxter International Inc.

Results of Review of Interim Financial Statements

We have reviewed the condensed consolidated balance sheet of Baxter International Inc. and its subsidiaries (the “Company”) as of March 31, 2020, and the related condensed consolidated statements of income, comprehensive income (loss), changes in equity and cash flows for the three-month periods ended March 31, 2020 and 2019, including the related notes, appearing under Part I, Item 1 of this Quarterly Report on Form 10-Q (collectively referred to as the “interim financial statements”). Based on our reviews, we are not aware of any material modifications that should be made to the interim financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of the Company as of December 31, 2019 and the related consolidated statements of income, comprehensive income, changes in equity and cash flows for the year then ended (not presented herein), and in our report dated March 17, 2020, which included a paragraph regarding the correction of misstatements in the 2018 and 2017 financial statements and a paragraph describing a change in the manner of accounting for leases in 2019, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the condensed consolidated balance sheet as of December 31, 2019, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

Restatement of Previously Issued Interim Financial Statements

As discussed in Note 2 to the condensed consolidated financial statements, the Company has restated its condensed consolidated financial statements for the three-month period ended March 31, 2019 to correct misstatements.

Basis for Review Results

These interim financial statements are the responsibility of the Company’s management. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our review in accordance with the standards of the PCAOB. A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

/s/ PricewaterhouseCoopers LLP

Chicago, Illinois

April 30, 2020

50

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

The information in Part I, Item 1, Note 7 is incorporated herein by reference.

Item 1A. Risk Factors

We do not believe that there have been any material changes to the risk factors previously disclosed in our 2019 Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In July 2012, we announced that our Board of Directors authorized us to repurchase up to $2.0 billion of our common stock on the open market or in private transactions. The Board of Directors increased this authority by an additional $1.5 billion in each of November 2016 and February 2018 and by an additional $2.0 billion in November 2018. During the first quarter of 2020 we did not repurchase any shares pursuant to Rule 10b5-1 plans. We had $897 million remaining under this program (as amended and after giving effect to stock repurchases) as of March 31, 2020. This program does not have an expiration date.

51

Item 6. Exhibits

Exhibit Index:

Exhibit Number	Description
4.1	Indenture between Baxter International Inc. and The Bank of New York Mellon Trust Company, N.A., dated as of March 26, 2020 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on March 27, 2020).
4.2	First Supplemental Indenture, to the Indenture dated as of March 26, 2020, between Baxter International Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee, dated as of March 26, 2020 (including form of 3.750% Senior Notes due 2025 and form of 3.950% Senior Notes due 2030) (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed on March 27, 2020).
4.3	Registration Rights Agreement, dated as of March 26, 2020, by and among Baxter International Inc. and Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC, as representatives of the Initial Purchasers (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K, filed on March 27, 2020).
10.1	Baxter International Inc. 2020 Equity Plan, effective as of March 16, 2020 (incorporated by reference to Exhibit C 10.22 to the Company’s Annual Report on Form 10-K, filed on March 17, 2020).
10.2	Offer Letter between Baxter International Inc. and José E. Almeida, dated as of March 12, 2020 (incorporated by reference to Exhibit C 10.25 to the Company’s Annual Report on Form 10-K, filed on March 17, 2020).
15*	Letter Re Unaudited Interim Financial Information
31.1*	Certification of Chief Executive Officer Pursuant to Rules 13a-14 (a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2*	Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1*	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document

_____________________________________

* Filed herewith.

52

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		BAXTER INTERNATIONAL INC.
		(Registrant)
Date: April 30, 2020
	By:	/s/ James K. Saccaro
		James K. Saccaro Executive Vice President and Chief Financial Officer (duly authorized officer and principal financial officer)

53

EX-15

EXHIBIT 15

April 30, 2020

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Commissioners:

We are aware that our reportdated April 30, 2020 on our reviewof interim financial information of Baxter International Inc., which appears in this Quarterly Report on Form 10-Q, isincorporated by reference in the Registration Statementson Form S-8 (Nos. 33-28428, 33-54069, 333-10520, 333-43563, 333-47019, 333-71553, 333-80403, 333-88257, 333-48906, 333-62820, 333-102140, 333-104420, 333-104421, 333-105032, 333-143063, 333-174400, 333-174401, 333-206700 and 333-206701) of Baxter International Inc.

Very truly yours,

/s/PricewaterhouseCoopers LLP

Chicago, Illinois

EX-31.1

EXHIBIT 31.1

Certification of Chief Executive Officer

Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as Amended

I, José E. Almeida, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Baxter International Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ José E. Almeida

José E. Almeida

Chairman of the Board and

Chief Executive Officer

Date: April 30, 2020

EX-31.2

EXHIBIT 31.2

Certification of Chief Financial Officer

Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as Amended

I, James K. Saccaro, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Baxter International Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ James K. Saccaro

James K. Saccaro

Executive Vice President and Chief Financial Officer

Date: April 30, 2020

EX-32.1

EXHIBIT 32.1

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350,

as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

José E. Almeida, as Chairman of the Board and Chief Executive Officer of Baxter International Inc. (the “Company”), certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ José E. Almeida

José E. Almeida

Chairman of the Board and

Chief Executive Officer

April 30, 2020

EX-32.2

EXHIBIT 32.2

Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350,

as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

James K. Saccaro, as Executive Vice President and Chief Financial Officer of Baxter International Inc. (the “Company”), certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James K. Saccaro

James K. Saccaro

Executive Vice President and Chief Financial Officer

April 30, 2020

XML

STOCKHOLDERS' EQUITY - Stock Repurchase Programs Narrative (Details) - USD ($) shares in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2020	Nov. 30, 2018	Feb. 28, 2018	Nov. 30, 2016	Jul. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock repurchase program, authorized amount						$ 2,000,000,000.0
Stock repurchase program, additional authorized amount			$ 2,000,000,000.0	$ 1,500,000,000	$ 1,500,000,000
Remaining value available under stock repurchase programs		$ 897,000,000
Purchases of treasury stock (in shares)	8.1

XML

Revenues - Narrative (Details) $ in Billions	Mar. 31, 2020 USD ($)
Revenue from Contract with Customer [Abstract]
Transaction price allocated to remaining performance obligations	$ 8.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-04-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	20.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	25.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	20.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	20.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	5.00%
Remaining performance obligations period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01
Revenue From Contract With Customer [Line Items]
Remaining revenue performance obligation, percentage of revenue expected to be recognized	5.00%
Remaining performance obligations period	1 year

XML

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Consolidated Statement of Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income	$ 333	$ 342
Other comprehensive (loss) income, net of tax:
Currency translation adjustments	(359)	(97)
Pension and other postretirement benefit plans	22	14
Hedging activities	(130)	(15)
Net other comprehensive income (loss)	(467)	(98)
Comprehensive (loss) income	$ (134)	244
As previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		347
Other comprehensive (loss) income, net of tax:
Currency translation adjustments		30
Pension and other postretirement benefit plans		8
Hedging activities		(15)
Net other comprehensive income (loss)		23
Comprehensive (loss) income		370
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		(5)
Other comprehensive (loss) income, net of tax:
Currency translation adjustments		(127)
Pension and other postretirement benefit plans		6
Hedging activities		0
Net other comprehensive income (loss)		(121)
Comprehensive (loss) income		(126)
Currency translation adjustments		127
Restatement impacts | Foreign Exchange Rate Used To Translate
Other comprehensive (loss) income, net of tax:
Currency translation adjustments		5
Restatement impacts | Offsetting Balance Sheet Impact Adjustments
Other comprehensive (loss) income, net of tax:
Currency translation adjustments		$ 132

XML

SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Summary of Financial Information for Our Segments

Financial information for our segments is as follows.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Net sales:
Americas	$	1,499	$	1,409
EMEA	754		707
APAC	549		522
Total net sales	$	2,802	$	2,638
Operating income:
Americas	$	544	$	538
EMEA	161		144
APAC	128		120
Total segment operating income	$	833	$	802

Operating Income to Income Before Income Taxes Reconciliation

The following is a reconciliation of segment operating income to income before income taxes per the condensed consolidated statements of income.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Total segment operating income	$	833	$	802
Corporate and other	(424)		(419)
Total operating income	409		383
Net interest expense	21		18
Other (income) expense, net	10		(21)
Income before income taxes	$	378	$	386

XML

ACQUISITIONS AND OTHER ARRANGEMENTS - Seprafilm Adhesion Barrier (Details) $ in Millions	1 Months Ended	3 Months Ended
	Feb. 29, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Acquisitions And Collaborations [Line Items]
Goodwill		$ 2,961	$ 3,030
Seprafilm Adhesion Barrier
Acquisitions And Collaborations [Line Items]
Cash consideration transferred	$ 342
Inventories	16
Goodwill	29
Other intangible assets	297
Total assets acquired	342
Net sales	13
Integration related costs		$ 9
Seprafilm Adhesion Barrier | Developed Product Rights
Acquisitions And Collaborations [Line Items]
Fair value of asset acquired	$ 287
Weighted-average useful life	10 years
Seprafilm Adhesion Barrier | Customer Relationships
Acquisitions And Collaborations [Line Items]
Fair value of asset acquired	$ 10
Weighted-average useful life	7 years
Seprafilm Adhesion Barrier | Measurement Input, Discount Rate | Developed Product Rights
Acquisitions And Collaborations [Line Items]
Discount rate used to measure intangible assets	0.148
Seprafilm Adhesion Barrier | Measurement Input, Discount Rate | Customer Relationships
Acquisitions And Collaborations [Line Items]
Discount rate used to measure intangible assets	0.110

XML

ACQUISITIONS AND OTHER ARRANGEMENTS (Tables)

3 Months Ended

Mar. 31, 2020

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the fair values of the assets acquired as of the acquisition date:

(in millions)
Assets acquired
Inventories	$	16
Goodwill	29
Other intangible assets	297
Total assets acquired	$	342

XML

INCOME TAXES

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

Our effective income tax rate was 11.9% and 11.4% for the three months ended March 31, 2020 and 2019, respectively. Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, increases or decreases in valuation allowances and liabilities for uncertain tax positions and excess tax benefits on stock compensation awards.

For the three months ended March 31, 2020, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to a favorable geographic earnings mix and excess tax benefits on stock compensation awards.

For the three months ended March 31, 2019, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily attributable to excess tax benefits on stock compensation awards.

XML

SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

We manage our business based on three geographical segments: Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia Pacific). Our segments provide a broad portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products.

We use operating income on a segment basis to make resource allocation decisions and assess the ongoing performance of our business segments. Intersegment sales are eliminated in consolidation.

Certain items are maintained at Corporate and are not allocated to a segment. They primarily include the majority of foreign currency hedging activities, corporate headquarters costs, certain R&D costs, certain GBU support costs, stock compensation expense, certain employee benefit plan costs, and certain gains, losses, and other charges (such as business optimization, acquisition and integration costs, intangible asset amortization and asset impairments). Our chief operating decision maker does not receive any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

Financial information for our segments is as follows.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Net sales:
Americas	$	1,499	$	1,409
EMEA	754		707
APAC	549		522
Total net sales	$	2,802	$	2,638
Operating income:
Americas	$	544	$	538
EMEA	161		144
APAC	128		120
Total segment operating income	$	833	$	802

The following is a reconciliation of segment operating income to income before income taxes per the condensed consolidated statements of income.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Total segment operating income	$	833	$	802
Corporate and other	(424)		(419)
Total operating income	409		383
Net interest expense	21		18
Other (income) expense, net	10		(21)
Income before income taxes	$	378	$	386

Refer to Note 10 for additional information on Net Sales by GBU.

XML

REVENUES (Tables)

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Net Sales from Contracts with Customers by Global Business Unit

The following tables disaggregate our net sales from contracts with customers by Global Business Unit (GBU) between the U.S. and international:

	Three months ended March 31,
							As Restated
	2020						2019
(in millions)	U.S.		International		Total		U.S.		International		Total
Renal Care 1	$	204	$	666	$	870	$	192	$	662	$	854
Medication Delivery 2	461		229		690		406		228		634
Pharmaceuticals 3	231		296		527		232		278		510
Clinical Nutrition 4	82		138		220		77		128		205
Advanced Surgery 5	137		87		224		120		79		199
Acute Therapies 6	60		96		156		48		81		129
Other 7	42		73		115		45		62		107
Total Baxter	$	1,217	$	1,585	$	2,802	$	1,120	$	1,518	$	2,638

1Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.

2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.

3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.

4Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.

5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.

6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).

7Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.

Sales-type Lease, Lease Income

The components of lease revenue for the three months ended March 31, 2020 and March 31, 2019 were:

(in millions)	Three months ended March 31, 2020		Three months ended March 31, 2019
Sales-type lease revenue	$	6	$	6
Operating lease revenue	14		15
Variable lease revenue	18		21
Total lease revenue	$	38	$	42

Operating Lease, Lease Income

The components of lease revenue for the three months ended March 31, 2020 and March 31, 2019 were:

(in millions)	Three months ended March 31, 2020		Three months ended March 31, 2019
Sales-type lease revenue	$	6	$	6
Operating lease revenue	14		15
Variable lease revenue	18		21
Total lease revenue	$	38	$	42

XML

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Interest Expense, Net

Interest Expense, Net

	Three months ended March 31,
(in millions)	2020		2019
Interest expense, net of capitalized interest	$	30	$	25
Interest income	(9)		(7)
Interest expense, net	$	21	$	18

Other Income, Net

Other (Income) Expense, Net

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Foreign exchange losses (gains), net	$	11	$	(1)
Pension and other postretirement benefit plans	(1)		(15)
Other, net	—		(5)
Other (income) expense, net	$	10	$	(21)

Inventories

Inventories

(in millions)	March 31, 2020		December 31, 2019
Raw materials	$	402	$	377
Work in process	188		185
Finished goods	1,104		1,091
Inventories	$	1,694	$	1,653

Property, Plant and Equipment, Net

Property, Plant and Equipment, Net

(in millions)	March 31, 2020		December 31, 2019
Property, plant and equipment, at cost	$	10,443	$	10,660
Accumulated depreciation	(6,103)		(6,148)
Property, plant and equipment, net	$	4,340	$	4,512

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)

3 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Summary of Gains and Losses on Derivative Instruments

The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended March 31, 2020 and 2019.

	Gain (loss) recognized in OCI				Location of gain (loss) in income statement	Gain (loss) reclassified from AOCI into income
(in millions)	2020		2019			2020		2019
Cash flow hedges
Interest rate contracts	$	(184)	$	(11)	Interest expense, net	$	—	$	—
Foreign exchange contracts	14		(9)		Cost of sales	(1)		—
Net investment hedges	49		14		Other (income) expense, net	—		—
Total	$	(121)	$	(6)		$	(1)	$	—

	Location of gain (loss) in income statement	Gain (loss) recognized in income
				As Restated
(in millions)		2020		2019
Undesignated derivative instruments
Foreign exchange contracts	Other (income) expense, net	$	2	$	(8)

Classification and Fair Values of Derivative Instruments

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2020.

	Derivatives in asset positions			Derivatives in liability positions
(in millions)	Balance sheet location	Fair value		Balance sheet location	Fair value
Derivative instruments designated as hedges
Interest rate contracts	Other non-current assets	$	—	Other non-current liabilities	$	226
Foreign exchange contracts	Prepaid expenses and other current assets	24		Accounts payable and accrued liabilities	3
Total derivative instruments designated as hedges		24			229
Undesignated derivative instruments
Foreign exchange contracts	Prepaid expenses and other current assets	5		Accounts payable and accrued liabilities	4
Total derivative instruments		$	29		$	233

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2019.

	Derivatives in asset positions			Derivatives in liability positions
(in millions)	Balance sheet location	Fair value		Balance sheet location	Fair value
Derivative instruments designated as hedges
Interest rate contracts	Other non-current assets	$	10	Other non-current liabilities	$	52
Foreign exchange contracts	Prepaid expenses and other current assets	10		Accounts payable and accrued liabilities	—
Total derivative instruments designated as hedges		20			52
Undesignated derivative instruments
Foreign exchange contracts	Prepaid expenses and other current assets	1		Accounts payable and accrued liabilities	2
Total derivative instruments		$	21		$	54

Derivative Positions Presented On Net Basis

The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.

	March 31, 2020				December 31, 2019
(in millions)	Asset		Liability		Asset		Liability
Gross amounts recognized in the consolidated balance sheet	$	29	$	233	$	21	$	54
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet	(7)		(7)		(11)		(11)
Total	$	22	$	226	$	10	$	43

Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges

The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:

	Carrying amount of hedged item				Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item (a)
(in millions)	Balance as of March 31, 2020		Balance as of December 31, 2019		Balance as of March 31, 2020		Balance as of December 31, 2019
Long-term debt	$	103	$	103	$	6	$	6

(a) These fair value hedges were terminated prior to December 31, 2019.

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for accounts receivable, current	$ 114	$ 112
Common stock, par value (in dollars per share)	$ 1	$ 1
Common stock, authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, issued (in shares)	683,494,944	683,494,944
Treasury stock, shares (in shares)	175,106,170	177,340,358

XML

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Millions	Total	Common Stock	Common Stock in Treasury	Additional Contributed Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Parent	Noncontrolling Interest
Beginning of period (in shares) at Dec. 31, 2018		683,000,000
Beginning of period at Dec. 31, 2018	$ 7,866	$ 683	$ (9,989)	$ 5,898	$ 15,075	$ (3,823)	$ 7,844	$ 22
Beginning of period, treasury shares (in shares) at Dec. 31, 2018			170,000,000
Adoption of new accounting standards					161	(161)
Net income	342				342		342
Other comprehensive (loss) income	$ (98)					(98)	(98)
Purchases of treasury stock (in shares)	8,100,000		8,000,000
Purchases of treasury stock	$ (586)		$ (586)				(586)
Stock issued under employee benefit plans and other (in shares)			(5,000,000)
Stock issued under employee benefit plans and other	166		$ 291	(59)	(66)		166
Dividends declared on common stock	(98)				(98)		(98)
Change in noncontrolling interests	1							1
End of period (in shares) at Mar. 31, 2019		683,000,000
End of period at Mar. 31, 2019	$ 7,593	$ 683	$ (10,284)	5,839	15,414	(4,082)	7,570	23
End of period, treasury shares (in shares) at Mar. 31, 2019			173,000,000
Beginning of period (in shares) at Dec. 31, 2019	683,494,944	683,000,000
Beginning of period at Dec. 31, 2019	$ 7,912	$ 683	$ (10,764)	5,955	15,718	(3,710)	7,882	30
Beginning of period, treasury shares (in shares) at Dec. 31, 2019	177,340,358		177,000,000
Adoption of new accounting standards	$ (4)				(4)		(4)
Net income	333				332		332	1
Other comprehensive (loss) income	(467)					(467)	(467)
Stock issued under employee benefit plans and other (in shares)			(2,000,000)
Stock issued under employee benefit plans and other	67		$ 87	(20)			67
Dividends declared on common stock	$ (111)				(111)		(111)
End of period (in shares) at Mar. 31, 2020	683,494,944	683,000,000
End of period at Mar. 31, 2020	$ 7,730	$ 683	$ (10,677)	$ 5,935	$ 15,935	$ (4,177)	$ 7,699	$ 31
End of period, treasury shares (in shares) at Mar. 31, 2020	175,106,170		175,000,000

XML

GOODWILL AND OTHER INTANGIBLE ASSETS, NET

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS, NET

GOODWILL AND OTHER INTANGIBLE ASSETS, NET

Goodwill

The following is a reconciliation of goodwill by business segment.

(in millions)	Americas		EMEA		APAC		Total
Balance as of December 31, 2019	$	2,428	$	385	$	217	$	3,030
Acquisitions	32		—		7		39
Currency translation adjustments	(86)		(14)		(8)		(108)
Balance as of March 31, 2020	$	2,374	$	371	$	216	$	2,961

As of March 31, 2020, there were no reductions in goodwill relating to impairment losses.

Other intangible assets, net

The following is a summary of our other intangible assets.

(in millions)	Developed technology, including patents		Other amortized intangible assets		Indefinite-lived intangible assets		Total
March 31, 2020
Gross other intangible assets	$	2,612	$	461	$	179	$	3,252
Accumulated amortization	(1,209)		(284)		—		(1,493)
Other intangible assets, net	$	1,403	$	177	$	179	$	1,759
December 31, 2019
Gross other intangible assets	$	2,309	$	464	$	173	$	2,946
Accumulated amortization	(1,190)		(285)		—		(1,475)
Other intangible assets, net	$	1,119	$	179	$	173	$	1,471

Intangible asset amortization expense was $52 million and $43 million for the three months ended March 31, 2020 and 2019, respectively.

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME

ACCUMULATED OTHER COMPREHENSIVE INCOME

Comprehensive income includes all changes in stockholders’ equity that do not arise from transactions with stockholders, and consists of net income, currency translation adjustments (CTA), certain gains and losses from pension and other postretirement employee benefit (OPEB) plans and gains and losses on cash flow hedges.

The following table is a net-of-tax summary of the changes in AOCI by component for the three months ended March 31, 2020 and 2019.

(in millions)	CTA		Pension and OPEB plans		Hedging activities		Total
Gains (losses)
Balance as of December 31, 2019	$	(2,954)	$	(715)	$	(41)	$	(3,710)
Other comprehensive income (loss) before reclassifications	(359)		10		(131)		(480)
Amounts reclassified from AOCI (a)	—		12		1		13
Net other comprehensive income (loss)	(359)		22		(130)		(467)
Balance as of March 31, 2020	$	(3,313)	$	(693)	$	(171)	$	(4,177)

	As Restated
(in millions)	CTA		Pension and OPEB plans		Hedging activities		Total
Gains (losses)
Balance as of December 31, 2018	$	(2,868)	$	(954)	$	(1)	$	(3,823)
Adoption of new accounting standard	9		(169)		(1)		(161)
Other comprehensive income (loss) before reclassifications	(97)		7		(15)		(105)
Amounts reclassified from AOCI (a)	—		7		—		7
Net other comprehensive income (loss)	(97)		14		(15)		(98)
Balance as of March 31, 2019	$	(2,956)	$	(1,109)	$	(17)	$	(4,082)

(a) See table below for details about these reclassifications.

The following is a summary of the amounts reclassified from AOCI to net income during the three months ended March 31, 2020 and 2019.

	Amounts reclassified from AOCI (a)
			As Restated
(in millions)	Three months ended March 31, 2020		Three months ended March 31, 2019		Location of impact in income statement
Amortization of pension and OPEB items
Amortization of net losses and prior service costs or credits	$	(15)	$	(8)	Other (income) expense, net
Less: Tax effect	3		1		Income tax expense
	$	(12)	$	(7)	Net of tax
Gains on hedging activities
Foreign exchange contracts	$	(1)	$	—	Cost of sales
Less: Tax effect	—		—		Income tax expense
	$	(1)	$	—	Net of tax
Total reclassifications for the period	$	(13)	$	(7)	Total net of tax

(a) Amounts in parentheses indicate reductions to net income.

Refer to Note 12 for additional information regarding the amortization of pension and OPEB items and Note 15 for additional information regarding hedging activity.

XML

Earnings Per Share - Reconciliation of Basic Shares to Diluted Shares (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Reconciliation of Basic Shares to Diluted Shares
Basic (in shares)	507	512
Effect of dilutive securities (in shares)	9	10
Diluted (in shares)	516	522

XML

Fair Value Measurements - Book Values and Fair Values of Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Book Values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Short-term debt	$ 221	$ 226
Current maturities of long-term debt and finance lease obligations	315	315
Long-term debt and finance lease obligations	5,996	4,809
Fair values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Short-term debt	221	226
Current maturities of long-term debt and finance lease obligations	315	315
Long-term debt and finance lease obligations	$ 6,324	$ 5,156

XML

Derivative Instruments and Hedging Activities - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details) - Long-term debt - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Contracts designated as fair value hedges	$ 103	$ 103
Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item	$ 6	$ 6

XML

Business Optimization Charges - Components of Restructuring Charges (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Restructuring Cost and Reserve [Line Items]
Charges	$ 25	$ 25
Cost of Goods Sold
Restructuring Cost and Reserve [Line Items]
Charges	8	16
Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Charges	16	0
Research and Development Expenses
Restructuring Cost and Reserve [Line Items]
Charges	1	9
Employee termination costs
Restructuring Cost and Reserve [Line Items]
Charges	19	8
Employee termination costs | Cost of Goods Sold
Restructuring Cost and Reserve [Line Items]
Charges	2	0
Employee termination costs | Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Charges	16	(1)
Employee termination costs | Research and Development Expenses
Restructuring Cost and Reserve [Line Items]
Charges	1	9
Contract termination costs
Restructuring Cost and Reserve [Line Items]
Charges		7
Contract termination costs | Cost of Goods Sold
Restructuring Cost and Reserve [Line Items]
Charges		7
Contract termination costs | Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Charges		0
Contract termination costs | Research and Development Expenses
Restructuring Cost and Reserve [Line Items]
Charges		0
Asset impairments
Restructuring Cost and Reserve [Line Items]
Charges	6	10
Asset impairments | Cost of Goods Sold
Restructuring Cost and Reserve [Line Items]
Charges	6	9
Asset impairments | Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Charges	0	1
Asset impairments | Research and Development Expenses
Restructuring Cost and Reserve [Line Items]
Charges	$ 0	$ 0

XML

Financing Arrangements - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020 USD ($)	Mar. 31, 2020 EUR (€)	Dec. 31, 2019 USD ($)
Debt Instrument [Line Items]
Annual interest rate, potential increase	0.25%
Annual interest rate, maximum potential increase	0.50%
Foreign Line of Credit
Debt Instrument [Line Items]
Line of credit, current borrowing capacity	$ 220,000,000	€ 200,000,000	$ 224,000,000
Line of credit facility, interest rate at period end	0.91%	0.91%
Senior Notes Due 2025 | Senior Notes
Debt Instrument [Line Items]
Senior notes	$ 750,000,000
Senior notes, interest rate	3.75%	3.75%
Senior Notes Due 2030 | Senior Notes
Debt Instrument [Line Items]
Senior notes	$ 500,000,000
Senior notes, interest rate	3.95%	3.95%

XML

Supplemental Financial Information - Interest Expense, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Interest Income Expense Net
Interest expense, net of capitalized interest	$ 30	$ 25
Interest income	(9)	(7)
Interest expense, net	$ 21	$ 18

XML

Supplemental Financial Information - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Operating lease right-of-use assets	$ 577		$ 608
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	15	$ 42
Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, additions	$ 49	$ 39

XML

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Summary of Financial Instruments Measured at Fair Value on Recurring Basis

The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.

			Basis of fair value measurement
(in millions)	Balance as of March 31, 2020		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Foreign exchange contracts	$	29	$	—	$	29	$	—
Marketable equity securities	3		3		—		—
Total	$	32	$	3	$	29	$	—
Liabilities
Foreign exchange contracts	$	7	$	—	$	7	$	—
Interest rate contracts	226		—		226		—
Contingent payments related to acquisitions	39		—		—		39
Total	$	272	$	—	$	233	$	39

			Basis of fair value measurement
(in millions)	Balance as of December 31, 2019		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Foreign exchange contracts	$	11	$	—	$	11	$	—
Interest rate contracts	10		—		10		—
Marketable equity securities	3		3		—		—
Total	$	24	$	3	$	21	$	—
Liabilities
Foreign exchange contracts	$	2	$	—	$	2	$	—
Interest rate contracts	52		—		52		—
Contingent payments related to acquisitions	39		—		—		39
Total	$	93	$	—	$	54	$	39

Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs

The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions.

	Three months ended March 31,
(in millions)	2020		2019
Fair value at beginning of period	$	39	$	32
Additions	4		—
Change in fair value recognized in earnings	(3)		—
Payments	(1)		(1)
Fair value at end of period	$	39	$	31

Book Values and Fair Values of Financial Instruments

the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of March 31, 2020 and December 31, 2019.

	Book values				Fair values(a)
(in millions)	2020		2019		2020		2019
Liabilities
Short-term debt	$	221	$	226	$	221	$	226
Current maturities of long-term debt and finance lease obligations	315		315		315		315
Long-term debt and finance lease obligations	5,996		4,809		6,324		5,156

(a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.

XML

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 4,110	$ 3,335
Accounts receivable, net of allowances of $114 in 2020 and $112 in 2019	1,892	1,896
Inventories	1,694	1,653
Prepaid expenses and other current assets	637	619
Total current assets	8,333	7,503
Property, plant and equipment, net	4,340	4,512
Goodwill	2,961	3,030
Other intangible assets, net	1,759	1,471
Operating lease right-of-use assets	577	608
Other non-current assets	1,105	1,069
Total assets	19,075	18,193
Current liabilities:
Short-term debt	221	226
Current maturities of long-term debt and finance lease obligations	315	315
Accounts payable and accrued liabilities	2,500	2,689
Total current liabilities	3,036	3,230
Long-term debt and finance lease obligations	5,996	4,809
Operating lease liabilities	486	510
Other non-current liabilities	1,827	1,732
Total liabilities	11,345	10,281
Commitments and contingencies
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2020 and 2019	683	683
Common stock in treasury, at cost, 175,106,170 shares in 2020 and 177,340,358 shares in 2019	(10,677)	(10,764)
Additional contributed capital	5,935	5,955
Retained earnings	15,935	15,718
Accumulated other comprehensive (loss) income	(4,177)	(3,710)
Total Baxter stockholders’ equity	7,699	7,882
Noncontrolling interests	31	30
Total equity	7,730	7,912
Total liabilities and equity	$ 19,075	$ 18,193
Common stock, par value (in dollars per share)	$ 1	$ 1
Common stock, authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, issued (in shares)	683,494,944	683,494,944
Treasury stock, shares (in shares)	175,106,170	177,340,358

XML

Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Currency translation adjustments, tax	$ (8)	$ 0
Pension and other postretirement benefits, tax	6	4
Hedging activities, tax	$ (39)	$ (5)

XML

BUSINESS OPTIMIZATION CHARGES (Tables)

3 Months Ended

Mar. 31, 2020

Restructuring and Related Activities [Abstract]

Summary of Business Optimization Charges

During the three months ended March 31, 2020 and 2019, we recorded the following charges related to business optimization programs.

	Three months ended March 31,
(in millions)	2020		2019
Restructuring charges	$	25	$	25
Costs to implement business optimization programs	7		10
Accelerated depreciation	—		3
Total business optimization charges	$	32	$	38

Components of Restructuring Charges

During the three months ended March 31, 2020 and 2019, we recorded the following restructuring charges.

	Three months ended March 31, 2020
(in millions)	COGS		SG&A		R&D		Total
Employee termination costs	$	2	$	16	$	1	$	19
Asset impairments	6		—		—		6
Total restructuring charges	$	8	$	16	$	1	$	25

	Three months ended March 31, 2019
(in millions)	COGS		SG&A		R&D		Total
Employee termination costs	$	—	$	(1)	$	9	$	8
Contract termination costs	7		—		—		7
Asset impairments	9		1		—		10
Total restructuring charges	$	16	$	—	$	9	$	25

Summary of Activity in Reserves Related to Restructuring Initiatives

The following table summarizes activity in the liability related to our restructuring initiatives.

(in millions)
Liability balance as of December 31, 2019	$	92
Charges	19
Payments	(21)
Currency translation	(2)
Liability balance as of March 31, 2020	$	88

XML

GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

The following is a reconciliation of goodwill by business segment.

(in millions)	Americas		EMEA		APAC		Total
Balance as of December 31, 2019	$	2,428	$	385	$	217	$	3,030
Acquisitions	32		—		7		39
Currency translation adjustments	(86)		(14)		(8)		(108)
Balance as of March 31, 2020	$	2,374	$	371	$	216	$	2,961

Schedule of Indefinite-Lived Intangible Assets

Other intangible assets, net

The following is a summary of our other intangible assets.

(in millions)	Developed technology, including patents		Other amortized intangible assets		Indefinite-lived intangible assets		Total
March 31, 2020
Gross other intangible assets	$	2,612	$	461	$	179	$	3,252
Accumulated amortization	(1,209)		(284)		—		(1,493)
Other intangible assets, net	$	1,403	$	177	$	179	$	1,759
December 31, 2019
Gross other intangible assets	$	2,309	$	464	$	173	$	2,946
Accumulated amortization	(1,190)		(285)		—		(1,475)
Other intangible assets, net	$	1,119	$	179	$	173	$	1,471

Schedule of Finite-Lived Intangible Assets

Other intangible assets, net

The following is a summary of our other intangible assets.

(in millions)	Developed technology, including patents		Other amortized intangible assets		Indefinite-lived intangible assets		Total
March 31, 2020
Gross other intangible assets	$	2,612	$	461	$	179	$	3,252
Accumulated amortization	(1,209)		(284)		—		(1,493)
Other intangible assets, net	$	1,403	$	177	$	179	$	1,759
December 31, 2019
Gross other intangible assets	$	2,309	$	464	$	173	$	2,946
Accumulated amortization	(1,190)		(285)		—		(1,475)
Other intangible assets, net	$	1,119	$	179	$	173	$	1,471

XML

SUPPLEMENTAL FINANCIAL INFORMATION

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUPPLEMENTAL FINANCIAL INFORMATION

SUPPLEMENTAL FINANCIAL INFORMATION

Interest Expense, Net

	Three months ended March 31,
(in millions)	2020		2019
Interest expense, net of capitalized interest	$	30	$	25
Interest income	(9)		(7)
Interest expense, net	$	21	$	18

Other (Income) Expense, Net

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Foreign exchange losses (gains), net	$	11	$	(1)
Pension and other postretirement benefit plans	(1)		(15)
Other, net	—		(5)
Other (income) expense, net	$	10	$	(21)

Inventories

(in millions)	March 31, 2020		December 31, 2019
Raw materials	$	402	$	377
Work in process	188		185
Finished goods	1,104		1,091
Inventories	$	1,694	$	1,653

Property, Plant and Equipment, Net

(in millions)	March 31, 2020		December 31, 2019
Property, plant and equipment, at cost	$	10,443	$	10,660
Accumulated depreciation	(6,103)		(6,148)
Property, plant and equipment, net	$	4,340	$	4,512

Non-Cash Operating and Investing Activities

Right-of-use operating lease assets obtained in exchange for lease obligations for the three months ended March 31, 2020 and 2019 were $15 million and $42 million, respectively.

Purchases of property, plant and equipment included in accounts payable and accrued liabilities as of March 31, 2020 and 2019 was $49 million and $39 million, respectively.

XML

STOCKHOLDERS’ EQUITY

3 Months Ended

Mar. 31, 2020

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCKHOLDERS' EQUITY

STOCKHOLDERS’ EQUITY

Stock-Based Compensation

Stock compensation expense totaled $29 million and $22 million in the first quarter of 2020 and 2019, respectively. Approximately 70% of stock compensation expense is classified within SG&A expense with the remainder classified in cost of sales and R&D expense.

We awarded stock compensation grants which consisted of 3.7 million stock options, 0.5 million restricted stock units (RSUs) and 0.4 million performance stock units (PSUs) during the first quarter of 2020. The grant date fair values of stock options, RSUs and PSUs awarded in the first quarter of 2020 were $59 million, $37 million and $29 million, respectively. Stock options and RSUs generally vest in one-third increments over a three-year period. One-fourth of the PSUs granted related to the establishment of the adjusted operating margin vesting condition for awards issued in 2018 and 2019 whereas the remainder were related to awards made in March 2020, which are equally divided into PSUs based on our compound annual sales growth rate performance, our adjusted return on invested capital performance and on our stock performance relative to our peer group. All of the PSUs granted vest at the end of the applicable three-year service period.

Stock Options

The weighted-average Black-Scholes assumptions used in establishing the fair value of stock options granted during the period, along with weighted-average grant date fair values, were as follows:

	Three months ended March 31,
	2020			2019
Expected volatility	26		%	19		%
Expected life (in years)	5.5			5.5
Risk-free interest rate	0.6		%	2.6		%
Dividend yield	1.2		%	1.0		%
Fair value per stock option	$	16		$	15

The total intrinsic value of stock options exercised was $52 million and $153 million during the first quarters of 2020 and 2019, respectively.

As of March 31, 2020, the unrecognized compensation cost related to all unvested stock options of $103 million is expected to be recognized as expense over a weighted-average period of 2.1 years.

RSUs

As of March 31, 2020, the unrecognized compensation cost related to all unvested RSUs of $73 million is expected to be recognized as expense over a weighted-average period of 2.0 years.

PSUs

As of March 31, 2020, the unrecognized compensation cost related to all unvested PSUs of $44 million is expected to be recognized as expense over a weighted-average period of 2.1 years.

Stock Options Award Modification

In the first quarter of 2020, we modified the terms of stock option awards granted to 123 employees. Specifically, we extended the term for certain stock options that were scheduled to expire in the first quarter of 2020 as applicable employees were not permitted to exercise these awards due to our announcement in February 2020 that our previously issued financial statements should no longer be relied upon. The stock options were extended in order to allow impacted employees to exercise their stock option awards for a brief period once we became current with our

SEC reporting obligations, which occurred in March 2020. As a result of the modifications, we recognized an additional $8 million of stock compensation expense during the quarter ended March 31, 2020.

Cash Dividends

Cash dividends declared per share for the three months ended March 31, 2020 and March 31, 2019 were $0.22 and $0.19, respectively.

Stock Repurchase Programs

In July 2012, the Board of Directors authorized the repurchase of up to $2.0 billion of our common stock. The Board of Directors increased this authority by an additional $1.5 billion in each of November 2016 and February 2018 and by an additional $2.0 billion in November 2018. During the first quarter of 2020, we did not repurchase any shares under this authority. During the first quarter of 2019, we repurchased 8.1 million shares pursuant to Rule 10b5-1 plans. We had $897 million remaining available under the authorization as of March 31, 2020.

XML

Earnings Per Share - Additional Information (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Anti-dilutive securities excluded from computation of EPS (in shares)	1	4

XML

Segment Information - Summary of Financial Information for Our Segments (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($) Segment	Mar. 31, 2019 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | Segment	3
Net sales	$ 2,802	$ 2,638
Total segment operating income	409	383
Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,802	2,638
Total segment operating income	833	802
Operating Segments | Americas
Segment Reporting Information [Line Items]
Net sales	1,499	1,409
Total segment operating income	544	538
Operating Segments | EMEA
Segment Reporting Information [Line Items]
Net sales	754	707
Total segment operating income	161	144
Operating Segments | APAC
Segment Reporting Information [Line Items]
Net sales	549	522
Total segment operating income	$ 128	$ 120

XML

Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange contracts	$ 29	$ 11
Interest rate contracts		10
Marketable equity securities	3	3
Total assets	32	24
Foreign exchange contracts	7	2
Interest rate contracts	226	52
Contingent payments related to acquisitions	39	39
Total liabilities	272	93
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange contracts	0	0
Interest rate contracts		0
Marketable equity securities	3	3
Total assets	3	3
Foreign exchange contracts	0	0
Interest rate contracts	0	0
Contingent payments related to acquisitions	0	0
Total liabilities	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange contracts	29	11
Interest rate contracts		10
Marketable equity securities	0	0
Total assets	29	21
Foreign exchange contracts	7	2
Interest rate contracts	226	52
Contingent payments related to acquisitions	0	0
Total liabilities	233	54
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange contracts	0	0
Interest rate contracts		0
Marketable equity securities	0	0
Total assets	0	0
Foreign exchange contracts	0	0
Interest rate contracts	0	0
Contingent payments related to acquisitions	39	39
Total liabilities	$ 39	$ 39

XML

Business Optimization Charges - Summary of Activity in Reserves Related to Restructuring Initiatives (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Restructuring Cost and Reserve [Line Items]
Charges	$ 25	$ 25
Severance and Other Employee Related Costs
Restructuring Cost and Reserve [Line Items]
Reserve, beginning balance	92
Charges	19
Payments	(21)
Currency translation	(2)
Reserve, ending balance	$ 88

XML

ACQUISITIONS AND OTHER ARRANGEMENTS - Other Business Development Activities (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2020	Mar. 31, 2020
Licensing Agreements
Business Acquisition [Line Items]
Payments to acquire intangible assets		$ 21
Payments for Development Regulatory and Commercial Milestones		$ 41
Developed Technology Rights Acquisition
Business Acquisition [Line Items]
Asset acquisition, consideration transferred	$ 60
Developed Technology Rights Acquisition | Developed Technology Intangible Asset
Business Acquisition [Line Items]
Finite-lived intangible asset, useful life	11 years

XML

Supplemental Financial Information - Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Property, plant and equipment, at cost	$ 10,443	$ 10,660
Accumulated depreciation	(6,103)	(6,148)
Property, plant and equipment, net	$ 4,340	$ 4,512

XML

Goodwill and Other Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset amortization expense	$ 52	$ 43

XML

STOCKHOLDERS' EQUITY - Stock Options Fair Value Assumptions (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected volatility	26.00%	19.00%
Expected life (in years)	5 years 6 months	5 years 6 months
Risk-free interest rate	0.60%	2.60%
Dividend yield	1.20%	1.00%
Fair value per stock option (in dollars per share)	$ 16	$ 15

XML

Revenues - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Line Items]
Net trade accounts receivable	$ 1,700	$ 1,800
Contract assets	133	131
Contract with Customer, Liability	19	12
Accounts and Other Receivables, Net
Revenue From Contract With Customer [Line Items]
Contract assets, current	66	63
Other non-current assets
Revenue From Contract With Customer [Line Items]
Contract assets, noncurrent	67	68
Other non-current liabilities
Revenue From Contract With Customer [Line Items]
Contract liability, noncurrent	12	12
Accounts payable and accrued liabilities
Revenue From Contract With Customer [Line Items]
Contract with customer, liability, current	7
Consumable Medical Products
Revenue From Contract With Customer [Line Items]
Contract assets, current	12	52
Manufacturing Arrangements
Revenue From Contract With Customer [Line Items]
Contract assets	37	36
Software Arrangements
Revenue From Contract With Customer [Line Items]
Contract assets, current	47	43
Bundled Equipment
Revenue From Contract With Customer [Line Items]
Contract assets	$ 49
Contract assets, current		$ 52
Minimum
Revenue From Contract With Customer [Line Items]
Global payment terms	30 days
Minimum | Consumable Medical Products
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	1 year
Minimum | Software Arrangements
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	1 year
Maximum
Revenue From Contract With Customer [Line Items]
Global payment terms	90 days
Maximum | Consumable Medical Products
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	7 years
Maximum | Manufacturing Arrangements
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	90 days
Maximum | Software Arrangements
Revenue From Contract With Customer [Line Items]
Revenue recognized contract period	5 years

XML

ACQUISITIONS AND OTHER ARRANGEMENTS - Other Business Combinations (Details) - Other Acquisitions $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Business Acquisition [Line Items]
Cash consideration transferred	$ 13
Contingent consideration	12
Contingent consideration, liability	$ 4

XML

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Consolidated Statement of Changes in Equity (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period (in shares)	683,494,944
Beginning of period	$ 7,912	$ 7,866
Treasury stock, shares (in shares)	175,106,170		177,340,358
Adoption of new accounting standards	$ (4)
Net income	333	342
Other comprehensive (loss) income	(467)	$ (98)
Purchases of treasury stock (in shares)		8,100,000
Purchases of treasury stock		$ (586)
Stock issued under employee benefit plans and other	67	166
Dividends declared on common stock	$ (111)	(98)
Change in noncontrolling interests		1
End of period (in shares)	683,494,944
End of period	$ 7,730	$ 7,593
Common stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period (in shares)	683,000,000	683,000,000
Beginning of period	$ 683	$ 683
End of period (in shares)	683,000,000	683,000,000
End of period	$ 683	$ 683
Common stock in treasury
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period	$ (10,764)	$ (9,989)
Treasury stock, shares (in shares)	175,000,000	173,000,000	177,000,000	170,000,000
Purchases of treasury stock (in shares)		8,000,000
Purchases of treasury stock		$ (586)
Stock issued under employee benefit plans and other (in shares)	(2,000,000)	(5,000,000)
Stock issued under employee benefit plans and other	$ 87	$ 291
End of period	(10,677)	(10,284)
Additional contributed capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period	5,955	5,898
Stock issued under employee benefit plans and other	(20)	(59)
End of period	5,935	5,839
Retained earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period	15,718	15,075
Adoption of new accounting standards	(4)	161
Net income	332	342
Stock issued under employee benefit plans and other		(66)
Dividends declared on common stock	(111)	(98)
End of period	15,935	15,414
Accumulated other comprehensive income (loss)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period	(3,710)	(3,823)
Adoption of new accounting standards		(161)
Other comprehensive (loss) income	(467)	(98)
End of period	(4,177)	(4,082)
Total Baxter stockholders' equity
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period	7,882	7,844
Adoption of new accounting standards	(4)
Net income	332	342
Other comprehensive (loss) income	(467)	(98)
Purchases of treasury stock		(586)
Stock issued under employee benefit plans and other	67	166
Dividends declared on common stock	(111)	(98)
End of period	7,699	7,570
Noncontrolling interests
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period	30	22
Net income	1
Change in noncontrolling interests		1
End of period	$ 31	23
As previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		7,816
Net income		347
Other comprehensive (loss) income		23
Purchases of treasury stock		(586)
Stock issued under employee benefit plans and other		166
Dividends declared on common stock		(98)
Change in noncontrolling interests		1
End of period		$ 7,669
As previously reported | Common stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period (in shares)		683,000,000
Beginning of period		$ 683
End of period (in shares)		683,000,000
End of period		$ 683
As previously reported | Common stock in treasury
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		$ (9,989)
Treasury stock, shares (in shares)		173,000,000		170,000,000
Purchases of treasury stock (in shares)		8,000,000
Purchases of treasury stock		$ (586)
Stock issued under employee benefit plans and other (in shares)		(5,000,000)
Stock issued under employee benefit plans and other		$ 291
End of period		(10,284)
As previously reported | Additional contributed capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		5,898
Stock issued under employee benefit plans and other		(59)
End of period		5,839
As previously reported | Retained earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		15,626
Net income		347
Stock issued under employee benefit plans and other		(66)
Dividends declared on common stock		(98)
End of period		15,970
As previously reported | Accumulated other comprehensive income (loss)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		(4,424)
Other comprehensive (loss) income		23
End of period		(4,562)
As previously reported | Total Baxter stockholders' equity
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		7,794
Net income		347
Other comprehensive (loss) income		23
Purchases of treasury stock		(586)
Stock issued under employee benefit plans and other		166
Dividends declared on common stock		(98)
End of period		7,646
As previously reported | Noncontrolling interests
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		22
Change in noncontrolling interests		1
End of period		23
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		50
Net income		(5)
Other comprehensive (loss) income		(121)
End of period		$ (76)
Restatement impacts | Common stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period (in shares)		0
Beginning of period		$ 0
End of period (in shares)		0
End of period		$ 0
Restatement impacts | Common stock in treasury
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		$ 0
Treasury stock, shares (in shares)		0		0
End of period		$ 0
Restatement impacts | Additional contributed capital
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		0
End of period		0
Restatement impacts | Retained earnings
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		(551)
Net income		(5)
End of period		(556)
Restatement impacts | Accumulated other comprehensive income (loss)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		601
Other comprehensive (loss) income		(121)
End of period		480
Restatement impacts | Total Baxter stockholders' equity
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		50
Net income		(5)
Other comprehensive (loss) income		(121)
End of period		(76)
Restatement impacts | Noncontrolling interests
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning of period		0
End of period		$ 0

XML

BASIS OF PRESENTATION - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Jan. 01, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings	$ 15,935		$ 15,718
Sales-type lease, net of investment in lease	127
Service contracts, implementation costs	8
Lease Term Originated in 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales-type lease, net of investment in lease	21
Lease Term Originated in 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales-type lease, net of investment in lease	18
Lease Term Originated in 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales-type lease, net of investment in lease	46
Lease Term Originated in 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales-type lease, net of investment in lease	36
Lease Term Originated in 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales-type lease, net of investment in lease	$ 6
Accounting Standards Update 2016-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings		$ (4)

XML

PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS

3 Months Ended

Mar. 31, 2020

Retirement Benefits [Abstract]

PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS

PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS

The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Pension benefits
Service cost	$	21	$	18
Interest cost	24		47
Expected return on plan assets	(41)		(72)
Amortization of net losses and prior service costs	19		15
Net periodic pension benefit cost	$	23	$	8
OPEB
Interest cost	$	1	$	2
Amortization of net loss and prior service credit	(4)		(7)
Net periodic OPEB cost (income)	$	(3)	$	(5)

XML

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.

			Basis of fair value measurement
(in millions)	Balance as of March 31, 2020		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Foreign exchange contracts	$	29	$	—	$	29	$	—
Marketable equity securities	3		3		—		—
Total	$	32	$	3	$	29	$	—
Liabilities
Foreign exchange contracts	$	7	$	—	$	7	$	—
Interest rate contracts	226		—		226		—
Contingent payments related to acquisitions	39		—		—		39
Total	$	272	$	—	$	233	$	39

			Basis of fair value measurement
(in millions)	Balance as of December 31, 2019		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Foreign exchange contracts	$	11	$	—	$	11	$	—
Interest rate contracts	10		—		10		—
Marketable equity securities	3		3		—		—
Total	$	24	$	3	$	21	$	—
Liabilities
Foreign exchange contracts	$	2	$	—	$	2	$	—
Interest rate contracts	52		—		52		—
Contingent payments related to acquisitions	39		—		—		39
Total	$	93	$	—	$	54	$	39

As of March 31, 2020 and December 31, 2019, cash and cash equivalents of $4.1 billion and $3.3 billion, respectively, included money market and other short-term funds of approximately $2.3 billion and $1.7 billion, respectively, which are considered Level 2 in the fair value hierarchy.

For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility.

Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques. The fair value of milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated. The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions.

	Three months ended March 31,
(in millions)	2020		2019
Fair value at beginning of period	$	39	$	32
Additions	4		—
Change in fair value recognized in earnings	(3)		—
Payments	(1)		(1)
Fair value at end of period	$	39	$	31

Financial Instruments Not Measured at Fair Value

In addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of March 31, 2020 and December 31, 2019.

	Book values				Fair values(a)
(in millions)	2020		2019		2020		2019
Liabilities
Short-term debt	$	221	$	226	$	221	$	226
Current maturities of long-term debt and finance lease obligations	315		315		315		315
Long-term debt and finance lease obligations	5,996		4,809		6,324		5,156

(a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.

The carrying value of short-term debt approximates its fair value due to the short-term maturities of the obligations. The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments approximate their fair values due to the short-term maturities of most of those assets and liabilities.

Equity investments not measured at fair value are comprised of other equity investments without readily determinable fair values and were $77 million at March 31, 2020 and $73 million at December 31, 2019. These amounts are included in Other non-current assets on our condensed consolidated balance sheets.

XML

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Tables)

3 Months Ended

Mar. 31, 2020

Accounting Changes and Error Corrections [Abstract]

Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements

The following tables were previously presented in our Annual Report on Form 10-K for the year ended December 31, 2019. See Note 19, Quarterly Financial Data (unaudited), to the consolidated financial statements in our Annual Report on Form 10-K. Below, we have presented reconciliations from our prior periods as previously reported to the restated amounts for each of our condensed consolidated financial statements for the three months ended March 31, 2019. The amounts as previously reported were derived from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 7, 2019.

Baxter International Inc.
Condensed Consolidated Statement of Income
(in millions, except per share)
	Three months ended March 31, 2019
	As previously reported		Restatement impacts		Restatement reference	As restated
Net sales	$	2,632	$	6	(e)	$	2,638
Cost of sales	1,552		6		(c)(e)	1,558
Gross margin	1,080		—			1,080
Selling, general and administrative expenses	600		1		(e)	601
Research and development expenses	129		—			129
Other operating income, net	(33)		—			(33)
Operating income	384		(1)			383
Interest expense, net	18		—			18
Other (income) expense, net	(25)		4		(a)(b)	(21)
Income before income taxes	391		(5)			386
Income tax expense	44		—			44
Net income	$	347	$	(5)		$	342
Earnings per share
Basic	$	0.68	$	(0.01)		$	0.67
Diluted	$	0.66	$	—		$	0.66
Weighted-average number of shares outstanding
Basic	512		—			512
Diluted	522		—			522

(a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in a decrease to other (income) expense, net of $5 million for the three months ended March 31, 2019.

(b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in an increase to other (income) expense, net of $1 million for the three months ended March 31, 2019.

(c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in an increase to cost of sales of $2 million for the three months ended March 31, 2019.

(e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to net sales of $6 million, cost of sales of $4 million and selling, general and administrative (SG&A) expense of $1 million for the three months ended March 31, 2019.

Baxter International Inc.
Condensed Consolidated Statement of Comprehensive Income
(in millions)
	Three months ended March 31, 2019
	As previously reported		Restatement impacts		As restated
Net income	$	347	$	(5)	$	342
Other comprehensive (loss) income, net of tax:
Currency translation adjustments	30		(127)		(97)
Pension and other postretirement benefit plans	8		6		14
Hedging activities	(15)		—		(15)
Total other comprehensive loss, net of tax	23		(121)		(98)
Comprehensive income	$	370	$	(126)	$	244

Baxter International Inc.
Condensed Consolidated Statement of Changes in Equity
(in millions)
	For the Three Months Ended March 31, 2019
	Baxter International Inc. stockholders' equity
	Common stock shares	Common stock		Common stock shares in treasury	Common stock in treasury		Additional contributed capital		Retained earnings		Accumulated other comprehensive income (loss)		Total Baxter stockholders' equity		Noncontrolling interests		Total equity
As previously reported
Balance as of January 1, 2019	683	$	683	170	$	(9,989)	$	5,898	$	15,626	$	(4,424)	$	7,794	$	22	$	7,816
Adoption of new accounting standards	—	—		—	—		—		161		(161)		—		—		—
Net income	—	—		—	—		—		347		—		347		—		347
Other comprehensive income (loss)	—	—		—	—		—		—		23		23		—		23
Purchases of treasury stock	—	—		8	(586)		—		—		—		(586)		—		(586)
Stock issued under employee benefit plans and other	—	—		(5)	291		(59)		(66)		—		166		—		166
Dividends declared on common stock	—	—		—	—		—		(98)		—		(98)		—		(98)
Changes in noncontrolling interests	—	—		—	—		—		—		—		—		1		1
Balance as of March 31, 2019	683	$	683	173	$	(10,284)	$	5,839	$	15,970	$	(4,562)	$	7,646	$	23	$	7,669
Restatement impacts
Balance as of January 1, 2019	—	$	—	—	$	—	$	—	$	(551)	$	601	$	50	$	—	$	50
Net income	—	—		—	—		—		(5)		—		(5)		—		(5)
Other comprehensive income (loss)	—	—		—	—		—		—		(121)		(121)		—		(121)
Balance as of March 31, 2019	—	$	—	—	$	—	$	—	$	(556)	$	480	$	(76)	$	—	$	(76)
As restated
Balance as of January 1, 2019	683	$	683	170	$	(9,989)	$	5,898	$	15,075	$	(3,823)	$	7,844	$	22	$	7,866
Adoption of new accounting standards	—	—		—	—		—		161		(161)		—		—		—
Net income	—	—		—	—		—		342		—		342		—		342
Other comprehensive income (loss)	—	—		—	—		—		—		(98)		(98)		—		(98)
Purchases of treasury stock	—	—		8	(586)		—		—		—		(586)		—		(586)
Stock issued under employee benefit plans and other	—	—		(5)	291		(59)		(66)		—		166		—		166
Dividends declared on common stock	—	—		—	—		—		(98)		—		(98)		—		(98)
Changes in noncontrolling interests	—	—		—	—		—		—		—		—		1		1
Balance as of March 31, 2019	683	$	683	173	$	(10,284)	$	5,839	$	15,414	$	(4,082)	$	7,570	$	23	$	7,593

The adjustments to the January 1, 2019 retained earnings and accumulated other comprehensive loss represent the cumulative impacts of foreign exchange gains and losses and the translation of our financial position and results of operations for our foreign operations into U.S. dollars for the periods prior to January 1, 2019. Retained earnings also includes the cumulative impacts of equipment leased to customers under operating leases and other miscellaneous adjustments for the periods prior to January 1, 2019.

See descriptions of the net income and other comprehensive income impacts in the condensed consolidated statement of income and condensed consolidated statement of comprehensive income for the three months ended March 31, 2019 sections above.

Baxter International Inc.
Condensed Consolidated Statement of Cash Flows
(in millions)
	For the Three Months Ended March 31, 2019
	As previously reported		Restatement impacts		Restatement reference	As restated
Cash flows from operations
Net income	$	347	$	(5)		$	342
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	195		(3)		(c)	192
Deferred income taxes	(6)		—			(6)
Stock compensation	22		—			22
Net periodic pension benefit and other postretirement costs	3		—			3
Other	19		(5)		(d)	14
Changes in balance sheet items:
Accounts receivable, net	32		—			32
Inventories	(82)		—			(82)
Accounts payable and accrued liabilities	(333)		(2)		(b)(f)	(335)
Other	(49)		1		(b)(e)(f)	(48)
Cash flows from operations - continuing operations	148		(14)			134
Cash flows from operations - discontinued operations	(6)		—			(6)
Cash flows from operations	142		(14)			128
Cash flows from investing activities
Capital expenditures	(198)		5		(c)	(193)
Acquisitions and investments, net of cash acquired	(109)		—			(109)
Other investing activities, net	1		—			1
Cash flows from investing activities	(306)		5			(301)
Cash flows from financing activities
Net increases in debt obligations with original maturities of three months or less	795		—			795
Cash dividends on common stock	(101)		—			(101)
Proceeds from stock issued under employee benefit plans	173		—			173
Purchases of treasury stock	(597)		—			(597)
Other financing activities, net	(32)		—			(32)
Cash flows from financing activities	238		—			238
Effect of foreign exchange rate changes on cash and cash equivalents	2		(3)		(a)(d)(e)	(1)
Increase (decrease) in cash and cash equivalents	76		(12)			64
Cash and cash equivalents at beginning of period	1,832		6		(e)	1,838
Cash and cash equivalents at end of period	$	1,908	$	(6)	(e)	$	1,902

The $5 million decrease to net income was driven by the items described above in the condensed consolidated statement of income for the three months ended March 31, 2019 section.

(a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in an increase to the effect of foreign exchange rate changes on cash and cash equivalents of $4 million for the three months ended March 31, 2019.

(b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in a decrease to changes in accounts payable and accrued liabilities of $1 million and an increase in other changes in balance sheet items of $1 million for the three months ended March 31, 2019.

(c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to depreciation and amortization of $3 million and capital expenditures of $5 million for the three months ended March 31, 2019.

(d) Classification of Foreign Currency Gains and Losses in our Consolidated Statements of Cash Flows—The corrections of these misstatements resulted in an increase to the effect of foreign exchange rate changes on cash and cash equivalents and a decrease to other adjustments to reconcile net income to net cash from operating activities of $5 million for the three months ended March 31, 2019.

(e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The corrections of these misstatements resulted in an increase in cash and cash equivalents at the beginning of the period of $6 million and decreases to other changes in balance sheet items of $1 million, cash and cash equivalents at the end of the period of $6 million and the effect of foreign exchange rate changes on cash and cash equivalents of $12 million for the three months ended March 31, 2019.

(f) Other miscellaneous adjustments—The correction of these misstatements resulted in an increase to other changes in balance sheet items of $1 million and a decrease in changes in accounts payable and accrued liabilities of $1 million for the three months ended March 31, 2019.

XML

REVENUES

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

REVENUES

REVENUES

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30-90 days.

The majority of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our geographic segments including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. For a majority of these sales, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.

To a lesser extent, in all of our segments, we enter into other types of contracts including contract manufacturing arrangements, equipment leases, and certain subscription software and licensing arrangements. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.

On March 31, 2020, we had $8.2 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more, which are primarily included in the Americas segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 20% of this amount as revenue over the remainder of 2020, 25% in 2021, 20% in each of 2022 and 2023, 5% in each of 2024 and 2025, and the remaining balance thereafter.

Significant Judgments

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration related to rebates, product returns, sales discounts and wholesaler chargebacks. These

reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accounts receivable, net and accounts payable and accrued liabilities on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. Revenue recognized during the three months ended March 31, 2020 and 2019 related to performance obligations satisfied in prior periods was not material.

Contract Balances

The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable was $1.7 billion and $1.8 billion as of March 31, 2020 and December 31, 2019, respectively.

For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are provided and billed, generally over one to seven years. Our contract asset balances totaled $133 million as of March 31, 2020, of which $37 million related to contract manufacturing services, $47 million related to software sales and $49 million related to bundled equipment and consumable medical products contracts. Our contract asset balances totaled $131 million as of December 31, 2019, of which $36 million related to contract manufacturing services, $43 million related to software sales and $52 million related to bundled equipment and consumable medical products contracts. Contract assets are presented within accounts receivable, net ($66 million and $63 million as of March 31, 2020 and December 31, 2019, respectively) and other non-current assets ($67 million and $68 million as of March 31, 2020 and December 31, 2019, respectively) in the accompanying condensed consolidated balance sheets. Contract liabilities as of March 31, 2020 and December 31, 2019 were $19 million and $12 million, respectively, and were included in accounts payable and other accrued liabilities ($7 million as of March 31, 2020) and other non-current liabilities ($12 million as of March 31, 2020 and December 31, 2019, respectively) in the accompanying condensed consolidated balance sheets.

Disaggregation of Net Sales

The following tables disaggregate our net sales from contracts with customers by Global Business Unit (GBU) between the U.S. and international:

	Three months ended March 31,
							As Restated
	2020						2019
(in millions)	U.S.		International		Total		U.S.		International		Total
Renal Care 1	$	204	$	666	$	870	$	192	$	662	$	854
Medication Delivery 2	461		229		690		406		228		634
Pharmaceuticals 3	231		296		527		232		278		510
Clinical Nutrition 4	82		138		220		77		128		205
Advanced Surgery 5	137		87		224		120		79		199
Acute Therapies 6	60		96		156		48		81		129
Other 7	42		73		115		45		62		107
Total Baxter	$	1,217	$	1,585	$	2,802	$	1,120	$	1,518	$	2,638

1Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.

2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.

3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.

4Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.

5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.

6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).

7Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.

Lease Revenue

We lease medical equipment, such as renal dialysis equipment and infusion pumps, to customers, primarily in conjunction with arrangements to provide consumable medical products such as dialysis therapies, IV fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices.

The components of lease revenue for the three months ended March 31, 2020 and March 31, 2019 were:

(in millions)	Three months ended March 31, 2020		Three months ended March 31, 2019
Sales-type lease revenue	$	6	$	6
Operating lease revenue	14		15
Variable lease revenue	18		21
Total lease revenue	$	38	$	42

XML

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

3 Months Ended

Mar. 31, 2020

Accounting Changes and Error Corrections [Abstract]

RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

We have restated herein our condensed consolidated financial statements for the three months ended March 31, 2019. We have also restated impacted amounts within the accompanying notes to the consolidated financial statements, as applicable. The restatement of our condensed consolidated financial statements for the three months ended March 31, 2019 was previously reported in our annual report on Form 10-K for the year ended December 31, 2019.

Restatement Background

On October 24, 2019, we reported that we had commenced an internal investigation into certain intra-company transactions that impacted our previously reported non-operating foreign exchange gains and losses. Our internal investigation, as it pertains to the evaluation of related financial statement impacts, is complete.

We previously had applied a longstanding convention for the initial measurement of foreign currency transactions and the subsequent remeasurement of foreign currency denominated monetary assets and liabilities (collectively, our historical exchange rate convention) that was not consistent with U.S. GAAP. U.S. GAAP requires that foreign currency transactions be initially measured and recorded in an entity’s functional currency using the exchange rate on the date of the transaction and it requires that foreign currency denominated monetary assets and liabilities be remeasured at the end of each reporting period using the exchange rate at that date. Under our historical exchange rate convention, all foreign currency transactions in a given month were initially measured using exchange rates from a specified date near the middle of the previous month. Additionally, all foreign currency denominated monetary assets and liabilities were subsequently remeasured at the end of each month using exchange rates from a specified date near the middle of the current month. Beginning years after the adoption of our historical exchange rate convention, certain intra-company transactions were undertaken, after the related exchange rates were already known, solely for the purpose of generating non-operating foreign exchange gains or avoiding foreign exchange losses.

We identified misstatements relating to foreign currency denominated monetary assets and liabilities and foreign currency derivative contracts that caused our Other income (expense), net and Income before income taxes to be overstated by $4 million for the three months ended March 31, 2019. Our quantification of those misstatements to our previously reported foreign exchange gains and losses was not limited to intra-company transactions undertaken for the purpose of generating foreign exchange gains or avoiding foreign exchange losses after the related exchange

rates were already known. Rather, we identified every legal entity within our consolidated group that had foreign exchange gains or losses above an immaterial threshold and, for those entities, we remeasured all foreign exchange gains and losses from foreign currency denominated cash balances and intra-company loan receivables and payables using the exchange rates required by U.S. GAAP. For those entities, we also quantified misstatements to our previously reported gains and losses on foreign currency derivative contracts, which had used foreign exchange rates determined under our historical exchange rate convention as inputs to the fair value measurements of those contracts. Our quantification of misstatements to the condensed consolidated financial statements did not include foreign currency gains or losses from short-term third-party and intra-company trade receivables and trade payables denominated in foreign currencies. We determined that any potential misstatements relating to such balances that arise in the ordinary course of business and are ultimately settled for cash within a short period of time, generally thirty to sixty days, would not be material to our condensed consolidated financial statements.

In order to correct our previously issued financial statements, we have restated herein our condensed consolidated financial statements for the three months ended March 31, 2019, in accordance with Accounting Standards Codification (ASC) Topic 250, Accounting Changes and Error Corrections. In addition to the misstatements described above relating to foreign exchange gains and losses, we corrected additional misstatements that were not material, individually or in the aggregate, to our previously issued condensed consolidated financial statements. Those other immaterial misstatements relate to equipment leased to customers under operating leases, classification of foreign currency gains and losses on cash balances and intra-company loan receivables and payables in our condensed consolidated statements of cash flows, translation of the financial position and results of operations of our foreign operations into U.S. dollars, other miscellaneous adjustments, and the income tax effects of those items.

We believe that the use of our historical exchange rate convention to generate non-operating foreign exchange gains and avoid losses had occurred for at least ten years. The cumulative impact of misstatements related to non-operating foreign exchange gains and losses that we corrected for periods earlier than 2019, as well as the cumulative impact of correcting other immaterial misstatements relating to those earlier periods, have been recorded as a reduction to our opening retained earnings as of January 1, 2019.

The categories of misstatements and their impact on our previously issued condensed consolidated financial statements for the three months ended March 31, 2019 are described in more detail below.

Description of Misstatements

Misstatements of Foreign Exchange Gains and Losses

(a) Foreign Currency Denominated Monetary Assets and Liabilities

As discussed above, we recorded adjustments to correct foreign exchange gains and losses on monetary assets and liabilities denominated in a foreign currency to reflect the gains and losses resulting from application of the exchange rates required by U.S. GAAP. The impacts of the foreign currency gain or loss misstatements are discussed in restatement reference (a) throughout this note.

(b) Foreign Currency Derivative Contracts

As discussed above, we recorded adjustments to correct gains and losses on foreign currency derivative contracts by using current exchange rates at the applicable measurement dates as inputs to the related fair value measurements. The impacts of the foreign currency derivative contract gain or loss misstatements are discussed in restatement reference (b) throughout this note.

Additional Misstatements

(c) Equipment Leased to Customers under Operating Leases

Our manufacturing subsidiaries often sell products to commercial subsidiaries within our consolidated group which then sell or lease those products to third-party customers. Under U.S. GAAP, intra-company sales, intra-company cost of sales, and any step-ups in the carrying amount of inventory from intra-company transactions are eliminated in consolidation. If we subsequently sell the products to a third-party customer, the related intra-company profit previously eliminated in consolidation is recognized in our condensed consolidated statements of income. For transactions in which we lease, rather than sell, our products to customers under operating lease arrangements, no profit or loss should be recognized at inception of the arrangement and any intra-company profit previously eliminated

in consolidation should be recognized as a reduction to the carrying amount of the related leased assets. Prior to the third quarter of 2019, our international operations incorrectly recognized intra-company profit previously eliminated in consolidation as a reduction of cost of sales, rather than as a reduction of leased assets, at inception of operating lease arrangements. Accordingly, we have recorded adjustments to increase cost of sales and decrease property, plant, and equipment, net in our condensed consolidated financial statements. Those adjustments include corrections of depreciation expense and accumulated depreciation resulting from the decreases to the carrying amounts of the related leased equipment. The impacts of the operating lease misstatements are discussed in restatement reference (c) throughout this note.

(d) Classification of Foreign Currency Gains and Losses in our Condensed Consolidated Statements of Cash Flows

We previously included foreign exchange gains and losses related to intra-company receivables and payables and cash balances within our cash flows from operations. In the accompanying condensed consolidated statements of cash flows, foreign exchange gains and losses, as restated, related to intra-company receivables and payables and cash balances are presented as reconciling items between income from continuing operations and cash flows from operations. The impacts of those misclassifications on our operating cash flows are discussed in restatement reference (d) throughout this note.

(e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars

U.S. GAAP specifies that the income statement of a foreign operation should be translated into the reporting currency using the exchange rates on the dates the income or expense was recognized and indicates that the use of weighted-average exchange rates during the period is generally appropriate. Similar to our convention for the initial measurement of foreign currency transactions, we historically translated the results of operations of our foreign operations for a given month into U.S. dollars using exchange rates from a specified date near the middle of the previous month. Accordingly, we have recorded adjustments to translate the income statements of our foreign operations into U.S. dollars using the applicable average foreign exchange rates for each month.

U.S. GAAP specifies that the assets and liabilities of foreign operations be translated into the reporting currency at the end of each reporting period using the exchange rate at that date. Similar to our convention for the subsequent remeasurement of foreign currency denominated monetary assets and liabilities, our financial reporting systems were previously configured to translate assets and liabilities at the end of each month using exchange rates from a specified date near the middle of the current month. In recent years, we separately computed the impact of translating assets and liabilities at period-end exchange rates and adjusted our condensed consolidated balance sheets to reflect that difference. However, due to an incorrect input in those manual calculations as of December 31, 2018, the currency translation adjustments component of our other comprehensive income (loss) was misstated in our condensed consolidated statement of comprehensive income (loss) for the three months ended March 31, 2019.

The impacts of misstatements related to the translation of the financial position and results of operations of our foreign operations are discussed in restatement reference (e) throughout this note.

(f) Other Miscellaneous Adjustments

We recorded adjustments to correct other out-of-period items and previously uncorrected misstatements that were not material, individually or in the aggregate, to our condensed consolidated financial statements. Those other misstatements were primarily related to a historical restructuring liability and amounts related to our separation of Baxalta in 2015. The impacts of the other miscellaneous adjustments are discussed in restatement reference (f) throughout this note.

Description of Restatement Tables

The following tables were previously presented in our Annual Report on Form 10-K for the year ended December 31, 2019. See Note 19, Quarterly Financial Data (unaudited), to the consolidated financial statements in our Annual Report on Form 10-K. Below, we have presented reconciliations from our prior periods as previously reported to the restated amounts for each of our condensed consolidated financial statements for the three months ended March 31, 2019. The amounts as previously reported were derived from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 7, 2019.

Baxter International Inc.
Condensed Consolidated Statement of Income
(in millions, except per share)
	Three months ended March 31, 2019
	As previously reported		Restatement impacts		Restatement reference	As restated
Net sales	$	2,632	$	6	(e)	$	2,638
Cost of sales	1,552		6		(c)(e)	1,558
Gross margin	1,080		—			1,080
Selling, general and administrative expenses	600		1		(e)	601
Research and development expenses	129		—			129
Other operating income, net	(33)		—			(33)
Operating income	384		(1)			383
Interest expense, net	18		—			18
Other (income) expense, net	(25)		4		(a)(b)	(21)
Income before income taxes	391		(5)			386
Income tax expense	44		—			44
Net income	$	347	$	(5)		$	342
Earnings per share
Basic	$	0.68	$	(0.01)		$	0.67
Diluted	$	0.66	$	—		$	0.66
Weighted-average number of shares outstanding
Basic	512		—			512
Diluted	522		—			522

(a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in a decrease to other (income) expense, net of $5 million for the three months ended March 31, 2019.

(b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in an increase to other (income) expense, net of $1 million for the three months ended March 31, 2019.

(c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in an increase to cost of sales of $2 million for the three months ended March 31, 2019.

(e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to net sales of $6 million, cost of sales of $4 million and selling, general and administrative (SG&A) expense of $1 million for the three months ended March 31, 2019.

Baxter International Inc.
Condensed Consolidated Statement of Comprehensive Income
(in millions)
	Three months ended March 31, 2019
	As previously reported		Restatement impacts		As restated
Net income	$	347	$	(5)	$	342
Other comprehensive (loss) income, net of tax:
Currency translation adjustments	30		(127)		(97)
Pension and other postretirement benefit plans	8		6		14
Hedging activities	(15)		—		(15)
Total other comprehensive loss, net of tax	23		(121)		(98)
Comprehensive income	$	370	$	(126)	$	244

The $5 million decrease to net income was driven by the items described above in the condensed consolidated statement of income for the three months ended March 31, 2019 section.

The $127 million decrease to currency translation adjustments for the three months ended March 31, 2019 is comprised of a $132 million decrease to correct the foreign exchange rates used to translate the financial position and results of operations of our foreign operations into U.S. dollars partially offset by a $5 million increase from the offsetting balance sheet impact of the adjustments to foreign exchange gains and losses on intra-company receivables and payables.

The $6 million increase to pension and other postretirement benefit plans for the three months ended March 31, 2019 is a result of the correction of the foreign exchange rates used to translate the financial position and results of operations of our foreign operations into U.S. dollars.

Baxter International Inc.
Condensed Consolidated Statement of Changes in Equity
(in millions)
	For the Three Months Ended March 31, 2019
	Baxter International Inc. stockholders' equity
	Common stock shares	Common stock		Common stock shares in treasury	Common stock in treasury		Additional contributed capital		Retained earnings		Accumulated other comprehensive income (loss)		Total Baxter stockholders' equity		Noncontrolling interests		Total equity
As previously reported
Balance as of January 1, 2019	683	$	683	170	$	(9,989)	$	5,898	$	15,626	$	(4,424)	$	7,794	$	22	$	7,816
Adoption of new accounting standards	—	—		—	—		—		161		(161)		—		—		—
Net income	—	—		—	—		—		347		—		347		—		347
Other comprehensive income (loss)	—	—		—	—		—		—		23		23		—		23
Purchases of treasury stock	—	—		8	(586)		—		—		—		(586)		—		(586)
Stock issued under employee benefit plans and other	—	—		(5)	291		(59)		(66)		—		166		—		166
Dividends declared on common stock	—	—		—	—		—		(98)		—		(98)		—		(98)
Changes in noncontrolling interests	—	—		—	—		—		—		—		—		1		1
Balance as of March 31, 2019	683	$	683	173	$	(10,284)	$	5,839	$	15,970	$	(4,562)	$	7,646	$	23	$	7,669
Restatement impacts
Balance as of January 1, 2019	—	$	—	—	$	—	$	—	$	(551)	$	601	$	50	$	—	$	50
Net income	—	—		—	—		—		(5)		—		(5)		—		(5)
Other comprehensive income (loss)	—	—		—	—		—		—		(121)		(121)		—		(121)
Balance as of March 31, 2019	—	$	—	—	$	—	$	—	$	(556)	$	480	$	(76)	$	—	$	(76)
As restated
Balance as of January 1, 2019	683	$	683	170	$	(9,989)	$	5,898	$	15,075	$	(3,823)	$	7,844	$	22	$	7,866
Adoption of new accounting standards	—	—		—	—		—		161		(161)		—		—		—
Net income	—	—		—	—		—		342		—		342		—		342
Other comprehensive income (loss)	—	—		—	—		—		—		(98)		(98)		—		(98)
Purchases of treasury stock	—	—		8	(586)		—		—		—		(586)		—		(586)
Stock issued under employee benefit plans and other	—	—		(5)	291		(59)		(66)		—		166		—		166
Dividends declared on common stock	—	—		—	—		—		(98)		—		(98)		—		(98)
Changes in noncontrolling interests	—	—		—	—		—		—		—		—		1		1
Balance as of March 31, 2019	683	$	683	173	$	(10,284)	$	5,839	$	15,414	$	(4,082)	$	7,570	$	23	$	7,593

The adjustments to the January 1, 2019 retained earnings and accumulated other comprehensive loss represent the cumulative impacts of foreign exchange gains and losses and the translation of our financial position and results of operations for our foreign operations into U.S. dollars for the periods prior to January 1, 2019. Retained earnings also includes the cumulative impacts of equipment leased to customers under operating leases and other miscellaneous adjustments for the periods prior to January 1, 2019.

See descriptions of the net income and other comprehensive income impacts in the condensed consolidated statement of income and condensed consolidated statement of comprehensive income for the three months ended March 31, 2019 sections above.

Baxter International Inc.
Condensed Consolidated Statement of Cash Flows
(in millions)
	For the Three Months Ended March 31, 2019
	As previously reported		Restatement impacts		Restatement reference	As restated
Cash flows from operations
Net income	$	347	$	(5)		$	342
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	195		(3)		(c)	192
Deferred income taxes	(6)		—			(6)
Stock compensation	22		—			22
Net periodic pension benefit and other postretirement costs	3		—			3
Other	19		(5)		(d)	14
Changes in balance sheet items:
Accounts receivable, net	32		—			32
Inventories	(82)		—			(82)
Accounts payable and accrued liabilities	(333)		(2)		(b)(f)	(335)
Other	(49)		1		(b)(e)(f)	(48)
Cash flows from operations - continuing operations	148		(14)			134
Cash flows from operations - discontinued operations	(6)		—			(6)
Cash flows from operations	142		(14)			128
Cash flows from investing activities
Capital expenditures	(198)		5		(c)	(193)
Acquisitions and investments, net of cash acquired	(109)		—			(109)
Other investing activities, net	1		—			1
Cash flows from investing activities	(306)		5			(301)
Cash flows from financing activities
Net increases in debt obligations with original maturities of three months or less	795		—			795
Cash dividends on common stock	(101)		—			(101)
Proceeds from stock issued under employee benefit plans	173		—			173
Purchases of treasury stock	(597)		—			(597)
Other financing activities, net	(32)		—			(32)
Cash flows from financing activities	238		—			238
Effect of foreign exchange rate changes on cash and cash equivalents	2		(3)		(a)(d)(e)	(1)
Increase (decrease) in cash and cash equivalents	76		(12)			64
Cash and cash equivalents at beginning of period	1,832		6		(e)	1,838
Cash and cash equivalents at end of period	$	1,908	$	(6)	(e)	$	1,902

The $5 million decrease to net income was driven by the items described above in the condensed consolidated statement of income for the three months ended March 31, 2019 section.

(a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in an increase to the effect of foreign exchange rate changes on cash and cash equivalents of $4 million for the three months ended March 31, 2019.

(b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in a decrease to changes in accounts payable and accrued liabilities of $1 million and an increase in other changes in balance sheet items of $1 million for the three months ended March 31, 2019.

(c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to depreciation and amortization of $3 million and capital expenditures of $5 million for the three months ended March 31, 2019.

(d) Classification of Foreign Currency Gains and Losses in our Consolidated Statements of Cash Flows—The corrections of these misstatements resulted in an increase to the effect of foreign exchange rate changes on cash and cash equivalents and a decrease to other adjustments to reconcile net income to net cash from operating activities of $5 million for the three months ended March 31, 2019.

(e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The corrections of these misstatements resulted in an increase in cash and cash equivalents at the beginning of the period of $6 million and decreases to other changes in balance sheet items of $1 million, cash and cash equivalents at the end of the period of $6 million and the effect of foreign exchange rate changes on cash and cash equivalents of $12 million for the three months ended March 31, 2019.

(f) Other miscellaneous adjustments—The correction of these misstatements resulted in an increase to other changes in balance sheet items of $1 million and a decrease in changes in accounts payable and accrued liabilities of $1 million for the three months ended March 31, 2019.

XML

FINANCIAL ARRANGEMENTS

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

FINANCIAL ARRANGEMENTS

FINANCING ARRANGEMENTS

Debt Issuance

In March 2020, we issued $750 million of 3.75% senior notes due in March 2025 and $500 million of 3.95% senior notes due in March 2030 (collectively, the senior notes). Pursuant to a registration rights agreement (the Registration Rights Agreement) with the initial purchasers of the senior notes, we agreed to use our commercially reasonable efforts to file a registration statement with respect to a registered offer to exchange the senior notes for new notes with terms substantially identical in all material respects to the senior notes and to have such registration statement declared effective under the U.S. Securities Act of 1933. If we fail to have such registration statement declared effective by September 17, 2021 (a registration default), the annual interest rate on the senior notes would increase by 0.25% for the 90-day period immediately following such registration default and by an additional 0.25% thereafter. The maximum additional interest rate is 0.50% per annum and if a registration default is corrected, the senior notes would revert to the original interest rates. The payment of additional interest is the sole remedy for the holders of the senior notes in the event of a registration default.

Credit Facilities

As of March 31, 2020 and December 31, 2019, we had €200 million ($220 million and $224 million, respectively) outstanding under our Euro-denominated credit facility at a 0.91% interest rate and no borrowings outstanding under our U.S. dollar-denominated credit facility.

XML

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Net sales	$ 2,802	$ 2,638
Cost of sales	1,639	1,558
Gross margin	1,163	1,080
Selling, general and administrative expenses	628	601
Research and development expenses	146	129
Other operating income, net	(20)	(33)
Operating income	409	383
Interest expense, net	21	18
Other (income) expense, net	10	(21)
Income before income taxes	378	386
Income tax expense	45	44
Net income	333	342
Net income attributable to noncontrolling interests	1	0
Net income attributable to Baxter stockholders	$ 332	$ 342
Earnings per share
Basic (in dollars per share)	$ 0.65	$ 0.67
Diluted (in dollars per share)	$ 0.64	$ 0.66
Weighted-average number of shares outstanding
Basic (in shares)	507	512
Diluted (in shares)	516	522

XML

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Reconciliation of Basic Shares to Diluted Shares

The following table is a reconciliation of basic shares to diluted shares.

	Three months ended March 31,
(in millions)	2020	2019
Basic shares	507	512
Effect of dilutive securities	9	10
Diluted shares	516	522

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Summary of Changes in AOCI by Component

The following table is a net-of-tax summary of the changes in AOCI by component for the three months ended March 31, 2020 and 2019.

(in millions)	CTA		Pension and OPEB plans		Hedging activities		Total
Gains (losses)
Balance as of December 31, 2019	$	(2,954)	$	(715)	$	(41)	$	(3,710)
Other comprehensive income (loss) before reclassifications	(359)		10		(131)		(480)
Amounts reclassified from AOCI (a)	—		12		1		13
Net other comprehensive income (loss)	(359)		22		(130)		(467)
Balance as of March 31, 2020	$	(3,313)	$	(693)	$	(171)	$	(4,177)

	As Restated
(in millions)	CTA		Pension and OPEB plans		Hedging activities		Total
Gains (losses)
Balance as of December 31, 2018	$	(2,868)	$	(954)	$	(1)	$	(3,823)
Adoption of new accounting standard	9		(169)		(1)		(161)
Other comprehensive income (loss) before reclassifications	(97)		7		(15)		(105)
Amounts reclassified from AOCI (a)	—		7		—		7
Net other comprehensive income (loss)	(97)		14		(15)		(98)
Balance as of March 31, 2019	$	(2,956)	$	(1,109)	$	(17)	$	(4,082)

(a) See table below for details about these reclassifications.

Summary of Reclassification from AOCI to Net Income

The following is a summary of the amounts reclassified from AOCI to net income during the three months ended March 31, 2020 and 2019.

	Amounts reclassified from AOCI (a)
			As Restated
(in millions)	Three months ended March 31, 2020		Three months ended March 31, 2019		Location of impact in income statement
Amortization of pension and OPEB items
Amortization of net losses and prior service costs or credits	$	(15)	$	(8)	Other (income) expense, net
Less: Tax effect	3		1		Income tax expense
	$	(12)	$	(7)	Net of tax
Gains on hedging activities
Foreign exchange contracts	$	(1)	$	—	Cost of sales
Less: Tax effect	—		—		Income tax expense
	$	(1)	$	—	Net of tax
Total reclassifications for the period	$	(13)	$	(7)	Total net of tax

(a) Amounts in parentheses indicate reductions to net income.

Refer to Note 12 for additional information regarding the amortization of pension and OPEB items and Note 15 for additional information regarding hedging activity.

XML

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operations
Net income	$ 333	$ 342
Adjustments to reconcile net income to cash flows from operations:
Depreciation and amortization	199	192
Deferred income taxes	(17)	(6)
Stock compensation	29	22
Net periodic pension benefit and other postretirement costs	20	3
Other	13	14
Changes in balance sheet items:
Accounts receivable, net	(60)	32
Inventories	(83)	(82)
Accounts payable and accrued liabilities	(110)	(335)
Other	(50)	(48)
Cash flows from operations – continuing operations	274	134
Cash flows from operations – discontinued operations	(2)	(6)
Cash flows from operations	272	128
Cash flows from investing activities
Capital expenditures	(172)	(193)
Acquisitions and investments, net of cash acquired	(443)	(109)
Other investing activities, net	11	1
Cash flows from investing activities	(604)	(301)
Cash flows from financing activities
Issuances of debt	1,240	0
Net increases in debt with original maturities of three months or less	0	795
Cash dividends on common stock	(111)	(101)
Proceeds from stock issued under employee benefit plans	66	173
Purchases of treasury stock	0	(597)
Other financing activities, net	(25)	(32)
Cash flows from financing activities	1,170	238
Effect of foreign exchange rate changes on cash and cash equivalents	(63)	(1)
Increase in cash and cash equivalents	775	64
Cash and cash equivalents at beginning of period	3,335	1,838
Cash and cash equivalents at end of period	$ 4,110	$ 1,902

XML

Supplemental Financial Information - Other Income, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Other Income, net
Foreign exchange losses (gains), net	$ 11	$ (1)
Pension and other postretirement benefit plans	1	15
Other, net	0	(5)
Other (income) expense, net	$ 10	$ (21)

XML

Goodwill and Other Intangible Assets, Net - Goodwill (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 3,030
Acquisitions	39
Currency translation adjustments	(108)
Goodwill, ending balance	2,961
Americas
Goodwill [Roll Forward]
Goodwill, beginning balance	2,428
Acquisitions	32
Currency translation adjustments	(86)
Goodwill, ending balance	2,374
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	385
Acquisitions	0
Currency translation adjustments	(14)
Goodwill, ending balance	371
APAC
Goodwill [Roll Forward]
Goodwill, beginning balance	217
Acquisitions	7
Currency translation adjustments	(8)
Goodwill, ending balance	$ 216

XML

INCOME TAXES - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Effective income tax rate	11.90%	11.40%
U.S. Federal statutory rate	21.00%	21.00%

XML

Fair Value Measurements - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Contingent payments, Fair value as of beginning of period	$ 39	$ 32
Contingent payments, additions	4	0
Contingent payments, change in fair value recognized in earnings	(3)	0
Contingent payments, payments	(1)	(1)
Contingent payments, Fair value as of end of period	$ 39	$ 31

XML

Derivative Instruments and Hedging Activities - Derivative Positions Presented On Net Basis (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gross amounts recognized in the consolidated balance sheet, Asset	$ 29	$ 21
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Asset	(7)	(11)
Total, Asset	22	10
Gross amounts recognized in the consolidated balance sheet, Liability	233	54
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, Liability	(7)	(11)
Total, Liability	$ 226	$ 43

XML

Business Optimization Charges - Summary of Business Optimization Charges (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 25	$ 25
Business Optimization Programs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	25	25
Costs to implement business optimization programs	7	10
Accelerated depreciation	0	3
Total business optimization charges	$ 32	$ 38

XML

Derivative Instruments and Hedging Activities - Summary of Gains and Losses on Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax	$ 49	$ 14
Other comprehensive income (loss), cash flow hedge and net investment hedge, gain (loss), before reclassification, tax	(121)	(6)
Other comprehensive income (loss), reclassification adjustment from AOCI, cash flow hedges and net investment hedges, net of tax	(1)	0
Other income, net
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax	0	0
Interest rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax	(184)	(11)
Interest rate contracts | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax	0	0
Foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax	14	(9)
Foreign exchange contracts | Cost of Sales
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax	(1)	0
Foreign exchange contracts | Other income, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income, undesignated derivative instruments	$ 2	$ (8)

XML

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Nonoperating Income (Expense)	$ (10)	$ 21
Selling, general and administrative expenses	$ 628	601
Common stock, par value (in dollars per share)	$ 1		$ 1
Common stock, authorized (in shares)	2,000,000,000		2,000,000,000
Common stock, issued (in shares)	683,494,944		683,494,944
Treasury stock, common (in shares)			170,495,859
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Nonoperating Income (Expense)	$ (4)	(4)
Selling, general and administrative expenses		$ 1

XML

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Consolidated Statement of Income (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales	$ 2,802	$ 2,638
Cost of sales	1,639	1,558
Gross margin	1,163	1,080
Selling, general and administrative expenses	628	601
Research and development expenses	146	129
Other operating income, net	(20)	(33)
Operating income	409	383
Interest expense, net	21	18
Other (income) expense, net	10	(21)
Income before income taxes	378	386
Income tax expense	45	44
Net income	$ 333	$ 342
Earnings per share
Basic (in dollars per share)	$ 0.65	$ 0.67
Diluted (in dollars per share)	$ 0.64	$ 0.66
Weighted-average number of shares outstanding
Basic (in shares)	507	512
Diluted (in shares)	516	522
As previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales		$ 2,632
Cost of sales		1,552
Gross margin		1,080
Selling, general and administrative expenses		600
Research and development expenses		129
Other operating income, net		(33)
Operating income		384
Interest expense, net		18
Other (income) expense, net		(25)
Income before income taxes		391
Income tax expense		44
Net income		$ 347
Earnings per share
Basic (in dollars per share)		$ 0.68
Diluted (in dollars per share)		$ 0.66
Weighted-average number of shares outstanding
Basic (in shares)		512
Diluted (in shares)		522
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales		$ 6
Cost of sales		6
Gross margin		0
Selling, general and administrative expenses		1
Research and development expenses		0
Other operating income, net		0
Operating income		(1)
Interest expense, net		0
Other (income) expense, net	$ 4	4
Income before income taxes		(5)
Income tax expense		0
Net income		$ (5)
Earnings per share
Basic (in dollars per share)		$ (0.01)
Diluted (in dollars per share)		$ 0
Weighted-average number of shares outstanding
Basic (in shares)		0
Diluted (in shares)		0
Restatement impacts | Foreign Currency Denominated Monetary Assets and Liabilities
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other (income) expense, net		$ 5
Restatement impacts | Equipment Leased to Customers under Operating Leases
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of sales		2
Restatement impacts | Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net sales		6
Cost of sales		4
Selling, general and administrative expenses		1
Restatement impacts | Foreign exchange contracts | Foreign Currency Derivative Contracts
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other (income) expense, net		$ 1

XML

Revenues - Net Sales from Contracts with Customers by Global Business Unit (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue From Contract With Customer [Line Items]
Net sales	$ 2,802	$ 2,638
U.S.
Revenue From Contract With Customer [Line Items]
Net sales	1,217	1,120
International
Revenue From Contract With Customer [Line Items]
Net sales	1,585	1,518
Renal
Revenue From Contract With Customer [Line Items]
Net sales	870	854
Renal | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	204	192
Renal | International
Revenue From Contract With Customer [Line Items]
Net sales	666	662
Medication Delivery
Revenue From Contract With Customer [Line Items]
Net sales	690	634
Medication Delivery | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	461	406
Medication Delivery | International
Revenue From Contract With Customer [Line Items]
Net sales	229	228
Pharmaceuticals
Revenue From Contract With Customer [Line Items]
Net sales	527	510
Pharmaceuticals | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	231	232
Pharmaceuticals | International
Revenue From Contract With Customer [Line Items]
Net sales	296	278
Clinical Nutrition
Revenue From Contract With Customer [Line Items]
Net sales	220	205
Clinical Nutrition | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	82	77
Clinical Nutrition | International
Revenue From Contract With Customer [Line Items]
Net sales	138	128
Advanced Surgery
Revenue From Contract With Customer [Line Items]
Net sales	224	199
Advanced Surgery | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	137	120
Advanced Surgery | International
Revenue From Contract With Customer [Line Items]
Net sales	87	79
Acute Therapies
Revenue From Contract With Customer [Line Items]
Net sales	156	129
Acute Therapies | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	60	48
Acute Therapies | International
Revenue From Contract With Customer [Line Items]
Net sales	96	81
Other
Revenue From Contract With Customer [Line Items]
Net sales	115	107
Other | U.S.
Revenue From Contract With Customer [Line Items]
Net sales	42	45
Other | International
Revenue From Contract With Customer [Line Items]
Net sales	$ 73	$ 62

XML

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended		132 Months Ended
	Mar. 31, 2020 USD ($) Site	Mar. 31, 2019 USD ($)	Dec. 31, 2018 Lawsuit	Dec. 31, 2019 USD ($)
Loss Contingencies [Line Items]
Litigation reserve	$ 53,000,000			$ 56,000,000
Litigation related receivables	$ 0			0
Proceeds from insurance dispute settlements		$ 35,000,000
Gain on insurance claims		$ 33,000,000
Minimum
Loss Contingencies [Line Items]
Number of law suits filed | Lawsuit			1,000
Superfund Sites | Environmental Clean-up
Loss Contingencies [Line Items]
Number of sites | Site	6
Environmental reserves	$ 18,000,000			$ 18,000,000

XML

Accumulated Other Comprehensive Income - Summary of Changes in AOCI by Component (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period	$ 7,912	$ 7,866
Other comprehensive income (loss) before reclassifications	(480)	(105)
Amounts reclassified from AOCI	13	7
Net other comprehensive income (loss)	(467)	(98)
End of period	7,730	7,593
ASU 2018-02
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard		(161)
CTA
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period	(2,954)	(2,868)
Other comprehensive income (loss) before reclassifications	(359)	(97)
Amounts reclassified from AOCI	0	0
Net other comprehensive income (loss)	(359)	(97)
End of period	(3,313)	(2,956)
CTA | ASU 2018-02
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard		9
Pension and OPEB Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period	(715)	(954)
Other comprehensive income (loss) before reclassifications	10	7
Amounts reclassified from AOCI	12	7
Net other comprehensive income (loss)	22	14
End of period	(693)	(1,109)
Pension and OPEB Plans | ASU 2018-02
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard		(169)
Hedging activities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period	(41)	(1)
Other comprehensive income (loss) before reclassifications	(131)	(15)
Amounts reclassified from AOCI	1	0
Net other comprehensive income (loss)	(130)	(15)
End of period	(171)	(17)
Hedging activities | ASU 2018-02
Accumulated Other Comprehensive Income (Loss) [Line Items]
Adoption of new accounting standard		(1)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning of period	(3,710)	(3,823)
End of period	$ (4,177)	$ (4,082)

XML

EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

EARNINGS PER SHARE

EARNINGS PER SHARE

The numerator for both basic and diluted earnings per share (EPS) is net income. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method.

The following table is a reconciliation of basic shares to diluted shares.

	Three months ended March 31,
(in millions)	2020	2019
Basic shares	507	512
Effect of dilutive securities	9	10
Diluted shares	516	522

The effect of dilutive securities included unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excluded 1 million and 4 million equity awards for the three months ended March 31, 2020 and 2019, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS. Refer to Note 8 for additional information regarding items impacting basic and diluted shares.

XML

BASIS OF PRESENTATION (Policies)

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we or our) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Annual Report).

In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year.

Certain reclassifications have been made to conform the prior period condensed consolidated statements to the current period presentation.

Risks and Uncertainties Related to COVID-19

Our global operations expose us to risks associated with public health crises and epidemics/pandemics, such as the novel strain of coronavirus (COVID-19). COVID-19 may have an adverse impact on our operations, supply chains and distribution systems and increase our expenses, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking. Due to these impacts and measures, we have experienced and may continue to experience reductions or increases in demand for certain of our products as health care customers re-prioritize the treatment of patients. For example, elective surgeries are being de-prioritized which has negatively impacted the usage of certain of our products, while other of our products are experiencing an increase in demand which we may not be able to meet in accordance with the customer’s desired timing. In addition to travel restrictions, countries have closed borders and imposed prolonged quarantines, often with uncertain duration, which has significantly impacted the ability of our employees to get to their places of work to produce products and may significantly hamper our products from moving through the supply chain. As a result, given the rapid and evolving nature of the virus, COVID-19 could negatively affect our sales, and it is uncertain how COVID-19 will affect our global operations generally if these impacts persist or exacerbate over an extended period of time.

New Accounting Standards

New Accounting Standards

Recently adopted accounting pronouncements

As of January 1, 2020, we adopted Accounting Standards Update (ASU) No. 2016-13, Financial Instruments - Credit Losses, which requires the measurement of expected lifetime credit losses, rather than incurred losses, for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. We adopted this ASU using the modified retrospective approach.

XML

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Consolidated Statement of Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2018
Cash flows from operations
Net income	$ 333	$ 342
Adjustments to reconcile net income to cash flows from operations:
Depreciation and amortization	199	192
Deferred income taxes	(17)	(6)
Stock compensation	29	22
Net periodic pension benefit and other postretirement costs	20	3
Other	13	14
Changes in balance sheet items:
Accounts receivable, net	(60)	32
Inventories	(83)	(82)
Accounts payable and accrued liabilities	(110)	(335)
Other	(50)	(48)
Cash flows from operations – continuing operations	274	134
Cash flows from operations – discontinued operations	(2)	(6)
Cash flows from operations	272	128
Cash flows from investing activities
Capital expenditures	(172)	(193)
Acquisitions and investments, net of cash acquired	(443)	(109)
Other investing activities, net	11	1
Cash flows from investing activities	(604)	(301)
Cash flows from financing activities
Net increases in debt with original maturities of three months or less	0	795
Cash dividends on common stock	(111)	(101)
Proceeds from stock issued under employee benefit plans	66	173
Purchases of treasury stock	0	(597)
Other financing activities, net	(25)	(32)
Cash flows from financing activities	1,170	238
Effect of foreign exchange rate changes on cash and cash equivalents	(63)	(1)
Increase in cash and cash equivalents	775	64
Cash and cash equivalents at beginning of period	3,335	1,838
Cash and cash equivalents at end of period	$ 4,110	1,902
As previously reported
Cash flows from operations
Net income		347
Adjustments to reconcile net income to cash flows from operations:
Depreciation and amortization		195
Deferred income taxes		(6)
Stock compensation		22
Net periodic pension benefit and other postretirement costs		3
Other		19
Changes in balance sheet items:
Accounts receivable, net		32
Inventories		(82)
Accounts payable and accrued liabilities		(333)
Other		(49)
Cash flows from operations – continuing operations		148
Cash flows from operations – discontinued operations		(6)
Cash flows from operations		142
Cash flows from investing activities
Capital expenditures		(198)
Acquisitions and investments, net of cash acquired		(109)
Other investing activities, net		1
Cash flows from investing activities		(306)
Cash flows from financing activities
Net increases in debt with original maturities of three months or less		795
Cash dividends on common stock		(101)
Proceeds from stock issued under employee benefit plans		173
Purchases of treasury stock		(597)
Other financing activities, net		(32)
Cash flows from financing activities		238
Effect of foreign exchange rate changes on cash and cash equivalents		2
Increase in cash and cash equivalents		76
Cash and cash equivalents at beginning of period		1,832
Cash and cash equivalents at end of period		1,908
Restatement impacts
Cash flows from operations
Net income		(5)
Adjustments to reconcile net income to cash flows from operations:
Depreciation and amortization		(3)
Deferred income taxes		0
Stock compensation		0
Net periodic pension benefit and other postretirement costs		0
Other		(5)
Changes in balance sheet items:
Accounts receivable, net		0
Inventories		0
Accounts payable and accrued liabilities		(2)
Other		1
Cash flows from operations – continuing operations		(14)
Cash flows from operations – discontinued operations		0
Cash flows from operations		(14)
Cash flows from investing activities
Capital expenditures		5
Acquisitions and investments, net of cash acquired		0
Other investing activities, net		0
Cash flows from investing activities		5
Cash flows from financing activities
Net increases in debt with original maturities of three months or less		0
Cash dividends on common stock		0
Proceeds from stock issued under employee benefit plans		0
Purchases of treasury stock		0
Other financing activities, net		0
Cash flows from financing activities		0
Effect of foreign exchange rate changes on cash and cash equivalents		(3)
Increase in cash and cash equivalents		(12)
Cash and cash equivalents at beginning of period		6
Cash and cash equivalents at end of period		(6)
Restatement impacts | Foreign Currency Denominated Monetary Assets and Liabilities
Cash flows from financing activities
Effect of foreign exchange rate changes on cash and cash equivalents		4
Restatement impacts | Foreign Currency Derivative Contracts | Foreign exchange contracts
Changes in balance sheet items:
Accounts payable and accrued liabilities		1
Other		1
Restatement impacts | Equipment Leased to Customers under Operating Leases
Adjustments to reconcile net income to cash flows from operations:
Depreciation and amortization		(3)
Cash flows from investing activities
Capital expenditures		5
Restatement impacts | Correction of Classification of Foreign Currency Gains and Losses in our Consolidated Statements of Cash Flows
Cash flows from financing activities
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents		5
Restatement impacts | Correction Of Translation Of The Financial Position And Results Of Operations Into U.S. Dollars Misstatements
Changes in balance sheet items:
Accounts payable and accrued liabilities		1
Other		1
Cash flows from financing activities
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents		12
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents		$ 6	$ 6

XML

BASIS OF PRESENTATION- Schedule Of Changes In Allowance for Doubtful Accounts (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance at beginning of period	$ 112
Adoption of new accounting standard	4
Charged to costs and expenses	7
Currency translation adjustments	(9)
Balance at end of period	$ 114

XML

STOCKHOLDERS' EQUITY - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($) u_baxEmployees $ / shares shares	Mar. 31, 2019 USD ($) $ / shares
Stockholders Equity Note [Line Items]
Stock compensation	$ 29	$ 22
Total intrinsic value of stock options exercised	$ 52	$ 153
Cash dividends declared per common share (in dollars per share) | $ / shares	$ 0.22	$ 0.19
Number of employees affected | u_baxEmployees	123
Selling, General and Administrative Expenses
Stockholders Equity Note [Line Items]
Share -based compensation allocation, percentage	70.00%
Employee Stock Option
Stockholders Equity Note [Line Items]
Gross stock options (in shares) | shares	3.7
Stock granted, value, share-based compensation, gross	$ 59
Unrecognized compensation cost related to all unvested stock options	$ 103
Weighted-average period for all unvested stock options	2 years 1 month 6 days
Incremental compensation cost	$ 8
Restricted Stock Units (RSUs)
Stockholders Equity Note [Line Items]
Grants in period (in shares) | shares	0.5
Stock granted, value, share-based compensation, gross	$ 37
Unrecognized compensation cost related to all unvested stock options	$ 73
Weighted-average period for all unvested stock options	2 years
Performance Shares
Stockholders Equity Note [Line Items]
Grants in period (in shares) | shares	0.4
Stock granted, value, share-based compensation, gross	$ 29
Unrecognized compensation cost related to all unvested stock options	$ 44
Weighted-average period for all unvested stock options	2 years 1 month 6 days

XML

Accumulated Other Comprehensive Income - Summary of Amounts Reclassification from AOCI to Net Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other (income) expense, net	$ (10)	$ 21
Income tax expense	45	44
Cost of sales	1,639	1,558
Net income (loss) attributable to Baxter	332	342
Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net income (loss) attributable to Baxter	(13)	(7)
Amortization of pension and OPEB items | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other (income) expense, net	(15)	(8)
Income tax expense	3	1
Net income (loss) attributable to Baxter	(12)	(7)
Gains (losses) on hedging activities | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income tax expense	0	0
Net income (loss) attributable to Baxter	(1)	0
Gains (losses) on hedging activities | Foreign exchange contracts | Amounts reclassified from AOCI
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of sales	$ (1)	$ 0

XML

Revenues - Lease Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Sales-type lease revenue	$ 6	$ 6
Operating lease revenue	14	15
Variable lease revenue	18	21
Total lease revenue	$ 38	$ 42

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

3 Months Ended

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs.

We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Chinese Yuan, Korean Won, Australian Dollar, Canadian Dollar, Japanese Yen, Colombian Peso, Brazilian Real, Mexican Peso and Swedish Krona. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce the net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.

We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using a mix of fixed- and floating-rate debt that we believe is appropriate. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.

We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features.

All derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value, or net investment hedges.

Cash Flow Hedges

We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt.

For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted third-party sales denominated in foreign currencies, forecasted intra-company sales denominated in foreign currencies, and anticipated issuances of debt, respectively.

The notional amounts of foreign exchange contracts designated as cash flow hedges were $583 million and $617 million as of March 31, 2020 and December 31, 2019, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at March 31, 2020 is 12 months for foreign exchange contracts. The total notional amounts of interest rate contracts designated as cash flow hedges were $550 million as of March 31, 2020 and December 31, 2019, respectively. The interest rate contracts have maturity dates in 2022 and hedge the variability in future benchmark interest payments attributable to changes in interest rates on the forecasted issuance of fixed-rate debt.

Fair Value Hedges

We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Fair value

hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt.

There were no outstanding interest rate swap contracts designated as fair value hedges as of March 31, 2020 and December 31, 2019.

Net Investment Hedges

In May 2017, we issued €600 million of senior notes due May 2025. In May 2019, we issued €750 million of senior notes due May 2024 and €750 million of senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI. As of March 31, 2020, we had an accumulated pre-tax unrealized translation gain in AOCI of $28 million related to the Euro-denominated senior notes.

Dedesignations

If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged items. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings.

There were no hedge dedesignations in the first three months of 2020 or 2019 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur.

If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first three months of 2020 or 2019.

If we remove a net investment hedge designation, any gains or losses recognized in AOCI are not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged.

Undesignated Derivative Instruments

We use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month.

The total notional amount of undesignated derivative instruments was $824 million as of March 31, 2020 and $619 million as of December 31, 2019.

Gains and Losses on Hedging Instruments

The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended March 31, 2020 and 2019.

	Gain (loss) recognized in OCI				Location of gain (loss) in income statement	Gain (loss) reclassified from AOCI into income
(in millions)	2020		2019			2020		2019
Cash flow hedges
Interest rate contracts	$	(184)	$	(11)	Interest expense, net	$	—	$	—
Foreign exchange contracts	14		(9)		Cost of sales	(1)		—
Net investment hedges	49		14		Other (income) expense, net	—		—
Total	$	(121)	$	(6)		$	(1)	$	—

	Location of gain (loss) in income statement	Gain (loss) recognized in income
				As Restated
(in millions)		2020		2019
Undesignated derivative instruments
Foreign exchange contracts	Other (income) expense, net	$	2	$	(8)

As of March 31, 2020, $6 million of deferred, net after-tax gains on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings.

Derivative Assets and Liabilities

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2020.

	Derivatives in asset positions			Derivatives in liability positions
(in millions)	Balance sheet location	Fair value		Balance sheet location	Fair value
Derivative instruments designated as hedges
Interest rate contracts	Other non-current assets	$	—	Other non-current liabilities	$	226
Foreign exchange contracts	Prepaid expenses and other current assets	24		Accounts payable and accrued liabilities	3
Total derivative instruments designated as hedges		24			229
Undesignated derivative instruments
Foreign exchange contracts	Prepaid expenses and other current assets	5		Accounts payable and accrued liabilities	4
Total derivative instruments		$	29		$	233

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2019.

	Derivatives in asset positions			Derivatives in liability positions
(in millions)	Balance sheet location	Fair value		Balance sheet location	Fair value
Derivative instruments designated as hedges
Interest rate contracts	Other non-current assets	$	10	Other non-current liabilities	$	52
Foreign exchange contracts	Prepaid expenses and other current assets	10		Accounts payable and accrued liabilities	—
Total derivative instruments designated as hedges		20			52
Undesignated derivative instruments
Foreign exchange contracts	Prepaid expenses and other current assets	1		Accounts payable and accrued liabilities	2
Total derivative instruments		$	21		$	54

While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives.

The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.

	March 31, 2020				December 31, 2019
(in millions)	Asset		Liability		Asset		Liability
Gross amounts recognized in the consolidated balance sheet	$	29	$	233	$	21	$	54
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet	(7)		(7)		(11)		(11)
Total	$	22	$	226	$	10	$	43

The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:

	Carrying amount of hedged item				Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item (a)
(in millions)	Balance as of March 31, 2020		Balance as of December 31, 2019		Balance as of March 31, 2020		Balance as of December 31, 2019
Long-term debt	$	103	$	103	$	6	$	6

(a) These fair value hedges were terminated prior to December 31, 2019.

XML

BASIS OF PRESENTAITON (Tables)

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of New Accounting Standards

The following table is a summary of the changes in our allowance for doubtful accounts for the three months ended March 31, 2020:

(in millions)	March 31, 2020
Balance at beginning of period	$	112
Adoption of new accounting standard	4
Charged to costs and expenses	7
Currency translation adjustments	(9)
Balance at end of period	$	114

XML

ACQUISITIONS AND OTHER ARRANGEMENTS

3 Months Ended

Mar. 31, 2020

Business Combinations [Abstract]

ACQUISITIONS AND OTHER ARRANGEMENTS

ACQUISITIONS AND OTHER ARRANGEMENTS

Seprafilm Adhesion Barrier

In February 2020, we acquired the product rights to Seprafilm Adhesion Barrier (Seprafilm) from Sanofi. The transaction closed in February 2020 and we paid approximately $342 million in cash for the acquired assets. Seprafilm is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera such as omentum, small bowel, bladder, and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel, and bladder. We concluded that the acquired assets met the definition of a business and accounted for the transaction as a business combination using the acquisition method of accounting.

The following table summarizes the fair values of the assets acquired as of the acquisition date:

(in millions)
Assets acquired
Inventories	$	16
Goodwill	29
Other intangible assets	297
Total assets acquired	$	342

The valuation of the assets acquired are preliminary and measurement period adjustments may be recorded in the future as we finalize our fair value estimates. The results of operations of the acquired business have been included in our condensed consolidated statement of income since the date the business was acquired. The acquisition contributed $13 million of net sales for the three months ended March 31, 2020. Net earnings from the acquisition were not significant during the three months ended March 31, 2020 and included acquisition and integration costs, primarily incremental cost of sales relating to inventory fair value step-ups, of $9 million.

We allocated $287 million and $10 million of the total consideration to the Seprafilm developed product rights and customer relationships with useful lives of 10 and 7 years, respectively. The fair values of the intangible assets were determined using the income approach. The discount rates used to measure the developed product rights and customer relationship intangible assets were 14.8% and 11.0%, respectively. We consider the fair value of the intangible assets to be Level 3 measurements due to the significant estimates and assumptions used by management in establishing the estimated fair values.

The goodwill, which is deductible for tax purposes, includes the value of potential future indications as well as the overall strategic benefits provided to our product portfolio of hemostats and sealants and is included in the Americas and APAC segments.

Other Business Combinations

We completed other individually immaterial acquisitions in the three months ended March 31, 2020 for total consideration of $13 million in cash at closing plus aggregate future potential contingent consideration of up to $12 million with an acquisition date fair value of $4 million. The acquisitions primarily resulted in the recognition of goodwill and other intangible assets.

We have not presented pro forma financial information for any of our acquisitions because their results are not material to our condensed consolidated financial statements.

Other Business Development Activities

In January 2020, we acquired the U.S. rights to an additional product for $60 million. The purchase price was capitalized as a developed-technology intangible asset in the quarter ended March 31, 2020 and is being amortized over its estimated useful life of 11 years.

In the three months ended March 31, 2020, we entered into distribution license arrangements for multiple products that have not yet obtained regulatory approval for upfront cash payments of $21 million. The cash paid was treated as research and development (R&D) expenses on our condensed consolidated statement of income. We could make additional payments of up to $41 million upon the achievement of certain development, regulatory or commercial milestones.

XML

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

We are involved in product liability, patent, commercial, and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of March 31, 2020 and December 31, 2019, our total recorded reserves with respect to legal and environmental matters were $53 million and $56 million, respectively, and there were no related receivables.

We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims.

In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.

Environmental

We are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from the Superfund cases noted above, we are involved in an ongoing voluntary environmental remediation associated with historic operations at our Irvine, California, United States facility. As of March 31, 2020 and December 31, 2019, our environmental reserves, which are measured on an undiscounted basis, were $18 million. After considering these reserves, management is of the opinion that the outcome of these matters will not have a material adverse effect on our financial position or results of operations.

General Litigation

In November 2016, a putative antitrust class action complaint seeking monetary and injunctive relief was filed in the United States District Court for the Northern District of Illinois. The complaint alleges a conspiracy among manufacturers of IV solutions to restrict output and affect pricing in connection with a shortage of such solutions. Similar parallel actions subsequently were filed. In January 2017, a single consolidated complaint covering these matters was filed in the Northern District of Illinois. We filed a motion to dismiss the consolidated complaint in February 2017. The court granted our motion to dismiss the consolidated complaint without prejudice in July 2018. The plaintiffs filed an amended complaint, which we moved to dismiss on November 9, 2018. The court granted our motion to dismiss the amended complaint with prejudice on April 3, 2020.

In April 2017, we became aware of a criminal investigation by the U.S. Department of Justice (DOJ), Antitrust Division and a federal grand jury in the United States District Court for the Eastern District of Pennsylvania. We and an employee received subpoenas seeking production of documents and testimony regarding the manufacturing, selling, pricing and shortages of IV solutions and containers (including saline solutions and certain other injectable medicines sold by us) and communications with competitors regarding the same. On November 30, 2018, the DOJ notified us that it had closed the investigation. The New York Attorney General has also requested that we provide information regarding business practices in the IV saline industry. We have cooperated with the New York Attorney General.

In August 2019, we were named in an amended complaint filed by Fayette County, Georgia in the MDL In re: National Prescription Opiate Litigation pending in the U.S. District Court, Northern District of Ohio. The complaint alleges that multiple manufacturers and distributors of opiate products improperly marketed and diverted these products, which caused harm to Fayette County. The complaint is limited in its allegations as to Baxter and does not distinguish between injectable opiate products and orally administered opiates. We manufactured generic injectable opiate products in our facility in Cherry Hill, NJ, which we divested in 2011.

In November 2019, we and certain of our officers were named in a class action complaint captioned Ethan E. Silverman et al. v. Baxter International Inc. et al. that was filed in the United States District Court for the Northern District of Illinois. The plaintiff, who allegedly purchased shares of our common stock during the specified class period, filed this putative class action on behalf of himself and shareholders who acquired Baxter common stock between February 21, 2019 and October 23, 2019. The plaintiff alleges that we and certain officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by making allegedly false and misleading statements and failing to disclose material facts relating to certain intra-company transactions undertaken for the purpose of generating foreign exchange gains or avoiding foreign exchange losses, as well as our internal controls over financial reporting. On January 29, 2020, the Court appointed Varma Mutual Pension Insurance Company and Louisiana Municipal Police Employees Retirement System as lead plaintiffs in the case. In addition, we have received a stockholder request for inspection of our books and records in connection with the announcement made in our Form 8-K on October 24, 2019 that we had commenced an internal investigation into certain intra-company transactions that impacted our previously reported non-operating foreign exchange gains and losses. As initially disclosed on October 24, 2019, we also voluntarily advised the staff of the SEC of our internal investigation and we are continuing to cooperate with the staff of the SEC.

In March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products. The plaintiffs seek damages, including compensatory and punitive damages in an unspecified amount, and unspecified injunctive and declaratory relief.

Other

As previously disclosed, in 2008 we recalled our heparin sodium injection products in the United States. Following the recall, more than 1,000 lawsuits alleging that plaintiffs suffered various reactions to a heparin contaminant, in some cases resulting in fatalities, were filed. In January 2019, the last of these cases was settled. In the first three months of 2019, following the resolution of an insurance dispute, we received cash proceeds of $35 million for our allocation of the insurance proceeds under a settlement and cost-sharing agreement related to the defense of the heparin product liability cases. We recognized a $33 million gain in connection with the resolution of the dispute with the insurer that is classified within other operating income, net on the condensed consolidated statement of income for the three months ended March 31, 2019.

XML

BUSINESS OPTIMIZATION CHARGES

3 Months Ended

Mar. 31, 2020

Restructuring and Related Activities [Abstract]

BUSINESS OPTIMIZATION CHARGES

BUSINESS OPTIMIZATION CHARGESIn recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. From the commencement of our business optimization activities in the second half of 2015 through March 31, 2020, we have incurred cumulative pre-tax costs of $1.0 billion related to these actions. The costs consisted primarily of employee termination costs, implementation costs, asset impairments and accelerated depreciation. We currently expect to incur additional pre-tax costs of approximately $30 million through the completion of these initiatives under

our current program. These costs will primarily include employee termination costs, implementation costs, and accelerated depreciation. To the extent further cost savings opportunities are identified, we may incur additional business optimization expenses.

During the three months ended March 31, 2020 and 2019, we recorded the following charges related to business optimization programs.

	Three months ended March 31,
(in millions)	2020		2019
Restructuring charges	$	25	$	25
Costs to implement business optimization programs	7		10
Accelerated depreciation	—		3
Total business optimization charges	$	32	$	38

For segment reporting purposes, business optimization charges are unallocated expenses.

Costs to implement business optimization programs for the three months ended March 31, 2020 and 2019, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. The costs were generally included within cost of sales, SG&A expense and R&D expense.

For the three months ended March 31, 2019, we recognized accelerated depreciation, primarily associated with facilities to be closed. The costs were recorded within cost of sales and SG&A expense.

During the three months ended March 31, 2020 and 2019, we recorded the following restructuring charges.

	Three months ended March 31, 2020
(in millions)	COGS		SG&A		R&D		Total
Employee termination costs	$	2	$	16	$	1	$	19
Asset impairments	6		—		—		6
Total restructuring charges	$	8	$	16	$	1	$	25

	Three months ended March 31, 2019
(in millions)	COGS		SG&A		R&D		Total
Employee termination costs	$	—	$	(1)	$	9	$	8
Contract termination costs	7		—		—		7
Asset impairments	9		1		—		10
Total restructuring charges	$	16	$	—	$	9	$	25

In conjunction with our business optimization initiatives, we sold property that resulted in a gain of $17 million. This benefit is reflected within other operating income, net in our condensed consolidated statement of income for the three months ended March 31, 2020.

The following table summarizes activity in the liability related to our restructuring initiatives.

(in millions)
Liability balance as of December 31, 2019	$	92
Charges	19
Payments	(21)
Currency translation	(2)
Liability balance as of March 31, 2020	$	88

Substantially all of our restructuring liabilities as of March 31, 2020 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2020.

XML

PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS (Tables)

3 Months Ended

Mar. 31, 2020

Retirement Benefits [Abstract]

Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans

The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.

	Three months ended March 31,
			As Restated
(in millions)	2020		2019
Pension benefits
Service cost	$	21	$	18
Interest cost	24		47
Expected return on plan assets	(41)		(72)
Amortization of net losses and prior service costs	19		15
Net periodic pension benefit cost	$	23	$	8
OPEB
Interest cost	$	1	$	2
Amortization of net loss and prior service credit	(4)		(7)
Net periodic OPEB cost (income)	$	(3)	$	(5)

XML

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2020

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The weighted-average Black-Scholes assumptions used in establishing the fair value of stock options granted during the period, along with weighted-average grant date fair values, were as follows:

	Three months ended March 31,
	2020			2019
Expected volatility	26		%	19		%
Expected life (in years)	5.5			5.5
Risk-free interest rate	0.6		%	2.6		%
Dividend yield	1.2		%	1.0		%
Fair value per stock option	$	16		$	15

XML

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

BASIS OF PRESENTATION

The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we or our) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (2019 Annual Report).

In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year.

Certain reclassifications have been made to conform the prior period condensed consolidated statements to the current period presentation.

Risks and Uncertainties Related to COVID-19

Our global operations expose us to risks associated with public health crises and epidemics/pandemics, such as the novel strain of coronavirus (COVID-19). COVID-19 may have an adverse impact on our operations, supply chains and distribution systems and increase our expenses, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking. Due to these impacts and measures, we have experienced and may continue to experience reductions or increases in demand for certain of our products as health care customers re-prioritize the treatment of patients. For example, elective surgeries are being de-prioritized which has negatively impacted the usage of certain of our products, while other of our products are experiencing an increase in demand which we may not be able to meet in accordance with the customer’s desired timing. In addition to travel restrictions, countries have closed borders and imposed prolonged quarantines, often with uncertain duration, which has significantly impacted the ability of our employees to get to their places of work to produce products and may significantly hamper our products from moving through the supply chain. As a result, given the rapid and evolving nature of the virus, COVID-19 could negatively affect our sales, and it is uncertain how COVID-19 will affect our global operations generally if these impacts persist or exacerbate over an extended period of time.

New Accounting Standards

Recently adopted accounting pronouncements

As of January 1, 2020, we adopted Accounting Standards Update (ASU) No. 2016-13, Financial Instruments - Credit Losses, which requires the measurement of expected lifetime credit losses, rather than incurred losses, for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. We adopted this ASU using the modified retrospective approach. The impact of the adoption of this ASU was an increase to our allowance for doubtful accounts and a decrease to retained earnings of $4 million.

The following table is a summary of the changes in our allowance for doubtful accounts for the three months ended March 31, 2020:

(in millions)	March 31, 2020
Balance at beginning of period	$	112
Adoption of new accounting standard	4
Charged to costs and expenses	7
Currency translation adjustments	(9)
Balance at end of period	$	114

ASU 2016-13 also requires disclosure by vintage year of origination for net investment in leases. Our net investment in sales-type leases was $127 million as of March 31, 2020, of which $21 million originated in 2016 and prior, $18 million in 2017, $46 million in 2018, $36 million in 2019 and $6 million in 2020.

As of January 1, 2020, we adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Our policies for capitalizing implementation costs incurred in a hosting arrangement were not impacted by this ASU. However, we have historically classified those capitalized costs within property, plant and equipment, net on our condensed consolidated balance sheets and as capital expenditures on our condensed consolidated statements of cash flows. Under the new ASU, those capitalized costs are presented as other non-current assets on our condensed consolidated balance sheets and within operating cash flows on our condensed consolidated statements of cash flows. We adopted this ASU on a prospective basis and capitalized $8 million of implementation costs related to hosting arrangements that are service contracts during the three months ended March 31, 2020.

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 21, 2020
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	1-4448
Entity Registrant Name	BAXTER INTERNATIONAL INC.
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-0781620
Entity Address, Address Line One	One Baxter Parkway,
Entity Address, City or Town	Deerfield,
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60015
City Area Code	224.
Local Phone Number	948.2000
Entity Central Index Key	0000010456
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		508,836,225
Common Stock, $1.00 per Value | NEW YORK STOCK EXCHANGE, INC.
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	BAX (NYSE)
Security Exchange Name	NYSE
Common Stock, $1.00 per Value | CHICAGO STOCK EXCHANGE, INC
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	BAX (NYSE)
Security Exchange Name	CHX
0.4% Global Notes due 2024 | NEW YORK STOCK EXCHANGE, INC.
Document Information [Line Items]
Title of 12(b) Security	0.4% Global Notes due 2024
Trading Symbol	BAX 24
Security Exchange Name	NYSE
1.3% Global Notes due 2025 | NEW YORK STOCK EXCHANGE, INC.
Document Information [Line Items]
Title of 12(b) Security	1.3% Global Notes due 2025
Trading Symbol	BAX 25
Security Exchange Name	NYSE
1.3% Global Notes due 2029 | NEW YORK STOCK EXCHANGE, INC.
Document Information [Line Items]
Title of 12(b) Security	1.3% Global Notes due 2029
Trading Symbol	BAX 29
Security Exchange Name	NYSE

XML

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 333	$ 342
Other comprehensive (loss) income, net of tax:
Currency translation adjustments, net of tax benefit of ($8) and zero for the three months ended March 31, 2020 and 2019, respectively	(359)	(97)
Pension and other postretirement benefits, net of tax expense of $6 and $4 for the three months ended March 31, 2020 and 2019, respectively	22	14
Hedging activities, net of tax benefit of ($39) and ($5) for the three months ended March 31, 2020 and 2019, respectively	(130)	(15)
Net other comprehensive income (loss)	(467)	(98)
Comprehensive (loss) income	(134)	244
Less: Comprehensive income attributable to noncontrolling interests	1	0
Comprehensive (loss) income attributable to Baxter stockholders	$ (135)	$ 244

XML

Supplemental Financial Information - Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 402	$ 377
Work in process	188	185
Finished goods	1,104	1,091
Inventories	$ 1,694	$ 1,653

XML

Goodwill and Other Intangible Assets, Net - Other Intangible Assets, Net (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	$ 3,252	$ 2,946
Accumulated amortization	(1,493)	(1,475)
Other intangible assets	179	173
Other intangible assets, net	1,759	1,471
Developed technology, including patents
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	2,612	2,309
Accumulated amortization	(1,209)	(1,190)
Other intangible assets, net	1,403	1,119
Other amortized intangible assets
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	461	464
Accumulated amortization	(284)	(285)
Other intangible assets, net	$ 177	$ 179

XML

Segment Information - Operating Income to Income Before Income Taxes Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating Income (Loss)	$ 409	$ 383
Net interest expense	(21)	(18)
Other (income) expense, net	10	(21)
Income before income taxes	378	386
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating Income (Loss)	833	802
Corporate and Other
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating Income (Loss)	$ (424)	$ (419)

XML

Derivative Instruments and Hedging Activities - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	May 31, 2019 EUR (€)	May 31, 2017 EUR (€)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, fair value, terminated	$ 0	$ 0
Deferred, net after-tax gains on derivative instruments	6,000,000
Undesignated derivative instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	824,000,000		$ 619,000,000
1.30% Senior Notes due May 2025
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Senior notes | €					€ 600,000,000
0.4% Senior Notes Due in May 2024
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Senior notes | €				€ 750,000,000
1.3% Senior Notes Due in May 2029
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Senior notes | €				€ 750,000,000
Net investment hedge
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Accumulated pre-tax unrealized translation gain in AOCI	28,000,000
Foreign exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 583,000,000		617,000,000
Maximum length of time hedge in cash flow hedge	12 months
Interest rate contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 550,000,000		550,000,000
Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, fair value, net	$ 0		$ 0

XML

Pension and Other Postretirement Benefit Programs - Net Periodic Benefit Cost Relating to Pension and Other Postemployment Employee Benefit Plans (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Pension benefits
Net periodic benefit cost
Service cost	$ 21	$ 18
Interest cost	24	47
Expected return on plan assets	(41)	(72)
Amortization of net losses and prior service costs	19	15
Net periodic cost	23	8
OPEB
Net periodic benefit cost
Interest cost	1	2
Amortization of net losses and prior service costs	(4)	(7)
Net periodic cost	$ (3)	$ (5)

XML

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Line Items]
Cash and cash equivalents	$ 4,110	$ 3,335
Other Assets
Fair Value Disclosures [Line Items]
Other equity investments without readily determinable fair values	77	73
Significant Other Observable Inputs (Level 2)
Fair Value Disclosures [Line Items]
Money market funds, at carrying value	$ 2,300	$ 1,700

XML

Derivative Instruments and Hedging Activities - Classification and Fair Value Amounts of Derivative Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	$ 29	$ 21
Derivative liability, fair value	233	54
Derivative instruments designated as hedges
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	24	20
Derivative liability, fair value	229	52
Derivative instruments designated as hedges | Interest rate contracts | Other non-current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	0	10
Derivative instruments designated as hedges | Interest rate contracts | Other non-current liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	226	52
Derivative instruments designated as hedges | Foreign exchange contracts | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	24	10
Derivative instruments designated as hedges | Foreign exchange contracts | Accounts payable and accrued liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	3	0
Undesignated derivative instruments | Foreign exchange contracts | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	5	1
Undesignated derivative instruments | Foreign exchange contracts | Accounts payable and accrued liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	$ 4	$ 2

XML

Business Optimization Charges - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Restructuring and Related Activities [Abstract]
Cumulative pre-tax costs incurred	$ 1,000
Expected additional pre-tax costs	30
Sale of properties	$ 17